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ABSTRACT
The apparent heterogeniety of breast cancer in terms of natural histoiy and response to
treatment has limited the development of both new drugs and regimens. Primary
systemic therapy has an advantage over standard post surgical adjuvant drug treatment
in that the effects of treatment can be directly observed by monitoring the primary
tumour response in situ. This concept underpins the studies described in this thesis.
The primary tumour response in terms of reduction in volume was monitored by serial
breast ultrasound scans in 95 patients treated with the anti-oestrogen tamoxifen and in
15 patients treated with the cytotoxic agents adriamycin and cyclophosphamide. After
three months of treatment 74% of patients treated with tamoxifen and 93% of those
treated with chemotherapy had demonstrated a response.
Tumour response was monitored at a cellular level using immunohistochemical
techniques to examine tumour biopsy material taken before and after treatment. Serial
tumour fine needle aspirates were also taken during treatment from subgroups of
patients undergoing either endocrine or cytotoxic therapy. These were analysed by
flow cytometric methods that were initially validated in human cancer cell lines grown
both in tissue culture systems and as xenografts. The results derived from patients
receiving chemotherapy, whilst interesting, were limited by the small number of
patients studied and an almost universally good response to treatment. However,
larger numbers of patients and a broad spectrum of tumour responses produced more
meaningful results in the tamoxifen-treated group. Several biological markers such as
the expression of oestrogen receptors, P-glycoprotein, Ki-Sl and Bel-2 were
significantly related to the observed clinical response after multivariate analysis. Pre-
treatment oestrogen receptor expression, measured by two different methods,
correlated with the subsequent reduction in tumour volume after tamoxifen treatment
with a high degree of significance. P-glycoprotein expression was significantly higher
in post-treatment samples from tumours that had not responded to tamoxifen in
comparison to responding tumours. This has potentially important implications for
tumour sensitivity to second line treatment with certain cytotoxic agents. The
expression of both Ki-Sl, a nuclear antigen acting as a marker of proliferation, and
Bcl-2, a marker of cellular resistance to cell death by apoptosis, were observed to
significantly decrease in responding tumours. These effects occured independently and
it is proposed that this may reflect two different pathways through which tamoxifen
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Chapter 1 : The Clinical Aspects of Breast Cancer - An Historical
Review
1.1 The Epidemiology of Breast Cancer
Breast cancer continues to represent a major cause of mortality and morbidity in
women in Scotland. Lung cancer has relatively recently become the greater cause of
death but breast cancer continues to have the larger incidence, responsible for
approximately 20% of all female cancer registrations. Given such a major problem,
obviously much research has been engendered and although understanding of the
disease has improved enormously there is yet to be significant improvements in overall
survival rates. Indeed if incidence and mortality rates are examined there has been a
persistent upward trend in both statistics during this century (Table l.lj.This trend is
confirmed by epidemiological studies elsewhere in the world (Table 1.2) with Miller
et a/.(Miller, 1991) estimating an annual increasing incidence in the USA of 1.16
percent between 1940 and 1982. A faster rate of increase in incidence has been noted
since 1982 and is thought to be mostly, if not entirely, due to the widespread
introduction of mammographic screening. As a crude measure of the effectiveness of
treatment it is interesting to plot the annual relative survival rates during the first five
years after diagnosis (Fig 1.1), the relatively small differences between time periods
are apparent.
Table 1.1 Age-Specific Death and Incidence Rates from Breast
Carcinoma in Scotland (per 100,000 population).
1911-15 17.8 1936-40 27.6 1961-65 35.4 (57.7)
1916-20 19.0 1941-45 28.7 1966-70 3 8.3 (64.7)
1921-25 23.3 1946-50 29.1 1971-75 40.9 (71.6)
1926-30 23.3 1951-55 31.2 1976-80 4 2.5 (82.8)
1931-35 25.4 1956-60 3 3.8 1981-85 (92.9)
figures in ( ) represent age-specific registration rates
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Table 1.2 Age-Adjusted Breast Cancer Mortality Rates in Selected
Countries
Country 1950 1955 1960 1965 1970 1975 1980 1983
England & Wales 23.2 23.7 23.8 24.4 26.4 27.8 28.2 28.4
Scotland 22.0 22.0 24.4 23.8 26.4 25.7 29.0 27.7
Northern Ireland 19.9 19.6 19.6 23.1 24.9 23.9 27.8 27.4
New Zealand 22.8 23.6 20.0 24.2 25.6 23.5 26.7 27.1
United States 21.3 22.0 21.7 22.2 22.5 21.9 22.0 22.1
Australia 19.4 20.4 18.7 18.7 19.9 19.4 19.2 20.4
France 12.7 14.4 16.0 16.9 17.0 18.8 18.3 19.2
Norway 17.3 18.6 17.0 18.3 17.0 17.4 17.5 16.7
Chile 7.7 7.6 9.6 9.8 12.1 11.4 12.1 12.7
Japan 4.0 4.0 3.8 3.9 4.4 5.0 5.5 5.9
Figure 1.1 Annual Relative Survival Rates in Scotland for Female



















Age is directly related to the incidence of breast cancer. The disease being relatively
rare before the age of 25, climbing steadily through the premenopausal years,
flattening at the menopause and then continuing to rise to peak in the over 80's.
Incidence and survival rates can be studied in these age groups in an attempt to
understand the underlying epidemiology and the relative effects of various preventative
and therapeutic interventions (Table 1.3).
The figures shown in Table 1.3 are for Scotland only but the trends are similar in the
rest of the United Kingdom. The number of new cases appears to have levelled out in
all age groups other than in the over 75's, reflecting, in the most part, the increasing
proportion of the general population in this older age group. Survival statistics show a
gradual small improvement in all age groups but as already demonstrated this is most
apparent over the first one to two years after diagnosis (see Fig l.l).This may be
explained in part by increasing public awareness and the introduction of breast
screening leading to an increased proportion of patients presenting at an earlier stage in
the disease. The overall impact of the widespread introduction of systemic cytotoxic
and hormonal adjuvant therapy is difficult to assess. The improved survival of
individual trial populations is clear but in relation to the breast cancer population as a
whole the effects are relatively small.
The facts remain that there appears to be a continuing overall increasing incidence of
breast cancer with, as yet, only minimal impact on survival from new therapeutic
interventions. The role of clinical and laboratory-based research in breast cancer must
therefore not only be directed towards the development of new therapies but also
making the optimal use of existing drugs and techniques.
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Table 1.3 Number of New Breast Cancer Registrations and Relative
5 Year Survival by Age Group and Year of Diagnosis (Scotland)
Age Period of Number of Relative Survival
Diagnosis Registrations Rate(%)
1 Year 5 Years
25-34 1968-72 243 87.3 55.0
1973-77 266 91.4 57.4
1978-82 269 93.8 64.6
1983-87 253 94.5 63.1
45-54 1968-72 1997 87.9 57.8
1973-77 2355 91.2 64.0
1978-82 2295 91.5 64.2
1983-87 2232 93.0 67.1
65-74 1968-72 2127 83.5 56.8
1973-77 2676 84.6 57.8
1978-82 2720 86.1 61.8
1983-87 2544 87.6 63.1
75-84 1968-72 1202 75.2 52.7
1973-77 1507 76.8 56.0
1978-82 1687 79.3 59.8
1983-87 1928 78.9 56.0
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1.2 Clinical Staging and Prognosis
One of the most important factors determining survival from breast cancer has been
shown in many studies to be the stage at which the disease first presents. Patients
presenting with tumours confined to breast tissue with no evidence of local invasion or
metastatic spread (Stage I) have an improved chance of survival compared to those
with axillary lymph node involvement (Stage II) or local advanced tumours (Stage III),
and much improved survival when compared to those with distant metastases at
presentation (Stage IV, see Fig 1.2).
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Years Since Registration
(Thames Cancer Registry - Unpublished Data)
These obvious differences in survival between what is generally accepted to be early
(Stage I) and late (Stage IV) disease form the basis for the rationale behind breast
screening programmes and also the formulation of treatment protocols.
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1.3 Current Concepts in the Treatment of Primary Breast Cancer
The treatment of primary breast cancer has until relatively recently been focused on the
control of local disease within the breast by surgery and/or radiotherapy. In the 1930's
Taylor was one of the first to suggest that ovarian oblation in addition to local therapy
could improve survival in premenopausal patients with early disease (Taylor, 1934).
However it was not until the mid 1970's with the publication of results of the first
large scale trials of adjuvant chemotherapy that an understanding of the disease as
potentially systemic, even at an apparently early stage, could be confirmed (Fisher,
1975; Bonadonna, 1976). Indeed it has been estimated that at diagnosis over 60% of
patients will have either clinical or occult metastatic disease (Henderson, 1980). The
importance of cytotoxic, hormonal and immune systemic therapy, in addition to local
treatment, for improved clinical outcome has been reaffirmed by the recent report of
the Early Breast Cancer Trialists' Collaborative Group (EBCTCG, 1992). The results
of this report were based on the analysis of 133 trials carried out before 1985
involving 75000 patients treated by hormonal manipulation, principally with
tamoxifen, and/or combined chemotherapy with CMF. Overall, in premenopausal
women, adjuvant therapy with CMF brought about an annual reduction of risk of
recurrence of 37% and tamoxifen a reduction of 11%. In postmenopausal patients the
relative efficacys of the two forms of treatment were reversed with reductions of risk
of 24% and 38% for CMF and tamoxifen (for 5 years) respectively. Clearly however
there are significant groups of patients who gain veiy little or no benefit from such
therapies and who are thus exposed to the immediate side effects of treatment and
potential long term complications. Although avoidance of a net potential harm to
patients is obviously the main factor in deciding against a particular treatment,
preventing a possible misdirection of financial resources must also be considered.
With the acceptance that the underlying biology of an individual tumour may not only
determine the potential for early metastatic spread but also the sensitivity to certain
therapies, there have followed attempts to select those patients who will most benefit
from a particular form of therapy. The two most accepted criteria are the axillary lymph
node status (indicating a predisposition to metastatic spread) and the presence of
steroid receptors (indicating less aggressive disease and a likelihood to respond to
hormonal therapies). The EBCTCG report analyses results of therapy in these two
patient sub groups and compared to the general study population notes a reduced risk
of recurrence in node positive patients treated with chemotherapy and patients with
oestrogen receptor positive tumours treated with tamoxifen. However the divide is not
absolute and of particular importance is the improved outcome in a small but
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significant group of node negative patients treated with adjuvant chemotherapy. This
finding had been suggested previously and has spawned a vast amount of research
aimed at identifying new prognostic indicators upon which to select patients for
systemic therapy (See Chapter 5).
Developments in the approach to the local treatment of the breast have been directed
towards less mutilating forms of local surgery. The similarity in treatment outcome
between conservative local excision ("lumpectomy") followed by radiotherapy and
total mastectomy is demonstrated by eight-year disease-free survival rates of 58% and
54%, respectively, for women with tumours up to four centimeters (Fisher, 1989) and
80% and 77%, respectively, for those with tumours up to two centimeters (Veronesi,
1986). These findings, in conjunction with other biological factors, discussed in the
ensuing chapter, have encouraged the development of primary or "neoadjuvant"
systemic therapy of primary cancers prior to surgeiy. In responsive tumours a
decrease in size may allow breast conservation rather than mastectomy and
encouraging results have been reported (Bonadonna, 1990).
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Chapter 2 : Primary Systemic Threrapv of Breast Cancer
2.1 Historical Aspects
The clinical recognition of the importance of a combination of local and systemic
treatment for breast cancer has stimulated developments in the understanding of both
tumour growth and response to chemotherapeutic and hormonal agents. It is clear that
there is a great diversity of short term responses and long term outcome to all agents
used to date. This has been illustrated at a primary tumour level by the early trials of
neoadjuvant chemotherapy employed principally to achieve response in locally
advanced disease prior to surgery and/or radiotherapy (Hortobagyi, 1983; Swain,
1987; Jacquillat, 1988). Thomlinson attempted to document these varied responses by
means of careful sequential measurements of primary tumours during treatment with
chemotherapy, hormonal agents and radiotherapy (Thomlinson, 1987). With the
possibility of monitoring the primary tumour "in situ" comes the potential to change
therapeutic approaches if the desired response is not observed.This tailoring of therapy
to individual tumours might be expected to have implications for all patients requiring
sytemic therapy, not only those with locally advanced disease.The pilot study of
primary sytemic therapy in Edinburgh (Forrest, 1986) included patients with operable
but large tumours, given that the likelihood of the presence of micrometastatic disease
is directly related to the size of the primary tumour (Ponten, 1990). In an attempt to
spare patients the morbidity associated with chemotherapy all patients were initially
treated with anti-oestrogens and their tumours monitored for response. Evidence of
failure to respond or progression of disease led to a change in therapy to cytotoxic
agents. The treatment protocol was revised so that those patients with oestrogen
receptor poor tumours (<20fmol/mg cytosol protein) were initially treated by
chemotherapy; this group having displayed a very poor response to anti-oestrogens.
However within these two treatment groups there are still patients who will fail to
respond or respond poorly to their assigned therapy.There is, therefore, a need to
identify further prognostic markers, in addition to the oestrogen receptor, for
therapeutic responsiveness and the human tumour model provides an ideal setting in
which to pursue such studies.
There are other underlying biological reasons supporting the principal of pre-operative
systemic therapy. Animal studies have shown that non-curative surgery accelerates
tumour cell proliferation at metastatic sites (Tyzzer, 1973). This response can be
blocked by treatment with cyclophosphamide or tamoxifen prior to surgery (Fisher,
1983). Commencing treatment as soon as possible may minimise the emergence of
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mutations conferring drug resistance (Goldie, 1985). Avoidance of a burst of
proliferative activity at surgery would also presumably reduce the risk of resistance
mutation.
The early clinical studies of primary systemic therapy are now being reported (Table
2.1). The emphasis has necessarily, with short term follow-up, been on an end point
allowing avoidance of mastectomy rather than a survival advantage. Indeed most
studies have been prospective, with consecutive patient recruitment, comparing the
response rates of different drug regimens. Interestingly similar studies have been
undertaken in other cancers with the aims of allowing or facilitating local surgical
and/or radiotherapeutic procedures. Examples include limb-salvage surgery in
osteosarcoma (Goorin, 1985) and the preservation of the larynx (Hong, 1989) and
bladder (Kaufman, 1989) affected by large invasive tumours.
Clearly the facilitation of local conservative treatment is an important outcome of
primary drug therapy, perhaps particularly from a psychological viewpoint in breast
cancer. The effect of this approach on recurrence and overall survival has yet to be
confirmed. Although early survival data from the consecutive trials reported appear
promising, there are, as yet, very few reported randomised comparitive trials of
conventional local treatment and subsequent adjuvant therapy against primary systemic
therapy followed by local treatment. Hopefully the multicentre NSABP (Protocol B-
18) trial commenced in the U.S.A. and Canada in 1988 will include sufficient patient
numbers to allow the questions of survival to be answered. A single centre French trial
reported in 1991, included 272 patients with a median follow-up of 34 months and
found an increased incidence of local recurrences in the primary therapy arm but an
improved overall survival (Mauriac, 1991). However there were differences in the
local therapeutic procedures employed with all in the conventional arm receiving a
mastectomy while those in the primaiy therapy arm received a either a mastectomy, a
wide excision followed by radiotherapy or radiotherapy alone. Interestingly there also
appeared to be greater clinical responses to chemotherapy in oestrogen receptor
negative tumours, which may fuel an argument for selected primary endocrine or
chemotherapy. The current Edinburgh trial, upon which part of this thesis is based,
was designed to help answer questions of disease-free and overall survival with
standardised local therapy and randomisation of selected primary therapy versus
conventional adjuvant therapy.
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2.2 The Scottish Trial of Selective Primary Sytemic Therapy for Large
Primary Breast Tumours in Women Under the Age of 70 Years
The early survival data resulting from the use of selective primary systemic therapy in
a consecutive series of 88 patients presenting to the Edinburgh Breast Unit with large
but operable tumours (>4cm), proved worthy of further investigation (Anderson,
1991). A pilot randomised controlled trial of primary systemic therapy versus
conventional treatment has been conducted in the Unit since January 1990. The trial
aims to compare the outcome of primary treatment, selected on the basis of tumour
oestrogen receptor content and followed by locoregional therapy with standard
postoperative unselected adjuvant systemic therapy.The measures of outcome are local
recurrence rate, distant disease free interval and overall survival. Unlike other studies
of primary systemic therapy previously quoted, potential downgrading of surgery
required is not a factor in this study and all patients are selected for a particular
procedure before commencing therapy. The design of the trial is outlined below (Fig
2.1) and the main inclusion/exclusion criteria include the following:
INCLUSION
i) Patients under the age of 70 years.
ii) Tumours greater than 3cm in clinical diameter.
iii) Stage T2 or T3 disease only.
iv) No evidence of distant metastases with standard staging investigations.
EXCLUSION
i) Patients with bilateral primary breast cancer.
ii) Patients with in-situ carcinoma only.
iii) Previous malignant disease (other than basal or squamous cell carcinoma of
skin or carcinoma-in-situ of the cervix).
iv) Tumours that cannot be monitored adequately by mammography or
ultrasound.
v) Patients with any medical condition that precludes adequate surgery,
adjuvant therapy or follow-up (eg. pregnancy, heart disease, mental illness).
vi) Premenopausal patients with a wish for a future pregnancy.
20
Fig 2.1 Trial Design
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Primary Therapy Arm
Patients randomised to the primary sytemic therapy arm of the trial undergo wedge
biopsy of the tumour under local anaesthetic. Approximately 0.6cm3 of tumour tissue
is removed. A portion of tissue is fixed for histology and the remainder stored in liquid
nitrogen for oestrogen receptor assay and further immunohistochemical and
biochemical studies.
Primary therapy commences after histological confirmation of the diagnosis and the
result of the oestrogen receptor analysis is known. Treatment is based on oestrogen
receptor and menopausal status, lasts for three months, and is as follows:
a) Premenopausal patients with tumours of ER level >20 fmol/mg cytosol protein
commence the LHRH agonist, Goserelin, by subcutaneous implant every 28 days. If a
significant response is achieved a bilateral oophorectomy is carried out at the time of
definitive breast surgery or shortly afterwards.
b) Postmenopausal patients with tumours of ER level >20 fmol/mg cytosol protein
commence tamoxifen, 20 mg per day. In those achieving a response, tamoxifen is
cotinued for five years after definitive surgery or until relapse.
c) All patients with tumours of ER level <20 fmol/mg cytosol protein commence CAP
combination chemotherapy comprising:
Cyclophosphamide lgm/m2 I.V. bolus.
Adriamycin 50mg/m2 I.V. bolus.
Prednisolone 40mg daily for 5 days orally.
Four cycles of therapy are given three-weekly prior to definitive surgery and if a
response is demonstrated two further cycles are given after surgery.
d) Patients receiving endocrine manipulation and whose tumours do not show a
significant response by 12 weeks are changed to CAP chemotherapy.
Definitive locoregional therapy comprises either i) mastectomy and axillaiy node
clearance or ii) wide local excision, axillary node clearance and post operative
radiotherapy. Tumour tissue is taken at surgeiy for histology, oestrogen receptor assay
(where relevant) and further immunohistochemical and biological studies.
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Conventional Therapy Arm
All patients in this arm of the trial proceed directly to definitive locoregional therapy as
has been described above. Thereafter adjuvant systemic therapy is given as follows:
a) Premenopausal patients with metastatic disease in axillary lymph node(s) are given
combination chemotherapy with CMF:
Cyclophosphamide 600mg/m21.V. bolus.
Methotrexate 50mg/m2 I.V. bolus.
5-Fluorouracil 600mg/m2 I.V. bolus.
Six cycles of treatment are given three-weekly.
b) All other patients commence tamoxifen, 20mg per day after surgeiy.
Follow Up
All patients are followed up regularly after surgery and disease recurrences and deaths
recorded.
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2.3 Monitoring the Response to Primary Systemic Therapy
The principles of primary systemic therapy for operable tumours arose from
approaches developed for the medical treatment of locally advanced inoperable disease,
as has been discussed. The observed response to chemotherapy of advanced tumours
has been reported to be of prognostic significance (Valagussa, 1990) and the same
appears to be applicable to operable tumours although follow up data of the initial
studies is still relatively short (Bonadonna, 1993). The debate continues, however, as
to the most appropriate method of assessment of response. The reported methods in
trials of primary chemotherapy have comprised serial calliper measurements and
usually additional mammography. According to U.I.C.C. guidelines, data from
calliper measurements allow the observed response to be classified as either a
"complete response", "partial response", "no change" or "progressive disease"
(Hayward, 1977). Mammographic measurements may be expressed similarly. Forrest
et al., reporting on the pilot series in Edinburgh, found an excellent correlation
between mammographic and clinical response (Forrest, 1986). Others have
demonstrated difficulties in quantifying the radiological response and that in a
substantial proportion of cases mammography lags behind clinical response to both
endocrine and chemotherapy (Moskovic, 1993). An explanation for the discrepancy
may be related to the underlying pathological changes with treatment. Hyalinisation or
a fibrous reaction within the tumour may alter the clinically palpable mass but not the
mammographic appearance. Indeed it is the pathological assessment of response which
appears to be of most prognostic significance in locally advanved disease (Feldman,
1986). Interestingly Feldman found that the absence of macroscopic disease in the
mastectomy specimen was a significant predictor for disease-free and overall survival
and that the absence of microscopic disease did not affect the relationship. Ultrasound
examination and measurement of breast tumours has been shown to correlate with
pathological examination more closely than mammography (Fornage, 1987) and has
proved useful in assessment of response to primary therapy in the Edinburgh study
(Forouhi, 1994). Ultrasound has the advantage of being painless and free from
potential long term side effects and therefore allows frequent serial assessments to
accurately follow the response. However there are still occasional tumours which will
fibrose or hyalinise in response to therapy without a significant change in their
ultrasonographic appearance. Duplex colour Doppler ultrasound has the advantage of
allowing both the standard measurement of the tumour and its blood flow. Most
malignant tumours are characterised by increased vascularity and an abnormal vessel
pattern. Doppler detection of this vascularity has proved sensitive and specific in the
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detection of breast cancer (Britton, 1990) and its serial quantitation, in a recent case
report, potentially useful in the assessment response to primary chemotherapy
(Madjar, 1993). Although the cost of the hardware at present limits its use it is likely
that in the not too distant future a combination of serial Doppler measurements and pre
and post treatment mammography will comprise the most useful form of assessment.
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Chanter 3 : The Elderly Patient With Breast Cancer
3.1 Historical Aspects
The incidence of breast cancer increases with age and indeed approximately a third of
all cases occur in those over the age of 70. However many other medical disorders
follow a similar pattern and with a decreasing life expectancy this group of patients
present particular problems when considering treatment protocols. Patients over the
age of 65 are excluded from most national screening programmes and clinical
therapeutic trials. One might expect therefore that patients in this group would
generally present with relatively large tumours that would merit a combined therapeutic
approach, had they been younger, but with little trial data to support this. A recent
review of evidence of determinants of the choice of therapy in the elderly quotes
concurrent additional medical complaints or "comorbidity" as a main factor guiding
decisions (Satarino, 1992). Two or more conditions (such as arthritis, cerebrovascular
and heart disease, cancer and diabetes) are reported by 61% of women aged between
70 and 79 and 70% aged 80 years and older. Satarino cites a study which indicates that
of breast cancer patients over the age of 50, 58.9% with "moderate to severe
comorbidity" received appropriate therapy compared with 81.3% with little or no
comorbidity. However even among patients with little or no comorbidity and stage 1
or 2 disease only 83% of patients aged 70 or over received "appropriate treatment"
compared to 95.6% of those aged between 50 and 69. It maybe therefore that
chronological age is used, to the detriment of many older women as a proxy for
general health and suitability for particular treatments. A similar conclusion was
reached in an Australian study showing that aggressiveness of local treatment was
inversely related to age in a group of patients over 70 but overall survival was similar,
although those with less aggressive local therapy had a greater incidence of local
recurrence often requiring a second procedure (Hainsworth, 1992). However, it is
also clear that there are many in this age group who obviously could not withstand
aggressive treatment or refuse such therapies.
Tamoxifen has been shown, in many studies, to significantly increase disease-free and
overall survival when used as adjuvant therapy in patients with breast cancer over the
age of 50 (EBCTCG, 1992). Similar results have been obtained in a single-centre
study in patients over 65 years of age (Cummings, 1993). This may not entirely be
due to the effects of tamoxifen on breast cancer as there appears to be a substantial
reduction in deaths due to other causes in those taking the drug, principally from
cardiac disease (McDonald, 1991; Rutqvist, 1993). In several trials therapy has been
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continued for up to five years with remarkably few significant side effects reported. It
is the combination of effectiveness and low toxicity that has prompted several studies
testing tamoxifen as sole therapy in the elderly patient. Data from such studies
demonstrate that overall approximately 60% of tumours will regress and a further 20%
remain static. A summary of results is shown below (Table 3.1)
Table 3.1 Review of Reported
for Operable Disease in Elderly
No. of
Trial Patients




Response Response Stasis Progression
Preece (1982) 67 18 14 17 18
Helleberg (1982) 27 15 5 2 5
Bradbeer & Kyngdon (1983) 161 44 55 39 23
Allan (1985) 53 29 14 6 4
Falk (1989) 43 14 19 - 10
McDonald (1990) 58 10 10 20 18
Robertson (1988) 57 22 9 9 17
TOTAL 466 152 126 93 95
% 100 32.6 27.0 20.0 20.4
Although these results appear encouraging, several studies have described a high rate
of relapse, particularly of local disease. An initial trial in Nottingham comparing
surgery with primary tamoxifen in a group of patients over the age of 70 with operable
disease but no other selection criteria, found no significant difference in overall
survival or cause of death between the two groups after five years (Robertson, 1992).
However after a mean follow-up of 65 months the majority of patients treated with
tamoxifen alone required a mastectomy for local relapse. The conclusion to be drawn
from such data is therefore that all elderly patients with operable disease and who are
fit should have surgery at presentation to avoid simply postponing an operative
procedure in a population in which a delay may be undesirable. However in one-third
of the patients, tamoxifen achieved control of disease for up to five years. Patients
themselves often wish to avoid surgery, if at all possible, and other selection factors
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may identify this subgroup who could be controlled in the long-term by tamoxifen
alone. The same group at Nottingham using oestrogen receptor status to select patients
for tamoxifen therapy demonstrated, after short-term follow-up, a much lower
incidence of early progression in oestrogen receptor positive tumours compared to the
unselected tumours of the earlier trial (Low, 1992). However with longer follow-up it
seems that even using this criteria disease control fails in approximately 60% of
patients after five years (Horobin, 1991). A study performed in Edinburgh aiming to
determine predictors of "worthwhile response" to primary tamoxifen in the elderly
confirmed the contribution of oestrogen receptor status but failed to demonstrate an
association with the early observed clinical response (Gaskell, 1992). Several other
predictive factors have been proposed including tumour cell expression of additional
steroid receptors, oestrogen inducible proteins and growth factor receptors but the
clinical relevance of the published data is inconclusive at present.
There seems little doubt that there is a group of patients who can be maintained on
tamoxifen alone in the long-term. One of the aims of this thesis is to attempt to identify
this group by means of a combination of clinical observation of response patterns and
of examination of underlying tumour biological characteristics and their response to
treatment. This approach may also identify patients with very aggressive disease who
will require extensive surgery and additional treatment such as radiotherapy to effect
good control.
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3.2 The Edinburgh Trial of Surgery and Tamoxifen versus Tamoxifen
alone for Primary Breast Cancer in Patients Over the age of 70 Years.
In an attempt to further the investigation of the role of tamoxifen in treatment of the
elderly patient a new study was commenced in Edinburgh in January 1992.The
principal aim was to determine long-term outcome of patients who had initially
responded to tamoxifen and had then been randomised to receive either locoregional
surgery or a continuation of primary therapy. The protocol is diagrammatically
represented below (Fig 3.1). The main inclusion and exclusion criteria are listed as
follows:
INCLUSION
a) Patients over 70 years of age.
b) Potentially operable disease (including small T4 lesions).
c) No evidence of metastatic disease.
d) Fit for general anaesthesia.
e) Oestrogen receptor positive tumour ( >10% cells staining with E.R.I.C.A. or >20
fmol/mg cytosol protein by dextran-charcoal saturation method).
EXCLUSION
a) Previous malignancy (other than basal cell or squamous carcinoma of the skin or
in-situ carcinoma of cervix).
b) Tumour not assessable by ultrasound scanning.
Incorporated within the study are two categories of biological assessment of tumour
characteristics. The first aims to compare the two most commonly used methods of
estimation of tumour oestrogen receptor expression; E.R.I.C.A. performed on material
from fine needle aspiration and the dextran-charcoal saturation method using tissue
obtained by open biopsy. These measurements can then be related to the subsequent
response to tamoxifen. Secondly the examination of tissue obtained before treatment at
the time of wedge biopsy can be compared to tissue obtained after treatment from those
who have not responded or those who have responded but have been randomised to
receive surgery. This enables biological characteristics to be related to clinical response
and may give further information into therapeutic mechanisms of tamoxifen and of
tumour resistance. Only those patients with tumours greater than three centimetres in
clinical diameter and who agree to the procedure undergo local anaesthetic biopsy.
All patients within the trial receive 20mg tamoxifen daily for an initial period of three
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months. The tumours are measured clinically and by ultrasound prior to
commencement of treatment (after wedge biopsy, in those undergoing this procedure)
and thereafter at four-weekly intervals. All patients are then reviewed at three months.
Those who have responded are randomised either to receive definitive locoregional
surgery or to continue tamoxifen. Those whose tumours have remained static continue
therapy for a further three months and if a response is observed they too are
randomised. All patients with progression of disease within the first three months or
static disease after six months undergo surgery.
All patients are under the care of one consultant surgeon and the form of locoregional
surgery performed is at his disgression. In responding patients a benefit of this
approach to tamoxifen therapy is very often a downgrading of the degree of surgery
required, so that many can be treated by a local excision of the tumour with
conservation of the breast, thus avoiding a full mastectomy. Tamoxifen is continued
postoperatively as adjuvant therapy.
Tamoxifen is continued in those patients randomised to receive it as sole therapy until
relapse. If the recurrent disease is purely locoregional patients will undergo surgery
but ifmetastatic at distant sites then second line hormonal therapy is given.
All patients are followed up at regular intervals to assess the state of their disease and
recurrences and deaths are recorded.
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Fig 3.1 Trial Design of the Edinburgh Trial of Surgery and Tamoxifen
versus Tamoxifen alone for Primary Breast Cancer in Patients Over the
age of 70 Years.
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3.3 Monitoring the Clinical Response to Treatment in the Elderly
All studies reported to date have used calliper measurements to assess the clinical
response to tamoxifen in elderly patients. Indeed the previous study conducted in
Edinburgh analysed the results of multiple measurements over the initial three months
of treatment as a possible predictor of long term outcome (Gaskell, 1992). The results
indicated this to be unsatisfactory but the authors felt a more accurate method of
assessment may improve the predictive value, for outcome, of such measurements.
For reasons alluded to previously, serial ultrasound scanning, alone or in combination
with more traditional methods of assessment, may prove helpful.
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Chanter 4 : Therapeutic Mechanisms
4.1 Adriamycin Based Chemotherapy Regimes
The anthracycline, Adriamycin (or doxorubicin) was first isolated in 1969 from a
chemically mutated strain oiStreptomyces peucetius var. caesius (Powis, 1987).
Since introduced into clinical practice in the early 1970's it has proved effective against
a wide range of both haematological and solid tumour malignancies. Toxicity
associated with all the anthracyclines includes myelosuppression, nausea, vomiting
and alopecia in the acute phase with cardiomyopathy as a dose-limiting cumulative
effect. The precise mode of action of the anthracyclines at a cellular level remains
unclear although at least three mechanisms have been proposed; i) High affinity
binding to DNA, blocking further DNA, RNA and protein synthesis, ii) alteration of
cell membrane fluidity and ion permeability and iii) the generation of free radicals
(Powis, 1987). Cell cycle analysis by flow cytometry has demonstrated both in vitro
and in vivo an accumulation of cells in the G2M region of DNA histograms of tumour
cells exposed to adriamycin (Engelholm, 1983; Remvikos, 1993a). This effect can be
distinguished from the effects of, for example, alkylating agents such as
cyclophosphamide, which provoke an accumulation within the S-phase of the cycle
(Engelholm, 1986). Investigation into the mechanisms of intrinsic and acquired
cellular resistance to adriamycin have recently centered around the expression of
multidrug resistance (MDR) genes. As the term suggests these genes, if activated, can
confer resistance, in most malignancies including breast cancer, to several lipophilic
cytotoxic agents. The mdr -1 gene has been extensively investigated and codes for
membrane P -glycoprotein, an active efflux pump that can maintain intracellular
concentrations of chemotherapeutic agents at nontoxic levels (Ro, 1990).
The accepted approach to chemotherapy for breast cancer involves the use of a
combination of different agents. The ratonale behind such practice can be justified
firstly by the need to reduce the likelihood of the development of resistance; secondly,
by the need to reduce the severity of toxic effects; thirdly, by the hope of increasing the
therapeutic effect by synergism or interaction with different aspects of the cell cycle.
Following this principle the Edinburgh study of primary systemic chemotherapy
employs a combination of adriamycin and cyclophosphamide. Cyclophosphamide is
an alkylating agent and exerts its cytotoxicity by inducing DNA strand cross linkage.
As mentioned above it appears to affect cells at a different point in the cell cycle than
does adriamycin, and does not produce the same cumulative cardiotoxicity. The
alkylating agents are potent suppressors of ovarian function and the significance of this
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possible contribution to the responses seen in breast cancer remains a topic for debate
(Pourquier, 1993; Toma, 1992). Several possible resistance mechanisms to
cyclophosphamide are known including MDR gene expression. This would
theoretically be contrary to one of the indications of multidrug therapy, but the clinical
significance of an apparent common mode of resistance to this drug combination
remains to be demonstrated.
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4.2 Tamoxifen and Hormone Manipulation
Tamoxifen is a non-steroidal anti-oestrogen, initially found to have antifertility
properties in rats and mice (Harper, 1967) and developed as a possible contraceptive
agent in man. Its potential clinical use in the treatment of advanced breast cancer was
soon identified (Cole, 1971) and its use has become increasingly widespread as both a
primary and an adjuvant therapeutic agent. The low incidence of attendant side effects
has even led to ongoing trials of tamoxifen as preventative therapy in women with a
perceived high risk of developing breast cancer (Powles, 1989).
The mechanism of action of tamoxifen is complex but is thought primarily to be
mediated through competitive inhibition of oestrogen binding at the oestrogen receptor
site, within those cancer cells in which it is expressed (Jordan, 1993). This inhibitory
action decreases cellular proliferation by direct and indirect pathways with effects on
gene transcription including reduced production of growth factors (Noguchi, 1993).
This theory is borne out in clinical practice with significant responses to primary
therapy seen only in cancers containing receptors. However with tamoxifen used as
adjuvant treatment although the best survival advantage is seen in patients with
oestrogen receptor positive tumours a significant improvement is also seen in patients
with receptor-poor tumours (EBCTCG, 1992). This observation has encouraged
studies of possible mechanisms of action other than via the oestrogen receptor. Two
potentially important alternative pathways by which tamoxifen may decrease cellular
proliferation are firstly via the inhibition of the production of autocrine growth factors
such as insulin-like growth factor (IGF-1), which have been shown to stimulate breast
cancer cell growth and are produced by normal tissues (Huyny, 1993) and secondly
through stimulation of the production of the inhibitoiy transforming growth factor
(TGFB) by tumour cells and stromal fibroblasts (Butta, 1992).The effects of tamoxifen
on cells that do express oestrogen receptors is further complicated by its ability to act
both as an antagonist and an agonist. Oestrogenic effects can be demonstrated in breast
cancer cell lines by, for example, the induction of oestrogen inducible proteins such as
pS2 (Johnson, 1989) and the progesterone receptor (Horwitz, 1978).These agonist
effects are manifested clinically, in postmenopausal women, through beneficial
protective effects on bone (Love, 1992) and the cardiovascular system (McDonald,
1991), and potentially harmful effects on blood coagulation and the endometrium
(Fornander, 1993).
This variety of effects and possible mechanisms of action against breast tumours make
the study of response and resistance to tamoxifen treatment extremely complex.
Nonetheless such studies are vital not only because tamoxifen is, arguably, the most
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potent endocrine agent available against a broad range of breast tumours but also its
mechanisms of action may hold the key to development of further curative and
preventative treatments.
Tamoxifen has been reported to cause tumour regression in 50-60% of primary
oestrogen receptor positive tumours (McGuire, 1975).The mechanisms underlying
these observations remain unclear since tamoxifen has classically been described as a
cytostatic agent acting through interference with the oestrogen stimulus to
proliferation. This effect has been further accurately defined as an induction of cell
cycle arrest with an accumulation of cells in the Go / Gi phase (Osborne, 1983;
Thomas, 1992). Other studies have also demonstated a decrease in 5-bromo-2-
deoxyuridine (BrdU) uptake and in the expression of the proliferation-associated
nuclear antigen, Ki-67, in cell lines exposed to tamoxifen (Danova, 1993). However,
to achieve tumour regression both a decrease in proliferation and an increase in cell
death are required. Cell death can result either from tissue necrosis or from an active
mechanism of programmed cell death known as apoptosis. Apoptosis can be induced
by a variety of anticancer agents as well as several other toxic cellular insults (Wyllie,
1993) and recently the tamoxifen analogue, toremifene, has been shown to both inhibit
growth and induce apoptosis in hormone-sensitive breast cancer cell lines (Warri,
1993).Although oestrogen withdrawal also led to apoptosis in these cell cultures,
mitoses still took place (albeit at a slower rate) and thus it is likely to be the combined
inhibitory and apoptotic effects of antioestrogens that lead to tumour regression. The
mechanism of induction of active cell death remains unclear although earlier work with
4- hydroxytamoxifen, a potent anti-oestrogenic metabolite of tamoxifen, confirmed
that this effect could be inhibited by oestrogen and thus occurs via an interaction with
the oestrogen receptor (Bardon, 1987). This would be in keeping with the proposed
role of apoptosis in normal tissues undergoing both proliferation/differentiation and
involution typified by the female breast and reproductive organs in which cyclical
changes are under hormonal control (Ferguson, 1981). An improved understanding of
the controlling mechanisms underlying these normal processes would allow a greater
perception of mechanisms of action of, and importantly resistance to, the
antioestrogens in breast cancer. Studies of apoptosis initially in lymphoma but later in
various malignancies and normal tissues have identified the importance of one
particular gene,bcl -2, in the control of this process (Hockenberry, 1990). The bcl -2
gene product has been shown to protect against apoptosis induced by a variety of toxic
insults including chemotherapeutic agents (Miyashita, 1992) and interestingly is found
in, amongst others, normal hormone-responsive tissues such as the ductal epithelium
of the breast (Lu, 1993). This gene has been confirmed to be, at least partly, under
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oestrogenic control but its role in tumour response and resistance to antioestrogens is
unknown. Expression of the gene has been associated with hormone resistance in
prostatic carcinoma (Colombel, 1993).
Long term follow-up studies have shown that of the 50-60% of patients with
oestrogen receptor positive tumours who initially respond to tamoxifen approximately
half will have relapsed after 5 years of treatment (Horobin, 1991). Many theories have
been proposed for both de-novo and acquired resistance to therapy but there is little
hard clinical or experimental evidence of actual resistance mechanisms. Some potential
mechanisms are displayed diagrammatically (fig 4.1) and discussed briefly below.
These can be roughly divided into four groups; firstly, mechanisms related to
tamoxifen levels within tumours lowered either by reduced inta-tumoral accumulation
or by altered metabolism; secondly, defects at the level of the oestrogen receptor with a
reduction in receptor levels or mutation and loss or alteration of function; thirdly
through altered signal transducton with modification of interactions of the receptor
complex with transcription factors or oestrogen response elements at the DNA level,
negating the effect of the oestrogen receptor complex on cell processes or influencing
the balance of oestrogenic/antioestrogenic effects of tamoxifen; fourthly, indirect
mechanisms mediated through altered levels of, or responsiveness to, growth factors
such as TGF-B, TGF-a and IGF-1 and expression of surface receptors such as c-erbB-
2 (Benz, 1992) and the epidermal growth factor receptor (Long, 1992).
Both xenograft and recent clinical data suggest that the intratumoral levels of tamoxifen
are lower in tumours that have acquired resistance than in those remaining sensitive
(Wiebe, 1993; Johnston, 1993).One might speculate that reduced levels are the result
of a cellular efflux pump mechanism such as P- glycoprotein coded for by the mdr -1
gene. Interestingly tamoxifen has been shown to reverse resistance to several
chemotherapeutic agents mediated by MDR, in vitro (Ramu, 1984), although clinical
trials to test this finding in vivo with high dose tamoxifen have been inconclusive
(Stuart, 1992). This effect is thought to take place in a competitive fashion (Leonessa,
1994) and it is therefore possible that at therapeutic levels tamoxifen is a substrate for
this pump mechanism. Further evidence for the presence of an efflux pump was the
demonstration that R-verapamil, an agent known to be capable of reversing MDR
mediated drug resistance, was also capable of reversing tamoxifen resistance in a rat
mamary carcinoma model (Kellen, 1991a). However the same group had also found,
in an earlier study, decreased levels of P -glycoprotein in resistant cells (Kellen,
1991b) and a more recent report has demonstrated a failure of induction of tamoxifen
resistance with over expression of mdr -1 in a transfected MCF-7, hormone sensitive,
breast cancer cell line (Clark, 1992). There is, as yet, little clinical evidence for the
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association between tamoxifen resistance and P -glycoprotein exists although
amplification of the mdr -1 has been noted on serial tumour samples obtained by fine
needle aspiration during tamoxifen therapy (Lonn, 1992). Decreased intratumoral
tamoxifen levels not only allows less competitive inhibition with oestrogen for
oestrogen receptor sites but paradoxically may result in stimulation of growth, and
another possible mechanism for observed relapse during tamoxifen therapy (Gottardis,
1989). Indeed, in certain instances, there is clinical evidence of a withdrawal response
of tumours that have relapsed, after an initial response to tamoxifen, when therapy is
discontinued. Lower detectable levels of tamoxifen may not only be the result of an
active efflux mechanism but also of intracellular binding to antioestrogen binding sites
(Pavlik, 1992) or an altered metabolism with the production of either weakly
antioestrogenic or potently oestrogenic metabolites (Morrow, 1993). It would
theoretically be possible to observe the balance of agonist/antagonist activity at the
oestrogen receptor by observing expression of oestrogen regulated genes in sensitive
and resistant tumours.
Detailed descriptions of the other potential mechanisms of tamoxifen resistance are
outwith the scope of this thesis but further brief discussion will be found in sections
dealing with the particular markers incorporated in this study. If the principal,
clinically relevant, mechanisms of resistance to tamoxifen are still to be defined then it
is obviously very difficult to predict prior to therapy the 40-50% of patients that will be
resistant de novo or the additional 25-30% that will relapse during treatment.
Conversely, if predictive factors are found then this may aid the detection of new
resistance mechanisms or confirm those already proposed.
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Chanter 5 : Prognostic and Predictive Indicators in Breast Cancer
5.1 Introduction
The heterogenous nature of breast cancer, particularly with respect to clinical natural
history and response to treatment, has understandably generated an enormous literature
on the subject of prognostic and predictive factors for the disease. With new and
potentially curative drugs or more potent methods of administering established agents
the definition of patient subgroups likely to benefit has assumed vital importance. This
being especially the case since these forms of treatment often carry a greater potential
for toxic side effects. The awareness of the problem has been heightened by a change
in the population of new patients with a greater proportion presenting with early stage
disease; a result of the extensive screening programmes introduced over the past 10-15
years. A prognostic indicator maybe defined as a factor which, at the time of
diagnosis, is able to give information onclinical outcome. A predictive factor is one
which may be able to aid selection of patients likely to respond to a specific form or
combination of systemic adjuvant (or neoadjuvant) therapy. It is outwith the remit of
this thesis to discuss prognostic factors in great detail but several of the classical
factors may also be predictive for response to primary systemic therapy. It is possible
to classify prognostic factors into three broad groups: i) patient characteristics; ii)
tumour characteristics; and iii) response to therapy.
i) Patient age at presentation is an established prognostic indicator and has been
described previously. Other factors which may be important include menopausal
status, ethnic origin, geographical origin, intercurrent disease, obesity and diet.
ii) Tumour characteristics include the nearly universal TNM staging upon which
selection of individual patients for particular therapies is usually based.This
classification takes into account tumour size (T), axillaiy nodal status (N) and the
presence of detectable, distant metastases (M). For primaiy breast cancer, with no
evidence of distant metastatic deposits, axillary node status is often the deciding factor
in prescription of systemic adjuvant therapy because of the relatively poor survival of
patients with lymph node positive disease. However 30% of patients with lymph node
negative disease will still relapse (McGuire, 1992), indicating the heterogenous nature
even of subgroups of disease, and it is this group particularly which has generated so
much work investigating additional prognostic factors (Table 5.1). Other tumour
characteristics can be divided into: a) histopathological, including histological type and
grade (Aaltomaa, 1992a); b) biological, including the widespread use of the oestrogen
receptor as a marker of differentiation and good prognosis (Desforges, 1992) as well
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as a predictive indicator for response to hormone therapy (Hawkins, 1980), and can be
further classified as shown below (Table 5.1); c) genetic alterations, including
possession of the proposed gene responsible for a subpopulation of breast and ovarian
carcinomas that are clearly familial, BRCA 1 (Miki, 1994).
McGuire et al. (1990) have formulated a useful overview of certain prognostic
indicators that are based on tumour characteristics. A critical appraisal is made of the
evidence for individual and combined prognostic factors and then a framework is
provided for using this information directly to make treatment decisions. With a
plethora of proposed prognostic markers, McGuire et al. offer sound advice as to the
criteria that must be fulfilled for such markers to be useful in clinical practice,
iii) Direct assessment of tumour response to treatment by primary systemic therapy
may be prognostic of overall survival (Bonadonna, 1993; Rodier, 1993) and thus
select patient subgroups according to response. Those who, for example, have
demonstrated a poor clinical response may benefit from more intensive therapy such as
high dose chemotherapy with autologous bone marrow transplant or an additional
treatment modality such as radiotherapy. Response can also be monitored at a cellular
level, and clinical studies such as those conducted in Edinburgh and described above
allow tumour tissue to be assessed for a variety of markers before, after and during
treatment. Potentially, patients may then be further subgrouped according to a
combination of clinical and biological responses and selected for additional or
alternative therapies as required.
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Adapted from (Gasparini, 1993)
5.2 Predictive Indicators of Chemoresponsiveness
At present there are no factors in clinical use able to predict accurately for response to
systemic chemotherapy. This may, in part, be due to the relatively few reported trials
of primary therapy and also to the relatively small patient numbers within those trials
from whom to draw meaningful data. Two early trials reported some conflicting
results with respect to the correlation of response with the classical clinical prognostic
indicators such as age, menopausal status, tumour size, histological grade and
oestrogen receptor status. An Italian study found the degree of response to be
inversely proportional to the initial tumour size and an increased frequency of response
in oestrogen receptor negative tumours (Bonadonna, 1990). A French study found a
similar relationship with initial tumour size but also found positive correlations with
histological grade and age, the incidence of complete regression being higher in less
differentiated tumours and in older patients (Jacquillat, 1990). The DNA content, or
ploidy, of cells in a particular tumour has been proposed as both a prognostic and
predictive factor. Aneuploid tumours have been reported to have a worse overall
prognosis although in most studies this does not reach independent significance in
multivariate analyses of prognostic indicators (Fisher, 1991a; Stanton, 1992).
Aneuploid tumours may, however, be more likely to respond to chemotherapy
initially, primarily due to an increased rate of proliferation when compared to diploid
tumours (Dawson, 1990; Gnant, 1992). In the neoadjuvant setting, Briffod et al.
(Briffod, 1989) confirmed this, but Bonadonna et al. (Bonadonna, 1990) found ploidy
to be of no predictive significance.
Most chemotherapeutic agents exert their effects on proliferating cells and one might
therefore expect that tumours with a high proportion of cells in the proliferative phase
of the cell cycle would demonstrate the best response. Several studies have shown this
to be the case (Remvikos, 1993b; Spyratos, 1992). Remvikos et al. also showed a
very poor prognosis (after 45 months follow-up) for patients with high S-phase
fractions, measured prior to neoadjuvant chemotherapy, who failed to respond. In
those patients who did respond pre-treatment S-phase fraction did not appear to affect
their long-term outcome. However, the value of S-phase measurement remains the
subject of ongoing debate particularly concerning its use as a prognostic indicator and
despite an enormous number of studies, with large numbers of patients, opinions are
divided. It is likely to be more useful in the short term prediction of response to
treatment. The physical determination of the proportion of cells in the "S-phase
section" of a cell cycle histogram also presents problems both in mathematical
analysis, particularly in aneuploid tumours, and because cells that have arrested in S-
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phase cannot be distinguished from normal cycling cells. To overcome the latter
problem more dynamic methods of estimating proliferation have been developed
including the use of 5-bromo-2-deoxyuridine (BrdU) labelling. This thymidine
analogue can be incorporated into tumour cells actively synthesising DNA during S-
phase either in vitro or in vivo and visualised with a flourescence-labelled monoclonal
antibody by flow cytometry. Very few studies have related BrdU labelling to
therapeutic response but one has shown a predictive power similar to that of S-phase
(Remvikos, 1993c). A principal intracellular target for anthracyclines has been shown
to be the enzyme topoisomerase II, a nuclear enzyme that alters DNA conformation
through breaking and rejoining both strands of the DNA backbone (Tewey, 1984).
Low levels of this enzyme in a variety of malignant cell lines has been correlated with a
relatively poor response to adriamycin (Kim, 1992; Deffie, 1989). Interestingly the
gene encoding topoisomerase Ila lies on chromosome 17q close to c-erbB-2, the
expression of which has also been proposed to predict for chemosensitivity in some
studies (Gasparini, 1993), and indeed, co-amplificaton has been demonstrated in
breast cancer biopsy specimens (Keith, 1993).
For a systemically administered cytotoxic agent to be effective it must obviously reach
the target compartment of the tumour cell in suficient concentrations. An interesting
small study has attempted to relate survival following a modified form of primary
systemic chemotherapy to tumour vascularity as determined histologically (Protopapa,
1993). For the 26 patients studied those with a lower degree of vascularization had a
shorter overall survival with a possible explanation of reduced drug penetration. A
non-invasive estimate of tumour vascularity may be possible through assessment of
tumour blood flow by colour flow doppler ultrasound scanning and it would be of
interest to test the predictive value of this relatively new technique. One of the most
significant predictive indices of chemosensitivity or resistance to emerge in recent
years, although still not widely accepted in clinical practice, is the presence of the mdr
-1 gene product, the 170-kDa membrane P -glycoprotein. The presence of this protein
has been associated with not only decreased intracellular accumulation of a variety of
cytotoxic agents , but also altered intracellular distribution with decreased intranuclear
concentration relative to cytoplasmic levels (Schuurhuis, 1993). There is clinical
evidence that the expression of P - glycoprotein can predict for poor response to
systemic chemotherapy in locally advanced disease (Ro, 1990). Indeed, with in vitro
evidence that the activity of P - glycoprotein can be inhibited by several substances,
attempts have been made to improve clinical outcomes by combining anthracycline
based regimes with agents such as verapamil, cyclosporine, tamoxifen and quinidine.
Most of these studies have been non-randomised but one placebo-controlled
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randomised trial failed to show any influence on response rate or survival in patients
with breast cancer treated with epirubicin plus quinidine (Wishart, 1994). As yet there
are no reports of its use in the prediction of response to neoadjuvant therapy. Although
the majority of tumours exhibiting the MDR phenotype express P -glycoprotein, there
are a subgroup which do not and additional efflux pump mechanisms have been
proposed. Enzymes such as the glutathione transferases, which detoxify oxygen free
radicals generated by cytotoxics such as adriamycin, have also been reported to be
present in higher levels in MDR cells (Batist, 1986) and their overexpression has been
proposed as a further predictive factor of chemoresistance. It is likely that there are a
variety of possible resistance mechanisms confering the MDR phenotype but at present
the most common marker, P -glycoprotein, deserves further clinical testing of its
predictive power as a marker of chemoresistance.
Other potential indicators of chemosensitivity include the expression of heat shock
protein (Ciocca, 1992) and the epidermal growth factor receptor (EGF-R) (Gasparini,
1993). Interestingly, adriamycin has been shown to up-regulate the expression of
EGF-R in a human tumour cell line. If this line is grown as xenografts in nude mice
the combination of adriamycin and anti - EGF-R antibody therapy appears to be
"profoundly synergistic" (Surbone, 1993).
It should be remembered that all these potential predictors of response to
chemotherapy, have been investigated, almost exclusively, with respect to the primary
tumour. Apart from the neoadjuvant setting when systemic therapy may be given to
allow surgical conservation of the breast, the principal reason for treatment is the
potential presence of micrometatsatic disease. It is obviously impossible to examine
effects of treatment on micrometastases and only relatively few studies have compared
primary tumour characteristics and response to that of axillary node metastases. Few
parameters have been examined but in one study a significant relationship between
proliferation, as measured by BrdU uptake, in both primary and nodal disease has
been reported (Goodson, 1993). The correlation was not influenced by age, level of
hormone receptors, tumour size or number of positive nodes. However, not only may
the micometastatic lesions have different biological characteristics but their local
environment is likely to differ considerably from that of the primary tumour and this
may have important implications for drug penetration.
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5.3 Markers of Hormone Responsiveness
The literature concerning potential markers of responsiveness to hormonal therapy is
far more extensive than that concerning chemotherapy. As with cytotoxic therapy none
of the classical clinical prognostic factors (ie tumour size, lymph node status or
histological type) appear to predict for sensitivity to hormonal therapy. At a cellular
level, reports are varied but tend to suggest that tumour ploidy does not predict for
response (Robertson, 1991; Skoog, 1991). In one study, however, locally advanced
tetraploid tumours were reported to be particularly sensitive to tamoxifen therapy
(Baildam, 1986). Cell proliferation, as determined by in vitro 3H-thymidine labeling,
has been related to the response to tamoxifen in a study of 52 patients with advanced,
oestrogen receptor positive breast cancer (Paradiso, 1988). A response was achieved
in 88% of "fast proliferating" tumours but only in 46% of "slow proliferating"
tumours, although the time taken for a response to become evident was longer in the
former group. However, in another study, with similar numbers of patients and using
the same technique to measure proliferation, the opposite conclusion was reached
(Amadori, 1993).
The major predictive indicator of hormone responsiveness has been the presence of
oestrogen receptors through which the response to antioestrogen therapy appears to be
primarily mediated (McGuire, 1975). Measurement of these receptors is routinely
undertaken by most specialist clinical centres by one of three methods. The dextran-
coated charcoal (DCC) technique originally introduced in 1970 (Korenman, 1970) is
being superceded by the simpler enzyme immunoassay (ER-EIA), for biopsy material,
and the immunocytochemical assay (ER-ICA) which can be performed on material
obtained from tumour fine needle aspirates. All techniques have been shown to
produce results which predict for response to tamoxifen therapy, with 50-60% of
receptor positive tumours responding in the short term. However, although there is a
high relapse rate ER-ICA has also been shown to be an accurate predictor of response
in the long term, when compared to clinical assessment of response over the first three
to six months of treatment (Gaskell, 1992). Although oestrogen receptor level is a
relatively good predictor of qualitative response to antioestrogen therapy there has been
little work to determine the relationship to quantitative response. This could be
particularly important in the neoadjuvant setting if an estimate of the likelihood of
avoiding mastectomy were required. In an attempt to improve the predictive value of
oestrogen receptors various other markers have been proposed. The presence of
progesterone receptors in addition to oestrogen receptors has been reported to predict
for response in 75-80% of patients (Thorpe, 1988) and independently to predict for
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time to treatment failure in patients with metastatic disease (Ravdin, 1992). The
expression of the progesterone receptor is under oestrogen regulation (Horwitz, 1978)
and its presence may indicate the possession of fully functional oestrogen receptor
apparatus by the tumour cell, which in turn influences susceptibility to antioestrogens
working via the oestrogen receptor. Tamoxifen has been shown to induce the
expression of progesterone receptors through an oestrogenic effect on the oestrogen
receptor (Horwitz, 1978) and a small study has shown a positive correlation of short
term induction of receptors (over a mean of 13 days) with subsequent clinical response
(Howell, 1987).The changes over a longer period of therapy may be somewhat
different and there is some evidence that oestrogenic induction might be a very early
effect (over days) and antiestrogenic inhibition occurs as a later (over weeks) effect
of tamoxifen (Noguchi, 1988). Since the possession of both steroid receptors is still
not wholly predictive of response to hormonal therapy, other oestrogen inducible
genes, and their protein products, may contribute as markers of intact and functional
oestrogen receptors. Principal among these has been the pS2 gene.
pS2 mRNA was first identified by differential screening of a complementary DNA
library derived from the oestrogen responsive, human breast cancer cell line, MCF-7
grown in the presence and absence of oestrogen (Masiakowski, 1982). pS2 mRNA
has since been demonstrated in various oestrogen responsive, human breast cancer cell
lines including ZR 75 and T47D but has not been found in non responsive lines (May,
1988). A summary of ten large studies examining the incidence of pS2 in clinical
material, by mRNA detection and immunocytochemistry for the protein product,
showed pS2 expression in 57% of oestrogen receptor positive tumours (Pichon,
1993). Interestingly pS2 was also found in 17% of oestrogen receptor negative
tumours but the studies summarised displayed a wide range of 0 to 39%. More recent
investigations have concluded that with accurate measurement, particularly of the
oestrogen receptor, receptors can be detected in only 2-5% of pS2 negative tumours
(Koemer, 1992). The gene has been sequenced (Jakowlew, 1984) and codes for an 84
amino acid-long, cysteine rich, secretory protein found, intracellularly, predominantly
in the golgi apparatus. The protein is, as yet, of unknown function, but has features
similar to several small protein growth factors such as IGF-1 and also close homology
to porcine pancreatic spasmolytic polypeptide (Baker, 1988) which has been reported
to have growth stimulatory effects on cell cultures (Hoosein, 1989). However,
experiments with pS2-specific antisense oligonucleotide have demonstrated that in
breast cancer cell lines which express pS2, it is not essential for cell growth (Shiu,
1993). pS2 has been detected in a variety of normal tissues, including breast (Piggot,
1991), and tumours other than of the breast, principally of the gastrointestinal system
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but also the ovary and endometrium (Henry, 1991a). The presence of pS2 in
moderately high levels in normal stomach epithelium, which is oestrogen receptor
negative, is suggestive of alternative mechanisms of control of expression other than
via the oestrogen receptor (Rio, 1988). Indeed, although the gene is flanked by
oestrogen responsive elements, the elements responsive to epidermal growth factor are
also closely assosocated (Nunez, 1989). Induction by epidermal growth factor has
been proposed as a possible control mechanism in oestrogen receptor negative breast
tumours, particularly as these tend to express epidermal growth factor receptors
(Foekens, 1991). However, it is likely that in breast tumours the gene is almost
entirely under hormonal control as evidenced by the relatively low rates of expression
in oestrogen receptor negative tumours. The potential usefulness of pS2 as an
additional predictive factor for response to endocrine therapy comes largely from the
suggestion that although under oestrogen control it appears to be regulated via a
different mechanism to that controlling the expression of progesterone receptors (Rio,
1987). Indeed, pS2 appears to be of prognostic value particularly in the subgroup of
oestrogen and progesterone positive tumours, perhaps indicating a better degree of
differentiation with a more completely biologically active oestrogen receptor system
(Foekens, 1990). Reports on the clinical value of pS2 expression with respect to the
prediction of response to antioestrogen therapy are varied. One large study has
examined the relationship between expression of pS2 and the "response" to adjuvant
post operative tamoxifen therapy and found it to be more predictive than either
oestrogen or progesterone receptors (Predine, 1992), while others found no
improvement over steroid receptors (Luqmani, 1993). It is likely, in the adjuvant
setting, that survival and effectiveness of tamoxifen may relate to each markers, with
those tumours expressing all three belonging to the best prognostic group. Two
studies have shown that pS2 expression in the primary tumour may define a subset of
oestrogen receptor positive tumours that on relapse are more likely to respond to
tamoxifen (Henry, 1991b; Schwartz, 1991). Studies of pS2 and the response to
primaiy tamoxifen are few and have tended to correlate the expression after primary
tamoxifen therapy with the prior response rather than testing it as a predictor of
subsequent response to treatment (Hemy, 1989). In cell lines, under certain
conditions, tamoxifen and its metabolites have been reported to induce pS2 expression
(Johnson, 1989), and if this phenomenon also occurs in vivo one cannot assume
post-treatment expression reflects the situation pre-treatment. In contrast to the case
with progesterone receptors there is no evidence relating the effect of tamoxifen on
pS2 expression in vivo with the clinical response achieved. In summary, the role of
pS2 as a predictive factor in primary antioestrogen therapy of operable tumours
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remains to be defined.
Other oestrogen regulated proteins have been proposed as prognostic factors in breast
cancer, most notably cathepsin-D. Tumour expression of this precursor of a lysosomal
protease does not, however, appear to predict for response to hormonal therapy (Klijn,
1992).
Growth factor receptors and principally the epidermal growth factor receptor (EGF-R)
have been studied extensively as both prognostic and predictive factors. EGF-R has
been shown to be present in approximately 48% of clinical breast tumours (Foekens,
1991), with an inverse correlation with the presence of oestrogen receptors
(Sainsbury, 1985). The receptor belongs to the c-erb group and mediates the
mitogenic effects of epidermal growth factor and also, perhaps more importantly,
TGFa (Derynk, 1986). A significant relationship between EGF-R expression and a high
rate of tumour cell proliferation has been noted in clinical breast tumour samples
(Nicholson, 1993). The expression of the receptor may well represent the progression of
a cell towards oestrogen independence with the ability to respond to autocrine growth
factors. Cell line experiments have demonstrated a decline in the expression of
oestrogen receptors and an increase in EGF-R as cells become hormone independent
and vice versa as cells regain hormone sensitivity (Long, 1992). Similar events have
been proposed to occur in vivo with a large proportion of tumours relapsing on
tamoxifen found to express EGF-R. Expression of EGF-R prior to treatment in locally
advanced or metastatic disease has also been shown to be a negative predictive factor
for response to primaiy therapy with antioestrogens (Nicholson, 1993).
Other predictive factors have been proposed including the c-erbB-2 proto-oncogene
discussed in the next chapter. However, the same argument holds as to that for
prediction of response to chemotherapy, namely that a presumption is made, when
considering systemic endocrine therapy for primaiy diseaese that occult
micrometastases will have similar characteristics to the primary tumour. Evidence from
studies of macroscopic lesions suggest that at least with respect to the expression of
steroid receptors this may not be the case (Mori, 1991).
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Chapter 6 : Oncogenes and Breast Cancer
6.1 Introduction
Oncogenes are dominantly acting genes which promote cell transformation. The
precursors of oncogenes, protooncogenes such as c-erbB-2, have a normal cellular
function regulating proliferation and differentiation. With inappropriate activation or
expression, these (proto)oncogenes can promote cell transformation usually with
excessive, uncontrolled, cell proliferation. The mechanisms underlying such
alterations in protooncogene function include gene amplification, overexpression of the
gene product or altered function of the gene product as a result of mutation or
translocation. A second class of genes also frequently found in mutated form in
neoplastic cells are the tumour suppressor genes such as p53. This class of genes
performs essential roles in control of the cell cycle and their loss of function by
mutation or allelic loss results in transformation through cell cycle dysregulation.
Studies of oncogenes and tumour suppresor genes in breast cancer, particularly in
relation to response to systemic therapy, are few and mostly report evidence
concerning c-erbB-2, p53 and more recently c-myc.
6.2 c-erbB-2
The c-erbB-2, HER-2 or neu proto-oncogene was initially described in neonatal rat
neuroblastoma , and has since been shown to induce mammary tumours in transgenic
mice by a single step process (Muller, 1988). The different terms used to describe this
gene are some what interchangeable, neu referring to the original rat gene and c-erbB-
2 and HER-2 reflecting different methods of cloning the human homologue. The gene
codes for a 185 kDa transmembrane glycoprotein (pi85) which shares homology,
particularly in the intacellular domain, with EGF-R. A recent review found c-erbB-2
gene amplification in 22% of 5941 patients with breast cancer involved in 39 studies
and pi85 overexpression in 22% of 10074 cases in 44 studies (Dawkins, 1993). The
external domain of the pi85 protein has structural similarities to growth factor
receptors, and recently several possible ligands have been identified which appear to
be quite distinct from the ligands for EGF-R. Stimulation of the receptors with these
ligands appears to induce a variety of responses including proliferation and
differentiation (Tripathy, 1994). Unlike the situation with the presence EGF-R, there
appears to be no, or only a weak, correlation of c-erbB-2 expression and a high
proliferative rate as measured by various indices including Ki-Sl, the proliferation-
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associated nuclear antigen (Kreipe, 1993). Interestingly several studies have confirmed
this finding in invasive carcinomas but have shown a strong positive correlation
between proliferation and c-erbB-2 expression in ductal carcinoma in situ (O'Reilly,
1991; Poller, 1991). One study has also shown a positive relationship between the two
indices in oestrogen receptor positive but not in oestrogen receptor negative disease
(Borg, 1990). There have been many reports on the use of c-erbB-2 as a prognostic
indicator with differing conclusions. Particular problems in interpreting these studies
include the relatively small percentage of tumours with evidence of gene activation and
the varying methodologies used to evaluate gene amplification, mRNA transcription or
oncoprotein expression. Also the observed increased expression in in situ disease,
with over 70% of lesions showing positivity, suggests that the prognostic significance
may be different for different stages of the disease (Allred, 1992a). Most studies do
agree that detection of gene amplification/overexpression or especially the pi85
oncoprotein does imply a poorer prognosis in a subset of patients with axillary node
positive disease (Toikkanen, 1992). The presence of the marker is however not
independently highly significant for poor prognosis and these patients are all likely to
receive adjuvant therapy as a result of their nodal status. The results of studies in node-
negative patients are unfortunately much more conflicting, this being the group of
patients for whom indicators of poor prognosis and the need for adjuvant therapy are
particularly needed. The expression of c-erbB-2 may aid in particular subsets of this
population and indeed appears to predict for poor outcome in patients with small,
oestrogen receptor positive, node-negative tumours (Allred, 1992b).
There are few studies examining the use of c-erbB-2 expression as a predictor for
response to systemic therapy. The implication of the poor clinical outcome of patients
receiving postoperative adjuvant chemotherapy for tumours overexpressing c-erbB-2
(both node-positve and -negative) has been that the gene confers a degree of
chemoresistance (Gusterson, 1992; Allred, 1992b).Furthermore antibodies directed
against c-erbB-2 receptor protein can enhance the cytotoxicity of adriamycin (Tripathy,
1994). However, data from a study of the effects of adriamycin on an MCF-7 cell line
transfected with c-erbB-2 gene could demonstrate no decrease in sensitivity (Benz,
1992). Interest in the situation regarding the response to hormone therapy has been
heightened by reports of an element of oestrogen control in the expression of c-erbB-
2, with oestrogens inhibiting expression in vitro at both mRNA and protein levels
(Dati, 1990). Conversely tamoxifen has been shown to increase the expression of c-
erbB-2 at both these levels in oestrogen responsive cell lines in vitro (Antoniotti,
1992). This effect was not found in hormone independent breast cancer cell lines
suggesting the effect of tamoxifen is mediated by the oestrogen receptor. There is no
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evidence, at present, of similar effects in vivo , although one study has shown a
decrease in c-erbB-2 expression with tamoxifen therapy but predominantly in
oestrogen receptor negative tumours (Le Roy, 1991). Indeed, most clinical studies
have found an inverse relationship between c-erbB-2 and oestrogen receptor
expression (Todd, 1992).The study of a c-erbB-2 transfected, hormone sensitive, cell
line demonstrated the induction of tamoxifen resistance, but retention of oestrogen
dependence, both in cell cultures in vitro, and in xenografts in vivo (Benz, 1992).
The role of c-erbB-2 in the prediction of clinical response to antioestrogens is still a
subject of debate, with some studies suggesting that overexpression of the gene
predicts for therapeutic resistance (Wright, 1992), while others have found no, or only
a weak correlation with response (Skoog, 1992; Nicholson, 1993). It may be difficult
to interpret these contrasting results since the first study looked at response in
advanced and recurrent carcinoma whilst the others comprised elderly patients treated
with primary tamoxifen. Nicholson's study also looked at the relationship between
EGF-R and c-erbB-2 oncoprotein expression and the response to tamoxifen. Whilst
high levels of EGF-R alone predicted lack of response to tamoxifen, in tumours
expressing moderate levels, coexpression of c-erbB-2 improved predictive value of
tamoxifen resistance.The combined expression of these related receptor proteins also
appears to select patients who have a particularly poor overall prognosis (Osaki,
1992).
In the light of the evidence presented it might be possible to suggest that c-erbB-2
activation may be particularly significant in oestogen receptor positive disease in which
it demonstrates a breakdown in the normal oestrogen mediated suppression of gene
expression. This breakdown of hormonal control may be important in the development
of antioestrogen resistance. In a similar fashion to EGF-R, c-erbB-2 may then mediate
signals resulting in increased cellular proliferation with the effects of the two markers
being additive in the small subset of tumours in which they are coexpressed. Other
markers have been looked at in conjunction with c-erbB-2 in an attempt to improve
both the understanding of its mechanism of action and its prognostic and predictive
value. Such markers include the tumour suppressor gene p53, the protein




The p53 gene protein is a nuclear phosphoprotein originally identfled in extracts of
transformed cells reacting with antiserum from animals innoculated with tumour cell
lines transformed by simian vims 40 (Lane, 1979). The p53 protein is thought to act,
in all normal cells, as a negative regulator of the cell cycle, inhibiting progression of
cells from the Gi to the S-phase of the cycle (Levine, 1991). It is therefore the loss of
function, through a variety of mutations of the gene, which is the tumorigenic step.
Indeed, transfection of the "wild-type" p53 gene into the T47D breast carcinoma cell
line, known to contain a mutant p53 gene, has been shown to lead to a failure of cell
growth (Casey, 1991). p53 mutations appear to be the most common genetic alteratons
in all human cancers. The gene has been postulated as the target for various
environmental carcinogens/mutagens such as aflatoxin and hepatitis B vims in
hepatocellular carcinoma, UV light in skin cancers, and tobacco and alcohol in lung
and oesophageal cancers (Coles, 1992). The gene has been localised to the short arm
of chromosome 17 and allelic loss in this area has been noted in appproximately 60%
of unselected breast cancers (Mackay, 1988). The abnormal p53 protein produced as a
result of genetic mutation is more stable than the wild-type protein, having a much
longer half-life. This allows detection of the mutant protein by immunohistochemistry,
a technique very difficult to employ in detecting the very short-lived wild-type protein.
However, there is some evidence that altered or abnormal p53 protein degradation may
allow wild-type protein to be detected in some circumstances (Wynford-Thomas,
1992). Immunohistochemical studies have shown nuclear p53 protein (as detected by
the pAbl801 antibody which detects mutant and wild-type p53 protein) to be present
in approximately 40-50% of breast cancers (Silvestrini, 1993; Bosari, 1992; Poller,
1992). Attempts to correlate p53 expression with other histopathological indices have
produced varying results. Most studies have shown a positive correlation with
increasing histological grade (Lipponen, 1993b) and a negative correlation with the
expression of oestrogen receptors. In view of the proposed mechanism of
tumorigenesis resulting from loss of p53 function, a relationship between the detection
of p53 protein and cell proliferation would be expected. A positive correlation between
proliferation, as measured by both flow cytometric S-phase fraction and expression of
the proliferation associated antigen Ki67, and abnormal p53 expression has been
demonstrated (Lipponen, 1993a; Allred, 1993).
The role of p53 as an independent prognostic or predictive factor remains under
discussion. Some authors demonstrate independent prognostic value for decreased
relapse-free and overall survival (Elledge, 1993) whilst others have found no
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independent value when S-phase fraction is included in multivariate analysis (Isola,
1992). There is very little evidence of the place of p53 in prediction of tumour
response to systemic therapy. It might be postulated that if p53 in normal cells is
associated with close regulation of the cell cycle allowing time for DNA repair, should
damage or mistakes in synthesis occur, response to DNA damaging cytotoxic agents
would be enhanced. An effect exacerbated by the increased proliferative rate associated
with abnormal p53 expression. Few data are available to test this hypothesis, but one
small study has shown no correlation of abnormal p53 expression, in 15 primary
tumours, with the response of respective recurrent disease to an adriamycin containing
chemotherapy regimen (Cantwell, 1992). With respect to the prediction of
chemoresistance it has been shown that expression of the mdr -1 gene may be
associated with some p53 mutations (Chin, 1992). Furthermore, there is evidence that
wild-type p53 represses the P -glycoprotein gene promoter, whilst mutant forms
enhance its activity (Zastawny, 1993). There appears to be no data relating p53 to
hormone therapy other than the inverse correlation with the expression of oestrogen
receptors.
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Chapter 7 : Clinical and Laboratory Techniques Emnloved in the
Prediction and Assessment of Tumour Response
7.1 Fine Needle Aspiration
The technique of fine needle aspiration to obtain material from tumours for cytological
examination was introduced in the 1930's but it was not until the 1950's that the
practice became widely accepted (Lever, 1985). By 1968 a Swedish group were able
to confirm the clinical diagnostic value of the technique by reporting on 3,479
consecutive aspirations from breast masses (Franzen, 1968). Fine needle aspiration
cytology was introduced into the Edinburgh Breast Clinic in 1977. One of the
important findings of reviews of early experience in Edinburgh was the importance of
a single operator in producing diagnostic sensitivity of 99 per cent with a specificity of
95 per cent (Dixon, 1984a). This advice has been followed in the work reported in this
thesis with all aspirates (other than those performed intra-operatively) performed by
the author after gaining experience as the sole "aspirator" in the new patient breast
clinics. The technique used also followed the established method in Edinburgh.
Fine needle aspiration is uncomfortable for the patient, but usually not unduly painful,
and has few side effects, with the most frequent being local bruising and occasional
haematoma formation. The possibility of local needle track seeding of tumour cells or
even of distal dissemination via blood or lymphatics has been raised periodically since
the introduction of the technique. An early American study, however, could find no
difference in overall 15 year survival rates between groups of patients who had fine
needle aspirations of their breast tumours and those who did not (Berg, 1962).
Although fine needle aspiration remains predominantly a diagnostic tool, its potential
in providing material for immunocytochemical, and more recently flow cytometric
analysis has been recognised. It is particularly suitable for monitoring cellular changes
during treatment as sequential aspirations can be performed with a minimum of
disturbance to the tumour. A problem with serial aspirations of the same tumour is,
however, the potential for intra-tumoural heterogeneity and a resulting difficulty in
making comparisons of, for example, antigen expression or cell proliferation (Mullen,
1989). The chances of such a problem can be reduced by passage of the needle
through different quadrants of the tumour during aspiration.
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7.2 Flow Cytometry
Flow cytometry is potentially the ideal technique for analysing the small amount of
material obtained by fine needle aspiration. Flow cytometers were initially developed
in the 1960's principally for the analysis of peripheral blood samples. The instrument
allows rapid and precise analysis of many thousands of individual cells, processed one
by one, in only a few seconds. By laser excitation of fluorochrome-labelled
monoclonal antibody and detection of resultant fluorescence a quantitive estimation of
bound antibody and thus antigen expression can be made. With an extensive range of
monoclonal antibodies against leucocyte antigens now available, haematology
departments tend to rely heavily on this technology. The application of the technique to
the analysis of solid tumours depended on the development of reliable methods of
tissue disaggregation and preparation of single cell suspensions. Although analysis of
membrane-bound, cytoplasmic and nuclear antigens has been made possible with the
development of the appropriate monoclonal antibodies, it has been the analysis of
DNA content and cell cycle kinetic parameters that has been most reported. DNA-
specific fluorochromes, such as propidium iodide, are made to fluoresce during
passage of cells through the flow cytometer. The resulting level of fluorescence
recorded for each cell is a measure of its DNA content. Cells in the Go/1-phase of the
cycle have a constant DNA content and form a peak in the cell cycle DNA distribution.
Cells in the G2/M-phase also have constant DNA content but twice that of the Go/i-
phase and form a second peak in the distribution histogram. S-phase cells are
undergoing accumulation of new DNA and form a continuum between the two peaks
of the histogram (Fig 10.1). Proportions of cells within each of the regions of the
histogram can then be calculated. A much debated limitation of such single-parameter
DNA analysis of tumour cell populations is the inability to distinguish diploid tumour
cells from normal infiltrating leukocytes or stromal cells. Aneuploid tumour cells by
definition have an abnormal DNA content and can be identifiedby the appearance of a
seperate set of peaks from those produced by normal cells.
Developments in flow cytometers now allow detection of fluorescence in two or three
wavelength bands simultaneously. Therefore, labelling different monoclonal
antibodies with different fluorochromes potentially allows the expression of two or
three antigens to be measured simultaneously on the same cell. This may not only
allow identification and exclusion of normal cells from diploid tumour DNA analyses
but also enables the relationships between the expression of different antigens on
individual cells to be studied. It also increases the number of analyses that can be
performed on small amounts of tissue, such as that obtained from fine needle
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aspiration. Flow cytometry, however, at present remains purely a research tool in
study of solid tumours, with its obvious potential not yet fully realised.
7.3 Immunohistochemistry
The technique of immunohistochemistry is now firmly established as both a diagnostic
and research tool. In common with flow cytometery it has relied upon advances in
monoclonal antibody technology with the basic methods being unchanged since its
inception. There have, however, been some refinements in methodology principally
directed at the improved exposure of particular antigens to the antibodies. These
include the treatment of fixed tissue sections with both a variety of enzymes and, more
recently, microwave heating.
The great advantage of immunohistochemical techniques over, for example, flow
cytometry, is the preservation of tissue architecture allowing spatial localisation of
antigen expression as well as an idea of the hetero/homogeneity of expression within
the sample taken. The disadvantages of the technique, however, include the length of
time taken both in processing and interpreting antibody staining and the difficulty in
producing a reproducible quantative estimate of antigen expression. There is also some
concern over the use, particularly in breast tumours, of one tissue section as
representative of the tumour as a whole.
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7.4 Animal Models
Since the initial observation made in the late 1960's that human colon adenocarcinoma
grew progressively in an athymic mutant strain of mouse (Rygaard, 1969), such
"nude" mice have been frequently used in cancer research. Generally the histological
and biochemical properties of tumours grown as xenografts are said to closely
resemble those of the original tumour specimens (Price, 1990). However, different
types of carcinoma vary in their abilities to grow in nude mice and primary breast
tumours have proved particularly difficult to establish as xenografts, with reported
"take rates" of only 6 - 15% (Mehta, 1993). Although primary tumours have, so far,
proved difficult to grow as xenografts, there are several human breast cancer cell lines,
that have been established by tissue culture techniques, which have proved much
easier to grow as xenografts in the nude mouse. Such cell line xenografts may have
many different properties to primary tumours in the human breast but they will also
share many similarities and may be useful tools in the study of biological therapeutic
mechanisms. As part of the work for this thesis cell line xenografts have been used to
establish methodology before examining the biological responses to systemic therapy
in patients undergoing primary systemic therapy.
Because of the potential problems of working with cell line xenografts more work
continues into improving xenografting techniques for primary breast tumours. Pilot
work performed in the department suggested that coimplantation of a mixture of
Matrigel (itself a mixture of laminin, collagen IV, heparan sulphate, and enactin),
fibroblasts and tumour cells could enhance the take rate of a cell line found to be
particularly difficult to grow as a xenograft (Professor P. Forrest, Personal
Communication). The particular contribution of Matrigel to improved xenograft
growth appears to have been since confirmed with tissue from primary breast tumours
and from a variety of other solid tumours (Mehta, 1993). A reliable method for
establishing individual tumours as xenografts would aid tremendously in tailoring
systemic treatment to particular tumours by providing a therapeutic test-bed.
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Chapter 8 : The Aims of the Thesis
The work leading to the compilation of this thesis set out to characterise the response
of primary breast carcinomas to primary systemic therapy. Monitoring of the
macroscopic response to treatment by the use of serial ultrasound scanning had been
successfully employed within the Edinburgh Breast Unit for assessing response to
chemotherapy and to a lesser extent hormonal therapy. The majority of patients studied
for this thesis were treated, under the protocol for elderly patients, with primary
tamoxifen. This gave an opportunity to characterise macroscopic responses to
tamoxifen by an accurate means of measurement, being data not, so far, reported.
Having an accurate assessment of the macroscopic response to therapy gave an
excellent opportunity to examine the corresponding cellular responses. Such data
would help to identify not only predictive biological factors for response to individual
therapies but also aid understanding of mechanisms of action of, and resistance to,
these treatments.
The philosophy adopted in attempting to examine these biological responses has been
to develop methodologies initially in human breast cancer cell line tissue culture
systems. To then apply some of the the same techniques to material obtained from cell
line xenografts and finally to tumour tissue obtained from patients with breast cancer.
Verifying the applicability of techniques to xenograft material was also important since
a long-term plan to follow on from this work is to develop a reliable method of
xenografting primaiy breast tumour material. If this becomes possible then testing
susceptibility of individual tumours, as xenografts, to a variety of agents would
significantly aid clinical management and, being more accessible, would allow even
closer observation of biological tumour responses to systemic therapy.
The immediate aims of the thesis can therefore be summarised as:
i) to further sharacterise the clinical response to primary systemic therapy of
breast cancer in the setting of two clinical trials,
ii) to determine whether it is possible to identify biological markers in pre-
treatment tumour specimens that predict for subsequent response to therapy,
iii) to determine the effects of treatment on these biological markers and whether
changes relate to the clinical response,
iv) to identify markers of resistance.
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MATERIALS and METHODS
Chapter 9 : Methods
9.1 Patient Recruitment
All patients studied presented to the Edinburgh Breast Unit, situated initially at
Longmore Hospital and latterly at the Western General Hospital in Edinburgh. Patients
were individually counselled after diagnosis and staging investigations were completed
and their suitability for either the "Primary Systemic Therapy" or the "Elderly Patient"
had been discussed by a multidisciplinary clinical team. Informed consent was
obtained from each patient and then those entered into the "Primary Systemic Therapy"
trial were randomised by the Scottish Cancer Trials Office. All clinical follow-up was
performed by the author for the length of the study period. Operative procedures were
performed under the authority of either Mr. U. Chetty or Mr. J.M. Dixon, consultant
surgeons in the Edinburgh Breast Unit.
9.2 Ultrasound Monitoring of Tumour Size
Patients within the Primary Systemic Therapy trial received either three-weekly cycles
of C.A.P. chemotherapy or hormonal therapy with either continuous tamoxifen for
postmenopausal patients or four-weekly LHRH agonist goserelin for premenopausal
patients. Patients were reviewed on a weekly basis to monitor symptoms and perform
ultrasound measurements. Ultrasounds were performed using a Siemens SL1 machine
(Siemens, Tokyo, Japan) with a 7.5-MHz linear array probe. Patients within the
elderly patient trial were seen for review and for tumour ultrasound measurements on a
four-weekly basis.
The probe was held at a right angle to the skin surface and moved over the tumour
until a maximum diameter was visualised. Four measurements were made at 45°
intervals, and the mean diameter and depth of the tumour measured with the machine's
electronic callipers. The tumour volume was calculated using the following formula, a
method recently reported from the Edinburgh Breast Unit (Forhoui, 1994):
Tumour Volume = D2 x d x n
6
(Where "D" = mean of diameters parallel to skin surface and "d" = those taken at 900).
Follow-up serial volumes were expressed as percentages of the initial volume, which
was measured, where possible, after wedge biopsy and certainly prior to
commencement of therapy.
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9.3 Procurement of Tissue Specimens
Tissue was obtained from each patient from the wedge biopsy prior to treatment and
from the mastectomy or wide local excision after primary therapy. With the help of Dr.
T. Anderson and colleagues in the Department of Pathology at the Western General
Hospital, fresh tumour material was obtained after specimen sectioning as soon as
possible after removal from the patient (an average time of approximately 20 minutes).
Tissue was immediately stored and then maintained in liquid nitrogen.
Fine needle aspirates were performed using a 21 gauge needle attached to a 10ml
syringe. Aspirates of the primary tumours in situ were taken before treatment by the
surgeon performing the wedge biopsy, and by the author in the outpatient clinic at
serial time-points during therapy. The same technique was employed to obtain post
treatment samples but from the surgical specimens obtained from mastectomies or
wide local excisions. Aspirates were taken by passage of the needle through four
quadrants of the tumour. The material obtained was divided and expelled either into a
storage medium, containing 10% DMSO in foetal calf serum, before freezing and
storing in liquid nitrogen, or into an incubation mixture for BrdU incorporation (See
section 9.7).
9.4 Preparation of Material from Fine Needle Aspirates
Material obtained from fine needle aspiration was analysed by flow cytometeiy which
requires tissue to be in the form, as much as possible, of a single cell suspension.
Material was thawed slowly to room temperature and washed free of storage medium
with PBS. To obtain a single cell suspension it was usually sufficient to pass the
specimen once through a 23 gauge needle. This was done after a fixation step, in the
preparation for analysis, to minimise cell damage.
9.5 Preparation of Tissue for Immunohistochemistry
Tissue samples from those specimens obtained prior to and after primary therapy and
stored in liquid nitrogen were fixed in 10% formaldehyde. These were then processed
to paraffin blocks by the Edinburgh University Department of Pathology. Sections,
thick, were cut, floated and dried onto plain glass slides. Staining for p53 and
Bcl-2 required microwaving of sections and for these analyses sections were dried
onto lysine-coated slides.
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9.6 Flow Cytometry - DNA Analysis
DNA analyses were performed by flow cytometry using a FACScan cytometer
(Becton Dickinson Immuncytometry Systems, Mountain View, California) with a
488nm argon laser for excitation.. Cells obtained from tissue culture of human breast
cancer cell lines or material obtained from fine needle aspirates of clinical primary
breast tumours were analysed to determine ploidy and cell cycle distribution.
Approximately 2 x 106 cells were fixed in 70% ethanol, washed and then resuspended
in 1ml of PBS. The sample was then stained by the addition 100/d of a .01% solution
of propidium iodide (Sigma) in PBS for 20 minutes in the dark at room temperature.
The samples were then run through the FACScan collecting 10,000 events, at
approximately 75 per second, with CellFIT software (Becton Dickinson). After gating
on forward versus side scatter and red fluorescence area versus width dot plots, DNA
histograms were analysed with the "SPIT" computer model.
Histograms were deemed uninterpretable if the cefficient of variation of tumour Go/Gi
peaks exceeded 5%. In clinical specimens, tumour ploidy was defined as either DNA
diploid in the presence of one Go/Gi peak or aneuploid with two peaks and a ratio of
tumour to non malignant cell Go/Gi peaks (DNA Index) of greater than 1.1. The DNA
diploid peak in an aneuploid histogram is attributed to normal breast cells, non-DNA
aneuploid tumour cell clones, tumour lymphocytes and connective tisue cells. The
tumours were described as DNA tetraploid if the DNA Index was between 1.95 and
2.05, the number of events in the tumour peak greater than 15% of the total histogram
events and a recognisable tumour G2/M was present, and multiploid if several peaks
were seen.
All clinical samples defined as diploid were examined histocytologically, after
cytospins had been made, to confirm the presence of tumour cells.
9.7 Flow Cytometry - BrdU Incorporation
Cells obtained from human breast cancer cell lines grown in tissue culture or as
xenografts in nude mice or from fine needle aspirates of clinical primary breast
tumours were incubated in the presence of BrdU. Cells were suspended in lml of
RPMI growth medium (Gibco) containing 10% foetal calf serum, 30/<mol BrdU and
20/imol Fluorodeoxyuridine (FdU), the latter included to block thymidine kinase
activity allowing maximum integration of BrdU. The mixture was incubated for 20-30
minutes at 370C and then the cells washed and resuspended in RPMI with 10% foetal
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calf serum. The mixture was incubated for a further two hours at 370C and then, after
the addition of 10% DMSO, frozen and stored in liquid nitrogen until analysis.
The detection of incorporated BrdU involved DNA denaturation and application of a
monoclonal antibody. Stored samples (approximately 2 x 106 cells) were thawed and
washed free of DMSO before fixing with 70% ethanol on ice for 30 minutes. To
ensure maximum nuclear yield and clean histograms samples derived from fine needle
aspirates were treated with a solution of pepsin (4mg in O.lmmol HCL) for 45 minutes
at 370C. DNA denaturation was achieved by a 4N HCL / Triton-X mixture for 30
minutes in the dark. After washing in borax (pH8.5) and then a washing solution
comprising PBS, 0.5% Tween-20 and 1% foetal calf serum, 20]A. of FTTC conjugated
anti-BrdU monoclonal antibody (Becton Dickinson) was added for 30 minutes in the
dark. After a further wash, samples were DNA counterstained with propidium iodide
as described above. Samples were then run through the FACScan and both red and
green fluorescent emissions collected for 10,000 events.
9.8 Flow Cytometry - Detection of Ki-67 Antigen
Cell samples were thawed and washed free of storage medium. To approximately
1x106 cells 200/d of "membrane shredding solution" was added for 15 minutes at
room temperature. After washing 15pil of FTTC conjugated monoclonal anti-Ki-67
antibody (Dako) was added for 15 minutes, on ice, in the dark. The samples were then
analysed on the flow cytometer collecting green fluorescent emissions and performing
analysis with LYSIS II software (Becton-Dickinson).
9.9 Flow Cytometry - Detection of Ki-Sl Antigen
Cell samples were thawed and washed free of storage medium. The cells were fixed in
lml of methanol at -20°C for 5 minutes. After washing in detergent-based buffer, anti-
Ki-Sl monoclonal antibody (2.5]i\, Prof. H.Kreipe) was added, and left for 60
minutes at room temperature. After repeat washing in buffer, anti-mouse FTTC (100/d
of 1:20 dilution, Dako) was added for 30 minutes, on ice, in the dark. After a further
wash cells were resuspended in lml of PBS and counterstained for DNA with the
addition of 100pil of propidium iodide. Red and green fluorescent emissions were
collected on the flow cytometer using cellFlT software and analysis was performed
using LYSIS II (Ki-Sl) and cellFIT (DNA) software.
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9.10 Flow Cytometry - Detection of pS2 and c-erbB-2 Gene Products
To maximise the information gathered from the relatively small amount of material
obtained from fine needle aspirates of clinical tumours, cells were dual-stained for pS2
protein and c-erbB-2 protein product. Cell samples were thawed and washed free of
storage medium and fixed in 70% ethanol for 30 minutes on ice. After a wash in
buffer, anti-pS2 antibody (100/d of a 1:5 dilution, Europath Ltd.),was added and left
for 30 minutes on ice. After a further wash, phycoerythrin (PE) conjugated anti-mouse
antibody (100/d of a 1:20 dilution, Dako) was added and again left on ice, in the dark,
for 30 minutes. Cells were then washed in buffer and anti-c-erfeB-2 protein antibody,
pre-conjugated to FITC label, (10/d, Novocastra) was added and left, on ice, in the
dark, for 30 minutes. After a wash in buffer, samples were run through the flow
cytometer collecting and analysing both red (pS2) and green (c-erb B-2) emissions
using LYSIS II software.
9.11 Flow Cytometry - B lymphocyte and Natural Killer Cell Detection
To determine the levels of both B lymphocytes and natural killer cells within fine
needle asptirates samples, these were dual stained with antibodies towards CD19 (B
cell specific) and CD56 (natural killer cell specific) surface antigens. Samples were
thawed and successively washed free of storage medium followed by PBS/5% foetal
calf serum buffer. Anti-CD 56 antibody (10//1, Dako) was added and left for 30
minutes on ice. After a wash, FTTC conjugate (100/d of 1:20 dilution) was added and
left for 30 minutes, on ice, in the dark. After further washing, PE-conjugated anti-
CD19 antibody (10/d, Dako) was added and leftr for 30 minutes, on ice, in the dark.
The samples were run through the flow cytometer with red and green fluorescence
collected and analysed by LYSIS II software. Importantly, cells demonstrating the
typical scatter pattern of lymphocytes were included in the gating process on analysis
(excluded on analysis of tumour cells).
9.12 Flow Cytometry - P -Glycoprotein Detection
Samples were thawed and washed free of storage medium, and then fixed for 5
minutes on ice with 50/50 solution of acetone and methanol. After washing in the
standard detergent based wash buffer, 100/d of mouse monoclonal anti-P -
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glycoprotein antibody, clone JSB-1 (Novocastra), diluted 1:5 was added for 45
minutes on ice. After washing in wash buffer, the samples were fluorescently labelled
with FTTC as described previously.After further washing and resuspension in PBS,
green fluorescent emissions were collected on the flow cytometer and analysed using
LYSIS II software.
9.13 Flow Cytometry - Adriamycin Detection
Several Patients receiving adriamycin therapy as part of the "Primary Systemic
Therapy Trial" underwent fine needle aspiration of their primary tumours prior to
chemotherapy and then again lhour after completion of the intravenous infusion.
These samples were taken at the time of the first and third cycles of chemotherapy.
Stored samples were thawed and washed and resuspended in PBS. Adriamycin is
intrinsically fluorescent, emitting in the red range, and therefore with no need of
further processing, the samples were run through the flow cytometer collecting red
fluorescence. The mean red flourescence of the sample taken prior to adriamycin
infusion, acting as a background control, could then be compared to that taken after
infusion as an estimate of cellular uptake at 1 hour.
9.14 Immunohistochemistry
The methods used to detect a variety of biological markers by immunohistochemistry
were essentially similar, with the exception of thcbcl- 2 and p53 proteins. The standard
method will be described below and antibodies and the dilutions used for individual
markers are listed in table 9.1.
For immunohistochemical assessment of tissue samples taken prior to, and after
treatment, 3pim sections were cut from paraffin embedded tumour blocks. The sections
were de-waxed and then placed in 1% Hydrogen peroxide in methanol to block
endogenous peroxidase activity. For some antibodies (see table 9.1), after washing in
tap water the sections were treated with distilled water containing 0.1% trypsin and
0.1% calcium chloride corrected to pH7.4 for 30 minutes at 370C. After successive
washes in water and tris buffered saline (TBS) the sections were incubated with 20%
foetal calf serum (FCS) to reduce non-specific staining. The sections were then
incubated with the respective monoclonal antibody, diluted with 20%FCS/TBS, for
30 minutes at room temperature. Control sections were maintained on 20% FCS. After
washes in TBS and incubation at room temperature for 20 minutes with biotinylated
rabbit-anti-mouse antibody (Dako) diluted 1:100 in 20%FCS/TBS, staining was
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visualised by a standard avidin-biotin-peroxidase method, originally described by Hsu
et al. (Hsu, 1981). Sections were finally counterstained with haematoxylin.
Immunostaining for both p53 and bcl -2 protein is aided by the use of microwave
heating to improve antigen retrieval. This treatment required that the sections had been
fixed to glass slides using an adhesive, poly-L-lysine. Sections, after dewaxing, were
placed in a citrate buffer and then microwaved for 10 minutes at full power in a
domestic, 800 watt, microwave oven (Shi, 1991). After microwaving sections were
stained as described above.
All sections were scored by an independent single pathologist, with no acess to clinical
information. The percentage of tumour cells staining was noted in 10 low power fields
and averaged. Sections were then given a score of 0 - 3 representing :
0 = 0- 5% of tumour cells staining
1=5- 25%
2 = 25 - 75%
3 = 75 - 100% "
Table 9.1 Antibodies Used in Immunohistochemical Investigations
Antigen Clonality Clone Supplier
Ki-Sl Mono Gift Prof H.Kreipe
pS2 Mono Novocastra
c-erbB-2 Mono CB-11 Novocastra
P- Glycoprotein Poly Novocastra
EGFR Mono EGFR-1 ICRF
Bcl-2 Mono 124 Dako
p53 Mono DO-7 Dako
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9.15 Oestrogen Receptor Assays
Oestrogen receptor levels were measured by two different assays as a routine clinical
service under the direction of Dr.R.A. Hawkins of the Depatment of Surgery, Royal
Infirmary of Edinburgh. ERICAs ( Oestrogen Receptor Immunocytochemical Assays)
were performed on material obtained from diagnostic fine needle aspirates taken prior
to treatment. ELAs (Enzyme Immunoassay) were performed on tissue cytosols of
tumour specimens obtained from wedge biopsies carried out prior to treatment and,
where possible, from specimens obtained at definitive surgery after primary treatment.
9.16 ZR 75.1 Cell Line Xenografts and Treatment with Tamoxifen
The ZR 75.1 human breast cancer cell line, grown as a xenograft was used to monitor
the cellular effects of tamoxifen treatment in vivo . Established xenograft material was
passaged into 18, 8-12 week old, female nude athymic mice (Hsd01a:ICRF-nu,
purchased from Harlan (UK), Bicester , Oxon) by implanting 1mm tumour fragments
subcutaneously into each flank. A pellet of a slow release preparation of oestradiol
(0.72mg, released over 60 days supplied by Innovative Research of America, Ohio,
U.S.A.) was implanted simultaneously. The tumours were allowed to grow for three
to four weeks until at least 5mm in diameter. The mice were divided into three groups
and two mice from each group had tumours removed from one flank under
anaesthesia.This tissue was then frozen and stored in liquid nitrogen. Fine needle
aspirates were taken from a single tumour of each of the remaining mice, the site being
carefully recorded. Tamoxifen pellets (drug released over 60 days and supplied by
Innovative Research of America, Ohio, U.S.A.) were then implanted subcutaneously
in mice belonging to two groups, one group receiving a 5mg pellet, the other 2.5mg.
The third group acted as a control. All tumours were measured in two diameters every
seven days and fine needle aspirates were performed, also at weekly intervals, on
those tumours aspirated prior to treatment. The material obtained by fine needle
aspiration was stored in liquid nitrogen and later analysed by flow cytometry for DNA
content and the expression of Ki-Sl, c-erbB-2 and pS2 as described above.
Measurements and aspirates were taken at twice-weekly and weekly intervals
respectively over a four week period and thereafter the animals were sacrificed and the
tumours removed for storage in liquid nitrogen. Tumour material was then processed
as described above for immunohistochemistry. Staining was performed with
antibodies against Ki-Sl, pS2, c-erbB-2, P - glycoprotein and EGFR.
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9.17 T1068 Xenografts and Treatment with Adriamycin
The primary breast cancer xenograft, T1068, established by Dr. F.Balkwill, was used
to assess the cellular effects of systemic treatment with adriamycin and their detection
by serial fine needle aspiration. Tumour material was passaged by subcutaneous
implantation into the flanks of 18 nude mice.The same procedure as described above
for hormonally manipulated xenografts was employed although no oestrogen pellets
were needed as the T1068 tumour is hormone-independent. The mice were given
adriamycin by intraperitoneal injection at doses of 1 and 2mg/kg in the two treatment
groups at weekly intervals and control mice given injections of isotonic saline. Fine
needle aspirates were taken immediately prior to injection and incubated in BrdU, as
described above.The aspirates were stored and later analysed by flow cytometry for
DNA content and BrdU uptake. Tumours were measured serially as described above,
and all mice were sacrificed after four weeks and the tumour material removed and




Chapter 10 : Cell Line Experiments
Preliminary flow cytometric studies were performed using a variety of established cell
lines to optimise and validate methodology. Secondary objectives were to examine the
relationship between the different parameters assayed and select those likely to be
informative when applied to material derived from fine needle aspirates of primary
tumours.
10.1 Markers of Proliferation
As discussed previously in the introductory section there are several different potential
methods of assessing cells in the process of division. These include estimation of the
nuclear DNA content, the rate of nucleotide (or analogue) incorporation and the levels
of antigens expressed specifically during the proliferative phase of the cell cycle by the
use of monoclonal antibodies. In the present investigations the potential markers of
proliferation that were examined were
a) DNA content and S-phase estimation
b) Incorporation of the thymidine analogue, Bromodeoxyuridine
c) Expression of the nuclear antigens Ki-67 and
d) Ki-Sl
These have been studied in two sets of experiments with established cell lines growing
i) in culture and described below and ii) in immunocompromised animals as reported
in chapter 11. The techniques have then been applied to material obtained by fine
needle aspiration of human primary breast tumours (chapter 12)
Cell lines in culture
A series of cell lines of both benign and malignant derivations and different origins
were studied. They were selected on account of being available, at the time of the
study, in the ICRF Unit of Medical Oncology and are listed in Table 10.1. Cells were
grown in standard plastic tissue culture flasks and harvested by trypsin at various
phases of growth. The growth phase at harvesting was not controlled as the primary
objectives of the experiment were to validate methodologies and compare absolute
values for individual proliferative markers at the same time point for each cell line.
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Table 10.1 Cell Lines Used in Experiments Examining Markers of
Proliferation
Cell Line Tumour Type Derivation
ZR 75.1 Breast Ascites
MCF-7 Breast Pleural effusion
MCF-7 LS Breast LHRH sensitive MCF-7
MDAMB231 Breast Pleural effusion




PEO 6 Ovary Ascites
PEO 14 Ovary Ascites







HT 29 Colon Primary colonic carcinoma
NX002 Lung Squamous carcinoma xenograft
CX 140 Lung Squamous carcinoma xenograft
CX 143 Lung Squamous carcinoma xenograft
Burgen Fibroblast Subcutaneous breast fat
Munro Fibroblast Subcutaneous breast fat
3T3 Mouse Fibroblast Swiss mouse embryo
CHO-KI Hamster Ovary Adult Chinese Hamster
ADR-R Hamster Ovary Exposure to ethyl methane sulfonate
ADR-1 Hamster Ovary Exposure to ethyl methane sulfonate
ADR-3 Hamster Ovary Exposure to ethyl methane sulfonate
ADR-6 Hamster Ovary Exposure to ethyl methane sulfonate
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a) S-phase : This was determined after staining of DNA with propidium iodide as
described in Section 9.6. Figure 10.1 shows a typical DNA histogram obtained with
cells of the ZR 75.1 human breast cancer cell line. The histogram demonstrates two
peaks representing nuclei with single and double compliments of DNA. The peaks
represent accumulations of cells at the Go/Gi phase and the G2/M phases respectively.
Between the peaks lie the cells accumulating DNA in preparation for mitosis, the S-
phase, and a computer generated estimate of this area is shown. A total of 29 different
cell lines were studied which displayed a wide range of values for S-phase fraction as
tabulated in Table 10.2 and shown in Figure 10.2.
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Figure 10.1 DNA Histogram Produced by Cells of the ZR75.1 Human
Breast Cancer Cell Line Growing in Log Phase
I
Car ^ j f\
-—J S- pha*L
200 400 RED FLUORESCENCE 500
Figure 10.1 shows a typical DNA histogram generated in this instance by propidium
iodide staining of the hormone-dependent ZR75.1 human breast cancer cell line. The
cells were grown in an oestrogen-supplemented medium and harvested in log-
phase.The axes display the number of events (ie. cells) plotted against the quantity of
red fluorescence recorded. The different phases of the cell cycle are labelled and a
rectangle is superimposed over the S-phase portion of the histogram. This has been
generated by the RFIT (Rectangular fit) model of the Becton Dickinson cellFIT
software and allows an estimation to be made of the small proportion of cells in the
Gq/Gi and G2/M peaks that are actually in early or late S-phase respectively.
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Table 10.2 S-phase and Bromodeoxyuridine Incorporation as Markers
of Proliferation in 29 Different Cell Lines
Cell Line S-phase (%) BrdU L.I.(%)
ZR 75.1 13.3 13.2
MCF-7 22.0 28.8
MCF-7 LS 33.4 39.8
MDAMB231 26.1 26.6
PEO 1 21.6 29.8
PEO 1R 32.7 21.8
PEO 4 16.9 19.7
PEO 6 13.2 15.3
PEO 14 0.6 0.0













HT 29 23.0 29.4
HBL 100 36.1 48.9
CX 140 30.7 28.7





Table 10.2 shows values obtained for S-phase fraction (%) and BrdU labelling
index (%) in 29 different cell lines. Cells were harvested at random growth phases,
incorporated with BrdU and dual stained with propidium iodide and anti-BrdU
monoclonal antibody before analysis by flow cytometry.
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Figure 10.2 shows the range of values obtained for S-phase fraction obtained from
DNA histograms generated from the flow cytometer after staining 29 different cell
lines with propidium iodide. Each of the cell samples had been dual stained with anti-
BrdU antibody after prior incorporation with BrdU.
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b) BrdU incorporation : Using the method described in Section 9.7 it was possible
to determine a simultaneous estimation of BrdU incorporation and S-phase fraction.
BrdU is incorporated into newly synthesised DNA and can be detected by
fluorescently labelled monoclonal antibody and flow cytometry. A computer generated
dot-histogram (Fig. 10.3), from the analysis of ZR 75.1 cells, shows the typical
horseshoe pattern demonstrating the greatest uptake of BrdU ( intensity of green
fluorescence) at the midpoint of S-phase. Each of the 29 cell lines for which S-phase
data has been presented above were also assessed for BrdU incorporation and the
absolute values for each parameter are shown in Table 10.2. The relationship between
the two indices of proliferation is depicted graphically in Figure 10.4, with there being
a highly significant correlation (p < 0.0001 ). Some of these cell lines were also
assessed for either Ki-67 or Ki-Sl expression to obtain a comparison of BrdU
incorporation and these other indices of proliferation and the results are discussed
below.
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Figure 10.3 Dot Plots Generated by the Flow Cytometer Demonstrating
BrdU Uptake in Relation to the Phase of the Cell Cycle.
BRDU INCORPORATION
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Figure 10.3 shows dot plots of the quantity of green flourescence against red
fluorescence in ZR 75.1 human breast cancer cells incubated previously with BrdU.
The cells have been stained with a) propidium iodide only as a control and b) with both
propidium iodide and fluorescein-conjugated anti-BrdU monoclonal antibody. The
increase in green tluoresence over background levels can be seen to peak in those cells
whose DNA content (red flourescence) places them in mid S-phase. The DNA
histogram, c) is included for reference.
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Figure 10.4 The Relationship Between S-phase Fraction and BrdU
Labelling Index in 29 Cell Lines.
S-phase (%)
Figure 10.4 shows the relationship between flow cytometric S-phase fraction
(expressed as the percentage of cells in S-phase of the cell cycle as computed by the
RFIT model of the cellFIT software) and BrdU labelling index (expressed as the
percentage of cells showing green flourescence above background in samples
incubated with BrdU and stained with FTTC-conjugated anti-BrdU monoclonal
antibody).
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c) Ki-67 expression : Employing the method described in Section 9.8 it was
posible to detect this antigen in cell lines and a typical histogram generated by the flow
cytometer would be identical to that shown in Figure 10.9 in relation to Ki-Sl
expression.
Fourteen of the cell lines described in b) above were also assessed for Ki-67 as a
comparison of the methods of determining the rate of proliferation. Cell samples, after
incorporation with BrdU to ensure identical time points, were split and either dual
stained for BrdU and DNA or for Ki-67 expression. The results are shown in Table
10.3, diagramatically in Figure 10.5, and the relationships between the parameters
graphically depicted in Figures 10.6-8. The correlation between Ki-67 and S-phase
although significant (p = 0.013) was as not as good as that between BrdU
incorporation and S-phase (p = 0.001). Indeed, Figures 10.5 and 10.6 also suggest
that the cell lines can be divided into two groups with "high" and "low" levels of Ki-67
expression and within these two groups the correlation with S-phase is poor.
Furthermore the absolute values for Ki-67 labelling index were higher than those for
S-phase, probably reflecting the long half-life of this protein, and points to a role in
determining general proliferative state (or number of "cycling cells") rather than a value
for the number of cells accumulating new DNA at a particular point in time.
Interestingly the correlation between Ki-67 expression and BrdU incorporation (p =
0.0005) was better than that with S-phase (see Figure 10.7) and also, in this particular
subset of cell lines, better than the correlation between S-phase and BrdU (Figure
10.8). This may illustrate one of the problems with S-phase in that cells that have
arrested with greater than normal amounts of DNA and are no longer cycling or viable
at a particular point in time are included in the estimate of S-phase fraction. In theoiy,
therefore, both BrdU incorporation and Ki-67 expression are possibly a more dynamic
estimation of the cycling population.
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Table 10.3 Cellular Proliferation as Assessed by S-phase, BrdU
Incorporation and Ki-67 Expression in Cell Lines
Cell Line S-phase (%) BrdU L.I.(%) Ki-67 L.I.(%)
MCF-7 22.0 28.8 58.8
MCF-7 LS 33.4 39.8 88.4
MDAMB231 26.1 26.6 72.6
PEO 1 21.6 29.8 81.4
PEO 6 13.2 15.3 7.3
PEO 14 0.6 0.0 3.9
PEO 23 5.7 8.0 15.9
NX002 27.2 29.5 59.2
HT 29 23.0 29.4 69.5
HBL 100 36.1 48.9 67.4
CX 140 30.7 28.7 61.9
CX 143 34.8 27.9 38.3
Burgen 0.8 0.7 30.5
Munro 0.2 1.1 9.5
Table 10.3 shows values obtained from 14 different cell lines assessed by flow
cytometry for markers of proliferation. Each of the 14 lines were incorporated with
BrdU and dual stained with propidium iodide to assess DNA content and particularly
S-phase fraction and with monoclonal antibody to BrdU to obtain a labelling index
(ie.the number of cells incorporating BrdU and staining with the specific antibody after
a 20 minute exposure).The cell lines were also stained with a monoclonal antibody to
the Ki-67 antigen and the number of cells staining with a greater fluorescence intensity
than background recorded as the labelling index.
BrdU L.I. = Bromodeoxyuridine Labelling Index, Ki-67 L.I. = Ki-67 Labelling
Index.
83





























Figure 10.5 shows the range of values obtained of the number of cells staining with
a fluorescence intensity over the background level for 14 different cell lines stained
with Ki-67 monoclonal antibody.
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Figure 10.6 The Relationship Between S-phase Fraction and Ki-67
Labelling Index in 14 Human Cancer Cell Lines
S-phase (%)
Figure 10.6 shows the relationship between flow cytometric S-phase fraction and
the Ki-67 labelling index (expressed as the percentage of cells showing green
fluorescence above background control levels after staining with a mouse anti-human
Ki-67 monoclonal antibody and visualising with a rabbit-anti-mouse FTTC conjugate).
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Figure 10.7 The Relationship Between BrdU and Ki-67 Labelling
Indeses in 14 Human Cancer Cell Lines
BrdU Labelling Index (%)
Figure 10.7 shows the relationship between BrdU and Ki-67 labelling indices of a
variety of human cancer cell lines. Both markers were measured on cells harvested
from the same tissue culture flask at the same time point.
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Figure 10.8 The Relationship Between BrdU Uptake and S-phase
fraction in a Subset of 14 Human Cancer Cell Lines
Figure 10.8 shows the relationship between BrdU uptake and S-phase fraction in
the subset of cell lines also examined for Ki-67 expression. A statistically significant
relationship is noted betwen these two parameters. The correlation is better than that
between Ki-67 and S-phase although is not statistically as good as that between BrdU
uptake and Ki-67 in this particular subset of 14 cell lines. This may demonstrate the
different approach to the assessment of proliferation that each of these markers
represents.
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d) Ki-Sl : This antibody, in a similar fashion to Ki-67, reported above, detects a
nuclear antigen expressed during the proliferative phases of the cell cycle. Ki-67
produced poor results with clinical material that had been frozen during storage (see
chapter 12), a finding confirmed by others (R. Camplejohn, Personal
Communication). The antigen for the relatively new antibody, Ki-Sl had been shown
to be much more stable and could also be stained by immunohistochemistiy in
paraffin-embedded tissue sections, another advantage over Ki-67.
To assess this new antibody a similar study design to those described previously was
adopted in which Ki-Sl expression was compared to S-phase fraction and BrdU
incorporation in a series of cell lines. A random group of 18 of the cell lines previously
described were incorporated with BrdU and then two aliquots were either dual stained
with anti-BrdU antibody and propidium iodide or stained singly with Ki-Sl antibody.
A typical histogram generated by the flow cytometer is shown in Figure 10.9. The
results of the experiment are shown in Table 10.4 and diagramatically displayed in
Figure 10.10.The results are similar to those obtained for Ki-67 antibody, although the
correlation between Ki-Sl and S-phase was not statistically significant there were
significant correlations between BrdU incorporation and S-phase (p = 0.0004) and Ki-
S1 and BrdU incorporation (p = 0.03) as shown in Figure 10.11.
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Figure 10.9 Ki-Sl Expression in the ZR-75.1 Breast Cancer Cell Line
Figure 10.9 shows superimposed histograms generated by the flow cytometer. The
number of events (cells) counted is plotted against the intensity of green fluorescence.
The mean fluorescence is seen to be greater in the sample of cells stained with Ki-Sl
antibody (and exposed to a fluorescein label) than in control cells. The control cells
demonstrate background fluorescence and the percentage of cells in the test sample
with fluorecence greater than background levels is termed the labelling index.
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Table 10.4 The Expression of Ki-Sl and the Relationship With Other
Proliferative Markers in Cell Lines
Cell Line S-phase (%) Ki-Sl L.I.(%) BrdU L.I.(%)
ZR 75.1 5.7 18.6 3.5
MDA MB231 10.1 40.8 10.2
PEO 1 21.8 20.2 20.1
PEO 1R 32.7 21.5 21.8
PEO 4 17.7 34.5 24.3
OVCAR3 17.3 0.0 18.2
OVCAR4 33.4 9.0 30.0
OVCAR5 17.5 20.3 23.6
2780 22.8 33.3 31.5
2780 AD 26.1 98.0 32.4
2780 PHX 34.9 4.9 26.9
CHO-KI 40.4 19.0 36.9
ADR-1 32.3 41.3 44.1
ADR-3 52.1 56.3 59.5
ADR-6 24.3 0.0 13.8
ADR-R 30.0 74.3 40.5
NX002 26.4 42.5 14.5
3T3 9.4 0.0 13.1
Table 10.4 shows the results obtained from flow cytometric assessment of
proliferation in 18 different cell lines.
BrdU L.I. = Bromodeoxyuridine Labelling Index, Ki-Sl L.I. = Ki-Sl Labelling
Index.
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Figure 10.10 The Range of Values Obtained for the Expression of Ki-






















Figure 10.10 shows the ranges of values obtained for the percentage of cells
staining with a fluorescent intensity above the control background levels. The test cells
having been stained with a fluorescent-labelled Ki-Sl monoclonal antibody.
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Figure 10.11 The Relationships Between S-phase, Ki-Sl Labelling
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Figure 10.11 shows the relationships between three markers of proliferation
measured in 18 different cell lines; i) A lack of correlation between Ki-Sl expression
and S-phase fraction, ii) a highly significant correlation between BrdU incorporation




These initial experiments with randomly selected cell lines allowed the development of
methodology and the study of the inter-relationships between three very different
methods of assessing cellular proliferation by flow cytometry. A consistent finding in
this model was of the highly significant correlation between the S-phase fraction as
assessed by cellular DNA content and the fraction of cells incorporating BrdU. The
expression of the nuclear proliferation-associated antigens, Ki-67 and Ki-Sl showed
better correlations with BrdU incorporation than with S-phase fraction.
The estimation of S-phase fraction has until recently been felt to be the most accurate
tool of cellular proliferation assessment in flow cytometry. With some debate over this
and the results to suggest that there is not a simple relationship between these
parameters it was felt to be important to pursue the measurement of S-phase, BrdU
incorporation and expression a nuclear proliferation antigen into a clinical setting.
Initially Ki-67, and then Ki-Sl expression was measured in clinical material when the
latter antibody became available and after problems of Ki-67 stability had become
apparent.
In order to assess the suitability of these techniques for measuring proliferation in solid
tumours, breast tumour xenografts in immunocompromised mice were studied. This
also afforded the opportunty of assessing these measurements as a reflection of
response to systemic anti-tumour therapy and the results are reported in the following
chapter.
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Chapter 11: Xenograft Experiments
This study was performed to test the methodology of assessing cellular proliferation,
as developed in tissue culture systems, in a solid tumour model with material obtained
by fine needle aspiration. There have been no previous reports, to our knowledge, of
the technique of fine needle aspiration being employed to obtain material from animal
xenografts and particularly for the assessment of response to systemic therapy.
11.1 ZR 75.1 Xenografts and the Response to Tamoxifen
Nude mice with established bilateral flank subcutaneous ZR 75.1 xenografts were
allocated to three groups; a control, untreated group, and two treated groups. The two
treated groups were given treatment by the subcutaneous implantation of either a
2.5mg or a 5mg slow release capsule of tamoxifen. Fine needle aspirates were
performed on the same tumour from each mouse on day 7, 14, 21 and 28 after the start
of the experiment.Tumour volumes were calculated from two diameter measurements
taken at weekly intervals and charted (Table 11.2 and Fig 11.2).
All four tumours in the control group showed an increase in volume during the
experiment although growth occurred at differing rates and one tumour decreased in
size between the penultimate and final time point. Tumours treated with 2.5mg of
tamoxifen all showed an increase in size (allbeit smaller than those in the control
group) until day 14 and thereafter a reduction in volume. Three of the four tumours
treated with 5mg of tamoxifen showed an increase at day 7 and thereafter a decrease in
volume. The fourth tumour displaying a decrease in volume at day 7.
There was a greater incidence of ulceration in those tumours treated with the higher
dose which made measurement and fine needle aspiration more difficult. Both doses
tended to cause a fibrotic reaction with the tumours becoming pale and firm. This may
be a reason for the relatively small change in volume noted in treated tumours, but one
might also interpret this observation as typical of the reaction to a supposed cytostatic
agent.
Serial measurements of S-phase on cellular material obtained by fine needle aspiration
showed clear differences between treated xenografts and controls (Table 11.2 and Fig
11.3). The S-phase fractions of control tumours remained constant or increased
marginally throughout the experiment wheras those from treated tumours decreased
progressively. The S-phase fraction of tumours treated at the higher dose of 5mg of
tamoxifen fell, initially, significantly faster than the lower dose. This may reflect the
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relative delay in response of the tumours treated at the lower dose as observed by the
serial measurements reported above. There was no significant difference, by the end of
the experiment, in either tumour volume or S-phase of the two treated groups.
The specimens obtained one week after commencement of treatment were spoiled
because of overheating whilst incorporating BrdU, due to a faulty thermostat.
Insufficient data was obtained to meaningfully report serial BrdU incorporations. The
relatively small size and firm consistency of the ZR 75 xenograft resulted in difficulty
in consistently obtaining sufficient material for the multi-step preparation required for
anti-BrdU staining.
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Table 11.2 Results of the Treatment of ZR 75.1 Xenografts in Nude
Mice with Tamoxifen
Mouse Day Volume (cm3) S-phase (%)




















lb 0 0.342 13.8
(2.5mg 7 0.343
Tamoxifen) 14 0.421 4.1
21 0.303 4.4
28 0.299 6.3

















lc 0 0.340 9.6
(5mg 7 0.325
Tamoxifen) 14 0.241 2.0
21 0.221 2.7
28 0.225 1.5














t Tumour fibrosed at day 28 and unable to obtain adequate FNA.
* Acellular FNA day 0.
**Tumour necrosis necessitating sacrifice of mouse prior to day 28.
Table 11.2 shows the raw data obtained from each of the twelve ZR 75.1 xenografts
studied. Group a) acted as controls, group b) treated with a 2.5mg implant of
tamoxifen and group c) a 5mg implant. Tumour volumes were calculated from two
diameter calliper measurements taken at weekly intervals. Fine needle aspirates were
taken weekly and S-phase fractions calculated from flow cytometric DNA histograms
obtained after propidium iodide staining. Dual staining enabled a BrdU labelling index
to be calculated in those samples generating sufficient cellular material. The data for the
individual tumours from each group have been combined and are graphically depicted
in figure 11.3.
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Figure 11.2 shows the change in mean tumour volume, expressed as a percentage
of that measured immediately prior to commencement of tamoxifen, of assessable
xenografts in four control mice and two other groups of four mice treated with 5mg
and 2.5mg of tamoxifen respectively. There is a clear difference between control and
treated xenograft; tamoxifen causing an initial decrease in the rate of growth and then a
decrease in tumour volume, but there is no significant difference between the two
doses of tamoxifen in the response observed.
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Figure 11.3 Serial S-phase Measurements in ZR 75.1 Xenografts in
Nude Mice Treated with Tamoxifen
Time (Days)
Figure 11.3 shows the change in S-phase fraction as assessed by flow cytometry
and DNA analysis of serial fine needle aspirates taken from ZR 75.1 xenografts in
groups of four nude mice treated with 5mg, 2.5mg or no tamoxifen. The data from
which the plot for the group treated with 2.5mg of tamoxifen was calculated was
derived from three xenografts as the pre-treatment specimen from the fourth tumour
was unassessable. The S-phase fractions in the control group remained stable wheras
those in the treated groups decreased corresponding to the decrease in tumour size (see
figure 11.2). The S-phase fraction of xenografts treated with 5mg of tamoxifen
appeared to drop significantly faster than those treated with only 2.5mg.
101
11.2 T1068 Xenografts and the Response to Adriamycin
In an attempt to determine the feasibility of observing the tumour biological response
to adriamycin by serial fine needle aspiration a similar experiment to that described
above was devised. The human breast cancer xenograft T1068 was used, being
derived from a mucoid carcinoma of the breast in an untreated postmenopausal woman
(Balkwill, 1984). This xenograft, grows very quickly and forms a soft cellular tumour
from which it is easy to obtain relatively good samples by fine needle aspiration
(unlike the ZR 75.1 xenografts descibed above) and is sensitive to adriamycin. Eight
nude mice with established tumours were divided into two groups. The first group
acting as controls were given weekly intra-peritoneal injections of saline and the other
were treated by intra-peritoneal adriamycin at a dose of 0.5mg/kg. Tumour volumes
were calculated by two-diameter calliper measurements taken weekly and charted
(Table 11.4 and Fig. 11.4).
There was no overall significant difference in the growth rate of treated and control
mice as shown in Figures 11.4 and 11.6. However mean tumour volumes of the
treated tumours at seven and 14 days were significantly lower than those of the control
tumours.
Fine needle aspirates of the T1068 xenograft yielded sufficiently cellular material to
enable both the BrdU labelling index and S-phase to be measured for the majority of
samples (Table 11.4). This allowed a more detailed examination of the relationships
between observed response and the two indices of cellular proliferation. Figure 11.5
shows the variation of the mean values for these two parameters over time and Figures
11.6 to 11.8 show graphically the inter relationships for each individual xenograft
studied. Interestingly the S-phase fraction declined with time in both the treated and
the control tumours (Figures 11.5 and 11.7). The values for S-phase in individual
tumours declined progressively in the control tumours, whereas in the treated
tumours, whilst the trend is towards a decrease, the values for serial S-phase
estimations are more erratic. A similar observation was noted with the serial
measurements of BrdU L.I. although the curves for treated tumours are relatively
smoother than those described previously for S-phase (Figure 11.8). Interestingly
each of the treated tumours showed an increase in BrdU F.I. (but not S-phase) at day
7 compared to the pre-treatment value. This might be a demonstration of the initial
stimulation of proliferation noted by some investigators on exposure of cell lines to
adriamycin (Dr. J. Cummings, Personal Communication).
The apparent difference in serial S-phase and BrdU F.I. measurements in the treated
tumours as opposed to the controls and the inferred poor correlation between S-phase
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and BrdU L.I. can be demonstrated by plotting the two indices against each other as
shown in Figures 11.9 and 11.10. Figure 11.10 represents combined data from each
of the tumours in a) the control and b) the treated group. The data from the control
group demonstrates the statistically significant relationship between S-phase and
BrdU, previously shown in cell line work above. This significance, however, is lost
in the samples from treated tumours.
It became apparent from this work on the measurement of cellular proliferation in
xenografts during systemic treatment that at least two approaches would be important
in monitoring the clinical response to treatment. Therefore these techniques were
applied to specimens obtained from primary breast tumours with the results as
described in the following chapter.
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Table 11.3 The Response of T1068 Xenografts in Nude Mice Treated
with a) Saline as a Control and b) 0.5mg/kg Adriamycin
Mouse Day Volume (cm3) S-phase (%) BrdU L.I.(%)
la 0 0.247 29.1 16.46
(Control) 7 0.622 14.4 11.37
14 0.989 11.9 6.35
21 1.512 9.9 4.29
28 2.745 8.4 2.67
31 2.807
35 7.5 2.42
2a 0 0.297 38.3 12.57
7 0.657 23.3 15.71
14 0.922 18.6 4.52




3a 0 0.085 41.9
7 0.363 33.5 13.76
14 0.631 29.5 6.79
21 0.936 17.9 5.09
28 2.207 21.2 3.74
31 1.461
35 20.1 5.10
4a 0 0.060 37.8 15.90
7 0.112 25.4 12.24
14 0.171 18.4 7.79
21 0.358 15.1 5.00





Mouse Day Volume (cm3) S-phase (%) BrdU L.I.(%)
lb 0 0.144 12.6 4.92
(,5mg/kg 7 0.215 14.0 12.45
Adriam'n) 14 0.174 19.4 12.10
21 0.320 19.5 9.60
28 0.475 21.0 8.00
31 0.397
35 13.6 11.57
2b 0 0.011 36.9 14.45
7 0.012 31.2 16.83
14 0.027 37.9 10.15
21 0.071 34.6 13.97
28 0.144 28.8 12.19
31 0.167
35 38.0 11.18
3b 0 0.124 39.3 12.25
7 0.168 18.6 15.13
14 0.262 27.9 11.56
21 0.646 12.7 8.43
28 0.807 18.5 5.37
31 0.864
35 5.32
4b 0 0.252 40.9 9.97
7 0.561 32.6 15.41
14 0.863 31.3 6.71
21 1.701 23.1 2.01




Figure 11.4 Growth Curves of the T1068 Human Breast Cancer
Xenograft in Nude Mice Treated with Adriamycin (0.5mg/kg)
Time (Days)
Figure 11.4 shows the growth curves produced by serial tumour mesurement prior
to weekly fine needle aspirates. Treated animals were given 0.5mg/kg adriamycin by
intra-peritoneal injection and controls were simply given the same volume of 0.9%
saline. The results shown are for five mice in each group. Given the broad standard
Error bars there appears to be no significant effect of adriamycin on the growth curve
at this dose after 31 days of treatment.
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Figures 11.5a and 11.5b Serial Measurements of S-phase and BrdU































Figures 11.5a and 11.5b show the change in the mean values of S-phase fraction
and BrdU uptake over time in four xenografts from each of control and treated groups
ofmice. Both parameters show a decline over time in each group. The only significant
difference between the groups appears to be an initial increase in BrdU uptake (but not
S-phase) in the treated tumours.
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Figure 11.6 Growth Curves of Individual T1068 Xenografts; a)





Figure 11.6 shows the growth curves of each of the four xenografts in the control
group (a) and those treated with 0.5mg/kg Adriamycin (b). On a log scale each tumour
displays linear growth with little difference in growth pattern between controls and
those treated with adriamycin.
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Figure 11.7 The Relationships between S-Phase Fraction and Time in






Figure 11.7 shows the variation with time of S-phase fraction as determined from
DNA histograms generated by flow cytometiy of serial fine needle aspirates taken
from a) control tumours and b) tumours treated with 0.5mg/kg Adriamycin. S-phase
tends to decrease with time in both the control and treated tumours despite the fact that
both groups showed tumour growth over this time period. The variation of S-phase is
more uniform in the controls compared to those undergoing treatment.
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Figure 11.8 The Relationships between BrdU Labelling Index and Time
in Individual T1068 Xenografts; a) Controls and b) Treated with
0.5mg/kg Adriamycin
a




Figure 11.8 shows the variance of the BrdU Labelling index with time in the four
adriamycin-treated and the four control T1068 xenografts. The Labelling index
decreases with time in both tumour groups although interestingly their appears to be an
initial increase over the first 7 days in each tumour in the treated group.
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Figure 11.9 The Relationships between BrdU Labelling Index and S-
Phase Fraction in Individual T1068 Xenografts; a) Controls and b)



















































Figure 11.9 shows the relationship between the two markers of proliferation, S-
phase and BrdU L.I. for individual tumours sampled serially by Fine Needle
Aspiration. Individual control tumours display a relatively good correlation whereas
treated tumours do not. This is further demonstrated in Figure 11.12.
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Figure 11.10 The Relationship Between BrdU Labelling Index and S-


















Figure 11.10 shows the relationship between S-phase and BrdU in a) control
tumours and b) tumours treated with 0.5mg/kg adriamycin. The points shown
represent all the individual samples taken from each of four tumours where a value for
both S-phase and BrdU L.I. could be obtained by dual staining. There is a significant
relationship in the control tumours but not in those which which have been treated.
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Chapter 12: Patient Samples
12.1 Markers of Proliferation
Four possible methods for determining cellular proliferation have been described
above in cell lines grown in tissue culture. Having thus tested the methodology an
assessment was needed to determine if the same approaches could be used to derive
measurements of cellular proliferation in material sampled from human tumours. Fine
needle aspiration is a minimally invasive technique for obtaining cellular material from
solid tumours but it was unclear whether such a technique could produce sufficient
good quality material for several flow cytometric assays.To address these questions,
therefore, fine needle aspirates were taken from surgical specimens obtained from an
unselected group of 38 patients. All patients had presented with a clinically palpable
primary breast cancer and had undergone definitive local regional surgery comprising
either a wide local excision or a mastectomy. Aspirates from the tumours were taken
immediately after surgical removal and the specimens incorporated with BrdU before
snap freezing in liquid nitrogen. The specimens were then stored at -80°C prior to
staining and flow cytometric analysis for BrdU, Ki-67 and DNA content.
The results are displayed in Table 12.1 and graphically in Figures 12.1, 12.2 and
12.3. There is a highly significant correlation between S-phase fraction and BrdU
labelling index, a similar result to that obtained with the cell line experiments.
However unlike the cell line results the correlations between Ki-67 labelling index and
both S-phase and BrdU uptake were not significant. This possibly represents, in part,
the instability of the Ki-67 antigen on freezing (Dr. R. Camplejohn, Personal
Communication) since the cell line work had been carried out with fresh cells.There
were doubts, therefore, as to the reliability of Ki-67 antibodies on our particular
samples. At the time this work was performed there were no reliable Ki-67 antibodies
available for the proposed comparative immunohistochemical studies on formalin-
fixed, paraffin-embedded samples, and, therefore, no further work was performed
with Ki-67 as a marker of proliferation in clinical samples.
The new antibody, Ki-Sl, was examined, at a later date, in a small series of FNA's
from 13 unselected primary breast tumours. In similar results to those obtained with
Ki-67 there was no significant correlation with S-phase fraction (Figure 12.4). Only
eight of these samples had an assessable BrdU labelling index and there was no
significant correlation with Ki-Sl labelling index. However, unlike Ki-67, Ki-Sl has
been shown to be stable with freezing and is also suitable for immunohistochemical
staining of formalin-fixed tissue.
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Human tumours, unlike cell lines grown in tissue culture or as xenografts, can be
classified by DNA content, broadly, as either diploid, tetraploid, aneuploid or
multiploid. DNA histograms obtained from diploid tumours are potentially more
difficult to analyse because of the vaiying contribution of DNA from normal, diploid,
stromal cells, and an inability to distinguish between cell types. This is illustrated by
the lack of correlation (allbeit in small numbers) between S-phase and BrdU labelling
index in the 10 tumours that were classified as diploid and the very good correlation in
the 28 non-diploid (tetraploid and aneuploid) tumours (Figure 12.5). There were no
significant correlations between either Ki-67 or Ki-Sl and S-phase or BrdU in either
diploid or aneuploid populations when assessed individually.
There was a lower rate of cellular proliferation, as determined by both the mean values
of S-phase and BrdU uptake, in diploid compared to non-diploid tumours (4.7% vs
9.2% and 2.1% vs 2.4%, respectively). Although these differences are not statistically
significant they do reflect previously reported findings as described in chapter 5.2.
The following chapters report results from the two clinical studies examining the
clinical response to primary systemic therapy of breast cancer and the associoated
biological responses. Based on the preliminary work reported above it was decided to
measure both S-phase and in vitro BrdU uptake in fine needle aspirates. In addition,
in order to compare the efficacy of fine needle aspiration and flow cytometry to
standard immunohistochemical techniques as tools for measuring biological response,
a further marker that coud be analysed by both techniques was required. The
measurement of Ki-S 1 expression appeared to fulfil this criteria.
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Table 12.1 S-Phase, BrdU and Ki-67 Labelling Indices in Samples
Obtained by Fine Needle Aspiration from 38 Human Primary Breast
Cancers.
Patient S-Phase BrdU L.I. Ki-67 L.I. DNA Index
1 0.20 1.59 23.42 1.00
2 7.50 2.42 11.67 2.67
3 13.60 2.44 18.59 1.78
4 7.10 1.53 21.96 1.69
5 7.10 2.15 4.79 2.18
6 3.90 1.02 0.90 1.79
7 12.20 2.52 14.30 1.94
8 1.40 0.34 42.21 2.25
9 28.20 1.31 21.48 2.03
10 22.60 3.45 8.20 1.99
11 12.20 3.80 21.20 1.00
12 7.00 1.87 10.99 1.78
13 6.00 1.41 0.42 1.00
14 2.80 4.53 9.50 1.00
15 11.10 3.63 23.03 2.01
16 3.00 1.01 31.65 1.49
17 0.30 1.23 14.53 1.94
18 4.60 0.30 0.18 1.00
19 4.20 3.39 10.00 1.00
20 2.50 0.81 4.40 1.93
21 2.80 0.93 36.24 1.18
22 19.20 5.65 2.56 1.51
23 10.50 1.75 22.02 1.86
24 16.60 6.10 5.76 1.74
25 12.40 0.87 10.35 1.00
26 19.90 2.31 6.17 1.66
27 10.70 4.59 15.66 1.60
28 2.00 0.72 24.60 2.67
29 8.80 5.23 28.41 1.90
30 13.30 8.46 15.04 1.62
31 3.10 1.50 29.32 1.00
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Table 12.1 Contd.
32 7.10 2.97 43.76 1.60
33 0.70 1.30 26.84 1.00
34 0.90 2.52 11.27 1.00
35 3.70 0.28 4.88 1.79
36 1.20 1.80 8.91 1.62
37 4.50 0.75 25.71 2.09
38 9.60 1.07 54.53 2.62
Table 12.1 shows data obtained from flow cytometric measurement of cellular
proliferation in samples obtained by fine needle aspiration from the primary tumours of
38 patients with breast cancer. Analysis of DNA histograms also enabled an estimate
of DNA index to be made (0.95-1.05 = diploid, 1.95-2.05 = tetraploid and others
aneuploid). The relationships between the different parameters are displayed
graphically in figures 12.1 to 12.3.
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Figure 12.1 The Relationship Between S-Phase and BrdU Labelling
Index in Fine Needle Aspirates from 38 Patients with Breast Cancer.
S-Phase (%)
Figure 12.1 shows graphically the correlation between S-phase and BrdU uptake in
dual-stained cells obtained by fine needle aspiration from an unselected group of 38
patients with primary breast cancer. There is a significant correlation between these
two parameters. This correlation appears to be better in a subset of 28 patients with
aneuploid tumours (see fig 12.4)
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Figure 12.2 The Relationship Between S-Phase and Ki-67 Labelling
















Figure 12.2 shows the relationship between S-phase fraction and Ki-67 Labelling
Index, as assessed by flow cytometry, in FNA samples taken from 38 primary breast
tumours in a group of unselected patients. There is no significant correlation between
these to parameters in this group of samples.
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Figure 12.3 The Relationship Between BrdU and Ki-67 Labelling

































BrdU Labelling Index (%)
Spearman r = -0.1111
p = NS
8 10
Figure 12.3 shows the relationship between Ki-67 expression and BrdU uptake, as
assessed by flow cytometry in a series of FNA's taken from unselected patients with
primary breast cancer. There appears to be no significant correlation. This is contrary
to the situation in cell lines grown in tissue culture and probably reflects the
unreliability of Ki-67 in frozen fresh tissue specimens.
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Figure 12.4 The Relationship Between S-Phase and Ki-Sl Labelling
Index in Fine Needle Aspirates from 13 Patients with Breast Cancer
Ki-Sl(%)
Figure 12.4 shows the relationship between Ki-Sl expression and S-phase fraction
in a small group of 13 primary breast tumours. There is no significant correlation
between these two parameters in this population.
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Figure 12.5 The Relationship Between S-Phase and BrdU Labelling
Index in Fine Needle Aspirates from Patients with Breast Cancer in a)






Spearman r = -0.200






Figure 12.5 shows the correlations between S-phase and BrdU uptake in FNA's
from aneuploid (including tetraploid) and diploid tumours. Although numbers are
small there is a highly significant correlation in non-diploid as opposed to diploid
tumours. This probably reflects the difficulty in determining S-phase in diploid DNA
histograms with no method of distinguishing tumour cell DNA from that from
"normal" stromal cells.
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CHAPTER 13 : Clinical Response to Primary Systemic Therapy
Clinical studies were performed to examine the response of breast tumours to primary
sytemic therapy with either chemotherapy or hormonal manipulation. These studies
involved the examination of response at a macroscopic level by serial ultrasound
measurements and also the consideration of response at a cellular level with
immunohistochemical and flow cytometric measurements of biological markers. Most
results relate to the group of elderly patients treated with primary tamoxifen because
this represented the largest population of patients recruited.
13.1 Ultrasound Measurements
Ultrasound scanning of the breast has previously been shown to be an accurate method
of measuring tumour volume as discussed in Chapter 2. To confirm this to be true in
the author's hands a series of 30 patients, whose response to tamoxifen was monitored
and reported below, were studied. The mean diameter of an individual tumour as
measured clinically by calliper or by ultrasound scanning immediately prior to surgery
was compared to the diameter measured by the pathologist on cutting the surgical
specimen. The mean values for each method of assessment represented the mean of
two diameters measured at 90° in the same plane. All calliper and ultrasound
measurements were performed by the author. The correlations between each method of
clinical assessment and the pathological measurement are displayed graphically in
figures 13.1 and 13.2. There are significant correlations with pathological diameter for
both calliper (p=0.0003) and ultrasound (p<0.0001) measurements. The correlation
between calliper and pathological measurements is the poorer of the two and the graph
demonstrates a particularly wide spread of calliper measurements at pathological
diameters less than 1.5cm. Small tumours are difficult to measure clinically with any
accuracy but such tumours are usually relatively easily identifiable by ultrasound as
demonstrated by a good correlation in such measurements with pathological direct
assessment. Indeed of the 30 patients studied 7 had tumours that, by the time of
surgery, could not be distinctly palpated and measured by calliper although still visible
by ultrasound. Figure 13.2 thus represents data from only 23 of the patients
studied.There is one obvious ouytlying point in the graph depicting the correlation of
ultrasound and pathological tumour measurement and this represents a large lobular
carcinoma which are a notoriously difficult histological tumour type to define precisely
on ultrasound scanning.
Ultrasound appears, therefore, not only to reflect the actual size of the tumour with
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greater accuracy but also to enable measurement and monitoring of the response of
those tumours which maybe small and/or deep-seated within the breast. One could
assume that the greater accuracy of ultrasound over calliper measurement would also
allow a better determination of small and early responses to therapy.
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Figure 13.1 The Relationship between Breast Tumour Diameter as
Determined by Ultrasound and the Direct Pathological Measurement
Figure 13.1 shows the correlation, in 30 patients, between the mean tumour
diameter as assessed by ultrasound scanning immediately prior to surgeiy and that
determined by direct measurement of the surgical specimen on cutting. A highly
significant correlation is represented between pathological measurements of 0.5 to
3.0cm with one outlier at 3.5cm. This point represents a large lobular carcinoma which
are notoriously difficult to define clearly on ultrasound scanning.
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Figure 13.2 The Relationship between Breast Tumour Diameter as
Determined Clinically by Calliper and Direct Pathological Measurement
Pathological Diameter (cm)
Figure 13.2 shows the correlation, in 23 patients, between the mean tumour
diameter as determined clinically, by calliper measurement and the direct pathological
measurement of the cut surgical specimen. There is a significant correlation between
the two methods of assessment although at pathological diameters below 1.5cm there
is a wide spread of corresponding clinical measurements. Data is represented from
only 23 of the study population of 30 patients as tumours in 7 patients could not be
clinically palpated or clearly defined for calliper measurement. The gradient and
intercept of the line of "best-fit" demonstrate the consistently greater diameter
measured clinically than that seen pathologically which is accounted for by the skin
and subcutaneous tissues included in calliper measurements.
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13.2 The Clinical Response to Tamoxifen in Elderly Patients
In order to examine the early tumour response to systemic therapy with tamoxifen a
group of 94 patients were assessed. All patients were over the age of 70 and had
presented with primary breast tumours. One patient presented with bilateral disease
and the response of each individual tumour was monitored and recorded. The mean
age of patients within the study was 76.1 years with a range of 70 to 87 years of age.
All patients were free of metastatic disease as determined by standard staging
investigations. Oestrogen receptor levels were measured by enzyme immunoassay
(ELA) of pre-treatment wedge biopsies and/or immunocytochemical assay (ER-ICA) of
pre-treatment fine needle aspirates. Adequate specimens for analysis were not obtained
in three patients (these three patients went on to receive tamoxifen despite unknown
ER status because of a wish not to undergo surgery and all demonstrated a subsequent
response). All other patients had ER +ve tumours, with receptor levels of
>20fmol/mg cytosol protein, as determined by ELA, or positive staining in >10% cells
by ER-ICA.
Tumour volumes were assessed by ultrasound scanning prior to the commencement of
treatment and at monthly intervals thereafter. All patients were monitored for at least
three months, with 26 patients monitored up to six months. The responses in
individual tumours were recorded as the percentage reduction in ultrasound assessed
volume, with respect to the pre-treatment value (Table 13.1). A response (>10%
reduction in tumour volume) was recorded in 70 of the 95 tumours (74%) after three
months of treatment. Of these responding patients the mean decrease in tumour volume
was 58.5% (range: 16.8 - 91.0%). The distribution of the degree of response after
one, two and three months are shown in Table 13.2 and Figures 13.3 to 13.6. A
typical series of ultrasound scans, and mammograms for comparison, from the same
responding patient are shown in figures 13.7 and 13.8. After one month 44% of
tumours demonstrated a response with the remainder showing no change in volume.
The majority of responders at this very early time point show a 10-50% reduction in
tumour volume but one tumour appeared to be extremely sensitive demonstrating a
reduction of >75%. No tumour increased in size after one month. By two months 64%
had demonstrated a response with a much greater proportion having volume reductions
of >50%. By this time point four tumours had increased in size. After three months 70
tumours had reduced in size with 19 (27%) displaying a reduction in tumour volume
of >75%. These figures can be illustrated practically in that sufficient reductions in
tumour volumes may enable the avoidance of mastectomy. Of 26 responding patients
who went on to definitive local surgery after primary tamoxifen treatment and would
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have required a mastectomy at presentation (tumours >4cm in diameter) 10 were
treated with a wide local excision. In addition nine of 17 tumours staged as T4 at
presentation became operable with treatment. Interestingly the one patient in whom
bilateral tumours were monitored showed different responses with one tumour
demonstrating a 66% reduction in volume whereas the other remained static with three
months of treatment.
Of the 26 tumours were monitored up to six months 20 had shown a response at three
months and had been randomised to continue treatment with tamoxifen alone in the
protocol of the "Elderly Patients Study". Of these, 14 went on to demonstrate a further
decrease in tumour volume (an additional mean reduction of 20.1%) and one tumour
showed no further change after the initial response. However five tumours that had
initially responded showed an increase in volume between three and six months. Of
the six tumours that had shown no response at three months, two increased in size by
five months and the remaining four did not change in volume.
As a comparison with conventional methods of response assessment, the tumours
have also been graded by U.I.C.C. response criteria, based on serial calliper
measurements, after three months of therapy (Table 13.2). Calliper measurements
were available for 80 of the 95 tumours studied (data not shown). Of these tumours 27
(34%) were classified as responders (19 partial and 8 complete responders) as
compared with 60 (75%) of the same population as assessed by ultrasound. The range
of values obtained for the percentage change in tumour volume, as assessed by
ultrasound, in each of the groups selected according to UICC response is shown in
Figure 13.9. Although there were statistically significant differences between the mean
redution in ultrasound assessed volumes in tumours classified as either "no-change",
"partial response" or "complete response" there was a degree of overlap. This was
particularly noted in the "no change" group with some tumours demonstrating
reductions in volume of over 80% as measured by ultrasound. Thus, there was no
clear "cut-off' in ultrasound assessed tumour reduction at which point all tumours
were also classified as responders by UICC criteria.
Ultrasound has enabled us to monitor accurately the early responses to tamoxifen and
to our knowledge this is the first time such data has been reported. After three months
of treatment the data suggest that all those tumours that will respond to tamoxifen have
demonstrated a volume reduction. The numbers of non responding patients monitored
to six months is, however, relatively small. There is clearly great potential in primary
treatment with tamoxifen in the elderly population to downgrade the operation required
for definitive local surgeiy and to enable inoperable locally advanced tumours to
become operable. The associations that were observed in this group of 94 patients
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between overall response / degree of response and the clinical characteristics of the
tumours (including oestrogen receptor data) are described below.
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Table 13.1 The Response to Primary Tamoxifen Therapy in 94 Patients
of 70 Years of Age or Over
Patient Age Stage Clin Diam LnVol (CSS) E.R. ERICA 1 Month 2 Months 3 Months 6 Months U.I.C.C. 3/12
. 1 78 T2NOMO 4.6 2.58 860 0.0 0.0 41.0 72.0 nc
2 72 T2N0M0 3.3 134 606 0.0 0.0 68.7 pr
3 80 T2N1M0 4.2 2.25 1491 41 30.0 55.0 72.0 pr
4 78 T2N0M0 2.8 1.33 22 0.0 48.3 24.9 nc
5 71 T2N0M0 3.4 1.40 325 33 0.0 35.0 54.0 nc
6 74 T2N0M0 3.8 3.54 29 10 0.0 0.0 0.0 nc
7 80 T2N0M0 3.6 2.20 425 0.0 59.0 69.9 nc
8 83 T4bNlM0 4.2 2.63 34 0.0 0.0 16.8 38.4 nc
9 70 T3N1M0 7.0 3.77 86 50 0.0 0.0 0.0 nc
10 71 T1N0M0 1.9 0.86 51 30.0 62.0 73.0 77.0 cr
11 85 T4bNlM0 5.8 3.01 605 55 0.0 28.0 48.0 pr
12 73 T2N0M0 2.5 1.55 60 46.7 58.2 69.6 *
13 70 T2N0M0 4.6 2.26 444 34 76.3 87.8 87.7 pr
14 70 T2N0M0 3.4 1.89 0.0 0.0 33.5 54.0 nc
15 72 T2N0M0 4.0 1.73 388 0.0 0.0 50.7 pr
16 71 T4bNlM0 43 2.60 87 40 0.0 0.0 0.0 prog 5/12 nc
17 83 T2N0M0 2.1 0.87 62 0.0 0.0 0.0 nc
18 70 T2N0M0 3.9 2.81 83 65.0 91.0 90.5 cr
19 80 T2N0M0 3.6 230 67 60.1 62.0 64.7 77.5 nc
20 72 T2N0M0 3.7 2.10 79 55 0.0 0.0 23.0 nc
21 71 T2N0M0 3.1 0.99 445 83 39.0 82.0 91.0 cr
22 79 T2N0M0 2.7 1.67 74 42.5 53.0 76.6 pr
23 73 T2N0M0 3.3 0.99 485 70 51.0 87.0 86.0 91.0 cr
24 78 T2N1M0 3.9 2.26 170 31 0.0 0.0 0.0 nc
25 75 T2N0M0 1.9 -0.10 84 0.0 -50.0 -48.0 ★
26 78 T2N0M0 4.1 1.60 68 17 0.0 0.0 18.0 nc
27 83 T4aNlM0 2.9 1.44 70 0.0 0.0 0.0 0.0 nc
28 83 T2N1M0 2.8 1.18 29 0.0 10.8 50.4 67.6 nc
29 72 T2N1M0 33 1.34 384 22 40.0 34.0 68.0 *
30 83 T2N0M0 43 2.21 651 76 18.0 513 84.5 **
31 80 T2N1M0 3.7 3.70 24 0 0.0 0.0 0.0 nc
32 73 T3N2M0 5.9 1.94 498 8 0.0 58.6 63.2 ★★
33 87 T2N0M0 2.0 0.48 442 65 0.0 0.0 25.0 nc
34 71 T2N0M0 3.1 1.52 186 37 0.0 28.0 53.0 pr
35 71 T2N0M0 4.0 1.75 510 0.0 28.7 44.8 nc
36 70 T2N0M0 4.4 238 150 0.0 49.9 29.3 nc
37 80 T1N0M0 1.2 -0.80 26 20.0 23.0 24.5 nc
38 72 T1N1M0 2.2 0.05 20 0.0 0.0 0.0 nc
39 71 T3N1M0 5.8 2.47 222 58 0.0 0.0 0.0 nc
40 72 T4bNlM0 4.0 235 72 38 18.8 26.9 37.0 783 pr
41 T3N0M0 4.9 3.30 46 51.3 61.2 65.2 nc
42 74 T3N1M0 53 3.20 23 0.0 0.0 0.0 nc
43 71 T2N1M0 3.9 2.23 93 41 0.0 21.7 33.6 **
44 74 T2N0M0 3.0 1.76 964 69 0.0 62.0 67.0 pr
45 82 T3N0M0 53 2.86 80 21.0 45.5 34.6 37.6 nc
46 70 T4bNlM0 6.0 3.17 138 26 18.4 16.2 22.9 nc
47 81 T2N0M0 4.4 1.49 262 61 173 28.7 29.1 nc
48 71 T2N1M0 4.0 2.66 463 42 0.0 38.0 49.0 **
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Table 13.1 Continued
Patient Age Stage Clin Diam LnVol (USS) E.R. ERICA 1 Month 2 Months 3 Months 6 Months U.I.C.C. 3/12
49 76 T2N1M0 4.1 2.29 837 44 0.0 35.6 80.1 nc
50 82 T2N1M0 3.0 1.02 519 53.1 71.2 84.5 84.0 *
51 85 T2N0M0 4.0 2.27 70 80 0.0 0.0 0.0 0.0 nc
52 81 T2N1M0 4.9 2.19 294 0.0 0.0 7.0 nc
53 71 T2N0M0 3.6 1.58 99 16 35.5 -23.8 -71.0 **
54 85 T2N1M0 4.5 2.27 95 0.0 70.0 64.0 nc
55 76 T4bN0M0 3.7 1.98 143 24 0.0 0.0 0.0 0.0 nc
56 71 T2N1M0 4.0 1.55 384 0.0 0.0 0.0 nc
57 72 T2N1M0 4.9 2.78 469 32 52.0 71.0 88.0 pr
58 71 T4bNlM0 5.4 3.15 557 23 30.1 55.0 71.9 pr
59 71 T2N0M0 2.0 1.20 27 0.0 0.0 -17.0 prog
60 71 T2N0M0 3.0 2.01 40 68.0 67.2 65.4 61.4 nc
61 79 T2N0M0 4.4 2.08 34.0 55.0 48.0 62.4 nc
62 84 T4bNlM0 4.0 1.80 59 15.0 33.7 40.4 61.0 nc
63 76 T2N0M0 2.5 0.57 65 0.0 16.5 77.5 cr
64 82 T4bN0M0 5.5 237 97 0.0 37.6 67.0 57.4 pr
65 73 T2N0M0 3.8 1.67 76 6 0.0 10.9 31.9 nc
66 83 T4bNlM0 3.6 2.01 285 25 23.0 47.7 37.8 nc
67 78 T3N2M0 5.1 2.84 1292 98 17.0 62.0 85.0 pr
68L 74 T2N1M0 5.0 3.49 371 83 0.0 60.0 66.0 ★*
68R T2N1M0 3.0 1.11 44 0.0 0.0 0.0 **
69 77 T2N0M0 2.6 2.15 426 0.0 28.9 83.0 51.0 pr
70 70 T4bN0M0 2.8 1.57 177 70 42.5 63.9 81.7 nc
71 70 T4bN0M0 5.7 3.41 65 33 0.0 0.0 0.0 0.0 nc
72 76 T2N0M0 4.1 2.42 91 22 15.0 24.7 61.0 **
73 72 T4bN2M0 8.4 233 72 25.0 29.0 89.0 52.0 pr
74 71 T2N0M0 2.2 0.19 17 39.0 41.0 41.0 89.0 pr
75 78 T2N0M0 3.9 1.81 166 61 0.0 30.1 58.9 pr
76 76 T2N1M0 4.4 0.87 27 323 383 28.6 -16.8 nc
77 87 T2N0M0 5.0 1.76 26.6 60.9 74.8 pr
78 78 T2N0M0 4.1 234 265 32.8 -203 -116.0 **
79 76 T4bNlM0 3.7 1.07 1496 41 0.0 42.0 68.0 nc
80 79 T4bNlM0 63 2.79 279 69 0.0 0.0 24.9 45.8 nc
81 80 T2N1M0 4.8 2.74 73 28 0.0 0.0 0.0 nc
82 85 T2N0M0 3.1 1.91 770 64 20.0 55.0 77.0 90.0 nc
83 75 T2N1M0 3.8 1.82 306 67 48.0 56.0 61.0 nc
84 78 T2N0M0 3.4 0.52 1388 83 55.0 61.0 76.0 cr
85 77 T2N0M0 5.0 2.99 40 0.0 0.0 0.0 prog at 4/12 nc
86 71 T2N0M0 4.9 2.18 201 0.0 0.0 -36.0 nc
87 85 T2N1M0 4.1 1.99 181 13 0.0 -49.0 -72.0 nc
88 78 T2N0M0 3.3 1.32 557 67 30.0 75.0 83.0 cr
89 75 T1N0M0 1.5 0.23 56 40.0 59.0 80.0 cr
90 74 T1N1M0 1.5 1.11 38 21.0 40.1 65.1 nc
91 76 T2N1M0 2.4 132 47 19.0 40.2 40.1 **
92 85 T2N0M0 33 1.71 161 38 16.0 30.0 74.0 nc
93 70 T4bNlM0 3.5 2.08 120 40 35.9 81.4 81.4 pr
94 75 T2N1M0 5.0 2.60 100 40 0.0 0.0 -16.0 **
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Table 13.1 shows data accrued from 94 patients presenting with 95 breast tumours
and receiving primary therapy with tamoxifen for at least three months. 91 patients
were deemed oestrogen receptor positive by either ELA on pre-treatment biopsies or
ER-ICA on pre-treatment FNA's. The remaining three patients were treated despite
unknown ER status. Clinical Diameter was assessed by calliper measurement and is
expressed in cm. Ultrasound measurements (in cm.) were made in three planes and
calculated volumes expressed as the In. ER levels as determined by ELA are expressed
in fmol/mg cytosol protein and ER-ICA results are expressed as % of cells staining.
Tumour response at one,two ,three and six months are expressed as a % decrease with
respect to the pre-treatment volume. An increase in tumour volume is denoted by a
negative value.
* Tumours became diffuse and not accurately measurable.
** Tumours for which some clinical measurements not available.
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Table 13.2 The Degree of Response Measured After One, Two and




uction in Tumour Volume
Increase Static 10-25% 25-50% 50-75% >75%
1 Month 0 53 14 19 8 1
2 Months 4 30 7 24 24 6
3 Months 7 18 7 19 25 19
Table 13.2 shows the numbers of patients, at monthly intervals from the
commencement of tamoxifen, that can be grouped in various response categories.
Non- responders either show a >10% increase in tumour volume or are defined as
static (<10% increase or decrease in volume). Responders are grouped according to the
% tumour volume reduction. There are increased numbers of non-responders showing
an increase in tumour volume by three months and also by this time point an increased
number of responders showing volume reductions of > 75%.
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10-25% 25-50% 50-75% 75-100%
Response (% Reduction in Tumour Volume)
Figure 13.3 shows the distribution of tumour responses at one month. The majority
of tumours have shown no change in volume although one tumour has decreased by
greater than 75%.
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Figure 13.4 The Response to Tamoxifen After Two Months of
Treatment
9
INCREASE STASIS 10-25% 25-50% 50-75% 75-100%
Response (%Reduction in Tumour Volume)
Figure 13.4 shows the distribution of responses after two months of tamoxifen
treatment. Four tumours have shown an increase in size and the majority of responding
tumours have decreased in volume by greater than 25%.
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INCREASE STASIS 10-25% 25-50% 50-75% 75-100%
Response (% Reduction in Tumour Volume)
Figure 13.5 shows the distribution of responses observed in a series of 95 tumours
after three months of tamoxifen therapy. 70 tumours were classified as responders
with the majority displaying >50% reduction in tumour volume.
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Figure 13.6 Composite Chart of Responses at One, Two and Three

















10-25% 25-50% 50-75% 75-100%
Response (% Reduction in Tumour Volume)
Figure 13.6 shows a composite chart comprising the distributions of tumour
responses after one, two and three months of tamoxifen therapy. There are
progressively fewer "static" tumours and more displaying either an increase in volume
or a greater decrease in volume.
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Figure 13.7 Series of Breast Ultrasound Scans Performed at Four-
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Figure 13.7 shows a series of four ultrasound scans taken before treatment and then
at four-weekly intervals thereafter. The tumour is demonstrated as a hypoechoic
roughly circular region in the centre of each scan with typical wall "shadows". The
tumour diameter, in the single plane view shown, as determined by electronic callipers
is recorded below each scan.
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Figure 13.8 Mammograms Performed before and after Treatment with
Tamoxifen
Figure 13.8 shows reproductions of mammograms performed on the same
responding patient whose ultrasound scans are shown in Figure 13.7. The X-Rays
were performed before and after three months treatment with tamoxifen and
demonstrate the comparative ease of tumour measurement by ultrasound.
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Figure 13.9 The Relationship Between Tumour Response Graded by




































Figure 13.9 shows the relationship between tumour response determined by calliper
measurements and then graded by UICC criteria and the response measured by
ultrasound scans. There are statistically significant differences between the mean
change in ultrasound assessed volume of the groups "NC" and "PR" (Mann-Whitney
U-Statistic 120, p < 0.0001) and groups "PR" and "CR" (Mann-Whitney U-Statistic
34.5, p = 0.03)
Prog = Progression
NC = No Change
PR = Partial Response
CR = Complete Response
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""^actors Predicting Response to Tamoxifen
-a) Tumour Size
To determine if the size of the primary breast tumour prior to treatment influenced the
subsequent observed response the range of values of ultrasound assessed initial
volumes were plotted for responders and non-responders (Figure 13.10). There was
no significant difference in pre-treatment volume between the two groups. Additionally
the initial tumour volume did not relate to the degree of response subsequently
observed in responding tumours (Figure 13.11). Grouping tumours into T stages (of
the TNM classification and based on calliper measured diameters) also did not produce
a significant relationship with response.
b) Lymph Node Status
The presence of axillaiy lymph node metastases from primaiy breast cancers has been
found to be one of the most consistent markers of poor prognosis. To determine
whether the presence of nodal metastases has an association with the response of the
primary tumour to tamoxifen, a subgroup of 51 patients who had undergone axillary
surgery after primary tamoxifen were studied. Patients were classified as histologically
node-negative or positive and these groups contained 26 and 25 patients respectively.
Although the mean reduction in volume at three months was lower in the node positive
group this failed to reach statistical significance (Figure 13.12).
c) Oestrogen Receptor Levels
All tumours included in the study were deemed ER positive (other than the three
tumours discussed above). Two methods for assessing ER levels were employed; ELA
on tumour wedge biopsies and ER-ICA on cells obtained by FNA. Results from each
of these two methods were available for 50 of the series of 95 tumours and this
enabled a direct comparison of their respective predictive values, with respect to
tamoxifen response, to be made. ER levels and the relationship to overall response are
displayed in Figures 13.13 and 13.14 for assays by EIA and ER-ICA respectively.
The median values of ER measurement by both EIA and ER-ICA are significantly
higher in responders compared to non responders. There is a greater degree of
statistical significance, however, for the data derived from EIA. Perhaps most
importantly, and clinically useful, there appears to be a clear cut-off in the EIA data
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with all tumours having ER levels of >250fmol/mg of cytosol protein showing a
response by three months. There is no such cut-off for ER-ICA estimations. To assess
the relationship between ER level as determined by the two methods and the degree of
response corresponding values for individual tumours were plotted and Spearmen rank
correlations performed (Figures 13.15 and 13.16). There are significant correlations
between both ELA and ER-ICA estimations of ER content and the degree of response
obseved by ultrasound measurement, but the correlation is of greater statistical
significance for the data derived by EIA.
Other biological factors which may predict or reflect the response to tamoxifen are
discussed in chapter 14.
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Figure 13.10 Pre-Treatment Tumour Volume and the Overall





Figure 13.10 shows the relationship, in 95 tumours, between pre-treatment
volume, as measured by ultrasound, and the subsequent overall response to tamoxifen
after three months of treatment. There is no significant difference between the median
volumes of the responding and non-responding groups (Mann-Whitney U-statistic =
687.5, p = 0.1141)
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Figure 13.11 Pre-Treatment Tumour Volume and the Degree of
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Figure 13.11 shows the relationship between pre-treatment tumour volume as
assessed by ultrasound and the degree of subsequent response to tamoxifen after three
months therapy. There is no significant correlation between these two variables.
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Figure 13.12 The Relationship between Pathological Lymph Node
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Figure 13.12 shows the relationship between lymph node status and the response to
tamoxifen as defined by % reduction in tumour volume. Node status was determined
histologically from specimens obtained at the time of definitive loco-regional surgeiy.
There is no statistically significant relationship between these two parameters.
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Figure 13.13 Pre-Treatment Oestrogen Receptor Levels as Determined













Figure 13.13 shows the relationship between pre-treatment ER levels as determined
by EIA and the subsequent overall response to tamoxifen. In this population of 50
tumours (a subset with ER measured by both EIA and ER-ICA) there is a significant
difference between median values of ER in responding and non-responding patients
(Mann-Whitney U-statistic = 64, p = 0.0001). There is also a clear cut-off in ER
values such that all tumours with an ER >250fmol/mg ( , above) demonstrated a
response at three months. Although there is overlap between responders and non-
responder in tumours expressing ER at lower levels, this could clearly be of clinical
significance.
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Figure 13.14 Pre-Treatment Oestrogen Receptor Levels as Determined
















Figure 13.14 shows the relationship between pre-treatment ER levels as determined
by ER-ICA on FNA samples and the subsequent overall response to tamoxifen. In this
group of 50 tumours there is a significantly higher median number of cells staining by
ER-ICA in subsequent responders compared to non-responders (Mann-Whitney U-
statistic = 141.5, p = 0.0294). Unlike the data for ER assay by ELA there is a
considerable degree of overlap in individual ER-ICA values in the responding and non-
responding groups.
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Figure 13.15 Pre-Treatment Oestrogen Receptor Levels as Determined
by EIA and Subsequent Degree of Response to Tamoxifen.
Log ER (fmol/mg)
Figure 13.15 shows the relationship, in 50 tumours, between pre-treatment ER
levels as determined by EIA and the degree of response as measured by the reduction
in tumour volume after three months of therapy. There is a highly significant
correlation.
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Figure 13.16 Pre-Treatment Oestrogen Receptor Levels as Determined
by ER-ICA and Subsequent Degree of Response to Tamoxifen.
100
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Cells Staining by ER-ICA (%)
Figure 13.16 shows the relationship between pre-treatment ER expression, as
determined by ER-ICA of cells obtained by FNA, and tumour response after three
months of therapy. There is a significant correlation between these two parameters.
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13.3 The Clinical Response to Chemotherapy and Hormone
Manipulation in the Trial of Primary Systemic Therapy
Forty-six patients were recruited and randomised in the Edinburgh trial of primary
systemic therapy. Twenty-two patients were randomised to receive primary therapy
and 24 to undergo conventional treatment with primary surgery and standard adjuvant
treatment as necessary. Their were two trial violations in the primary therapy arm; one
patient decided to proceed to conventional therapy after randomisation, and one patient
required repeat wedge biopsies to confirm the histological diagnosis with the result that
there was little identifiable tumour left to monitor response. Both these patients
underwent conventional therapy and are included in that arm for follow-up purposes.
Five patients were treated by primary systemic therapy as per protocol outwith the trial
through their personal choice. For the purposes of this thesis they will be included
with the patients registered in the trial. This makes totals of 25 and 26 patients included
in the primary systemic and conventional therapy arms of the trial respectively. The
mean ages of patients assigned to the primary systemic and conventional therapy
groups respectively were 51.7 years (range: 32-68) and 51.8 years (range: 27-68).
The clinical responses observed in those patients undergoing primary sytemic therapy
are summarised in Table 13.3. Fifteen patients with ER poor tumours (<20 fmol/mg
cytosol protein by ELA of wedge biopsy material) were given four pre-operative cycles
of chemotherapy with cyclophosphamide, adriamycin and prednisolone (CAP).
Fourteen patients responded with an average decrease in tumour volume of 87%
(range: 58 to 100%) with three patients acheiving a complete pathological response. A
plot of the variation in mean tumour volume over time is shown in Figure 13.17. One
patient with a borderline ER positive tumour and who was pre-menopausal at
presentation received three months treatment with the LHRH agonist, Goserelin. With
no response to this therapy she received four cycles of CAP with a moderate response.
Of the remaining nine patients with ER positive tumours seven responded to tamoxifen
with a mean decrease in tumour volume of 70%. Individual plots illustrating the
decrease in tumour volume over time are shown in Figure 13.18. The two patients
who did not respond to tamoxifen also failed to respond when switched to CAP
chemotherapy.
The numbers of patients studied are too small to make significant conclusions about
patterns of response but given this limitation the CAP regime appears to have
significant activity in terms of short-term response. A mean decrease in tumour volume
of 87%, as seen in this series, would allow significant numbers of patients to avoid
mastectomy. This option was not available in the Edinburgh protocol and so all
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.patients proceeded to mastectomy regardless of the degree of response. The avoidance
of mastectomy has, however, been cited by other authors as an important principle
behind the use of primary systemic therapy (see Chapter 2).
The prime aim of the Edinburgh study was to observe long-term survival in a group of
patients randomised to either undergo primary systemic therapy or conventional
primary surgery and adjuvant therapy. To date, in the series reported here, the mean
follow-up times are 24.9 months (range: 15-31 months) and 24.9 months (range: 12-
36 months) respectively. These are relatively short periods of time in the natural
history of breast cancer and it is thus difficult to make significant comments on relapse-
free and overall survival times in this group at present.
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Table 13.3 The Response to Treatment in 25 Patients Treated According
to the Protocol of the Edinburgh Trial of Primary Systemic Therapy
Patient No. Treatment Stage Clin Diam Ln Vol (USS) 4 Weeks 8 Weeks 12 Weeks
2 C.A.P. T2N1M0 5.0 2.3 66.2 71.4 100.0
5 C.A.P. T2N1M0 4.9 2.0 62.0 85.9 86.4
7 C.A.P. T3NOMO 6.3 2.9 * 82.3 58.1
9 C.A.P. T2N1M0 2.9 0.3 0.0 0.0 0.0
10 C.A.P. T2N0M0 5.0 3.2 59.1 90.0 95.3
12 C.A.P. T2N1M0 3.1 2.2 74.6 96.0 96.3
15 C.A.P. T2N0M0 4.1 2.6 28.1 62.6 68.8
16 C.A.P. T3N0M0 5.9 3.5 64.2 79.1 95.8
18 C.A.P. T3N0M0 5.6 2.8 45.5 71.2 68.6
20 C.A.P. T2N0M0 3.5 2.6 53.0 91.0 95.6
21 C.A.P. T3N1M0 5.1 2.4 62.0 82.0 90.0
b C.A.P. T3N1M0 4.8 2.9 78.6 92.2 95.4
c C.A.P. T3N1M0 5.9 3.4 62.5 86.8 94.9
d C.A.P. T3N1M0 5.8 3.5 38.9 65.5 73.4
e C.A.P. T2N0M0 4.6 2.9 79.0 92.5 98.8
8 LHRH + C.A.P. T3N1M0 6.2 3.4 0.0 0.0 0.0
11 TAM +C.A.P. T2N0M0 2.9 1.5 0.0 0.0 5.4
4 TAM + C.A.P. T3N1M0 8.2 3.6 0.0 0.0 0.0
1 TAM T2N1M0 4.9 2.4 38.2 74.8 77.0
6 TAM T2N0M0 4.0 2.1 57.5 74.4 73.3
13 TAM T2N0M0 3.9 1.6 0.0 45.1 65.8
14 TAM T2N0M0 3.8 1.9 31.2 48.0 40.3
19 TAM T2N0M0 3.2 2.0 66.2 93.6 99.0
22 TAM T2N0M0 3.8 1.7 0.0 23.1 40.0
a TAM T2N0M0 4.6 2.1 62.3 86.1 93.3
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Table 13.3 shows the responses measured in 25 patients given either chemo- or
hormonal therapy, or both, according to the protocol of the Edinburgh Trial of Primary
Systemic Therapy.
C.A.P. = Cyclophosphamide, Adriamycin and Prednisolone chemotherapy.
LHRH = LHRH Agonist, Goserelin.
TAM = Tamoxifen.
Clin Diam = Tumour diameter measured by callipers (cm).
Response at 4, 8 and 12 weeks is expressed in terms of percentage reduction in
tumour volume as assessed by ultrasound.
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Figure 13.17 The Tumour Response over Time in 14 Patients Treated
with Primary C.A.P. Chemotherapy.
Figure 13.17 shows the response of 14 breast tumours treated with four, three-
weekly, cycles of primary C.A.P. chemotherapy. The values plotted are the means of
the percentage tumour volumes (as compared with pre-treatment volumes) at the times
indicated. The volumes were all measured by ultrasound. The mean value at the two
week time point represents data from only five of the 14 tumours but is included in an
attempt to improve definition of the early response.
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Figure 13.18 The Tumour Response over Time in 7 Patients Treated










Figure 13.18 shows individual response curves for the seven tumours treated with
tamoxifen as part of the Trial of Primary Systemic Therapy. Tumour volumes were
assessed by serial ultrasound scans and related to the pre-treatment volume to measure
response. Patient numbers refer to previous tables of clinical data presented for patients
recruited to the trial.
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Chapter 14: Biological Factors Predicting and Reflecting the Response
to Primary Systemic Therapy
In Chapter 13 the clinical responses, as observed by serial measurements of individual
tumours were reported in two groups of patients treated with either primary tamoxifen
or chemotherapy. The data thus accumulated provided a basis on which to examine the
corresponding cellular characteristics of the tumours studied. Tumour material was
examined by both immunohistochemistiy (reported below) and flow cytometry
(Chapter 15).
14.1 Tumours from Patients Treated with Primary Tamoxifen Therapy
Fifty-two tumours were assessed by immunohistochemistry. Patients had been treated
for a mean of 18.8 weeks with the response recorded over the first 12 weeks of
threrapy. Material was available from these tumours from pre-treatment wedge
biopsies and post-treatment definitive surgical procedures.
Tissue sections were stained with antibodies to seven different antigens; Ki-Sl, Bcl-2
protein, pS2, c-erb B-2, P - Glycoprotein, EGF Receptor and p53. The relationship of
these antigens to response was assessed both as predictive factors prior to treatment
and as reflective factors by changes in expression with treatment. Oestrogen receptor
levels have been shown in chapter 14 to be significantly related both to the overall and
the degree of response to tamoxifen. EIA values for receptor content were available for
all but one of the tumours prior to treatment and could thus be compared to the
expression of these other antigens as a predictor of response.
A full table of immunohistochemical results and relevant clinical data is shown in Table
14.1. The results for individual markers will be presented initially and then the results
of a multi-variate analysis will be discussed.
162
Table 14.1 Immunohistochemical Data from 52 Elderly Patients Before
and After Primary Tamoxifen Therapy
Patient Rx Sample Ki-Sl pS2 c-erbB-2 P-Glyc. Bcl-2 EGFR p53 ER (EIA) L.N. Response
1 Pre 2 3 0 0 1 0 0 606 69%
19 Post 1 3 0 0 1 3 0 96 n/a
2 Pre 2 0 0 0 2 2 0 23 73%
21 Post 0 2 0 0 1 0 1 46 +
3 Pre 2 0 * 2 0 0 0 325 54%
18 Post 1 0 0 0 1 2 0 18 -
4 Pre 1 1 0 1 3 1 0 29 Static
22 Post I 0 0 2 2 0 0 27 -
5 Pre 0 0 0 0 1 0 0 86 Static
18 Post 1 0 0 2 1 1 0 58 +
6 Pre 1 2 0 0 1 0 0 605 48%
16 Post 0 2 0 0 0 2 0 97 -
7 Pre 2 2 1 0 3 3 0 444 88%
15 Post 0 3 0 0 2 3 0 71 -
8 Pre 1 0 0 1 1 2 0 * 34%
21 Post 0 2 1 2 3 2 0 141 -
9 Pre 2 2 0 3 0 1 0 87 Static
18 Post 0 2 1 2 3 3 0 n/a +
10 Pre 1 2 0 0 2 0 0 445 91%
15 Post 0 2 1 1 0 0 0 n/a -
11 Pre 2 0 2 0 3 1 1 79 23%
19 Post 0 0 0 0 3 0 3 23 +
12 Pre 0 0 0 0 1 0 0 170 Static
18 Post I 1 3 1 1 0 0 26 -
13 Pre 1 0 2 0 0 0 0 68 18%
20 Post 0 0 1 0 0 0 0 65 -
14 Pre 1 1 0 1 2 0 0 290 33%
25 Post 0 1 0 0 0 0 0 102 -
15 Pre 0 0 1 0 3 0 0 70 Static
27 Post 1 0 0 0 2 0 0 58 +
16 Pre 0 0 3 0 3 0 0 384 68%
19 Post 0 2 3 0 2 0 0 168 -
17 Pre 2 3 3 0 1 0 0 498 63%
12 Post 2 2 3 0 0 0 0 75 +
18 Pre 1 3 0 1 1 0 1 186 53%
18 Post 1 3 0 2 0 0 1 67 -
19 Pre 2 3 0 0 3 0 0 510 45%
19 Post 2 2 3 0 2 0 * 92 +
20 Pre 0 0 0 1 0 0 0 222 Static
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Table 14.1 Continued
Patient Rx Sample Ki-Sl pS2 c-erbB-2 P-Glyc. Bci-2 EGFR p53 ER (EIA) L.N. Response
26 Post 1 0 0 3 2 0 0 90 +
21 Pre 3 3 0 2 0 0 0 72 37%
23 Post 0 2 0 0 0 1 0 n/a +
22 Pre 1 0 0 0 2 3 0 93 34%
12 Post 1 0 0 0 1 2 * 0 -
23 Pre 0 0 0 0 3 3 n/a 964 67%
19 Post 0 0 0 0 * 0 0 n/a -
24 Pre 1 2 0 0 2 2 0 262 29%
21 Post 2 3 1 0 2 1 0 n/a -
25 Pre 0 2 0 1 3 0 0 463 49%
18 Post 0 2 0 1 1 1 0 3 +
26 Pre 2 2 0 I 2 0 0 837 80%
12 Post 3 1 0 1 1 0 0 n/a +
27 Pre 2 1 0 0 2 0 3 70 Static
24 Post 3 1 2 0 0 0 3 48 -
28 Pre 0 2 0 2 2 0 0 143 27%
36 Post 0 0 0 1 3 0 n/a n/a +
29 Pre 1 3 3 1 0 0 0 384 Static
20 Post 0 0 0 0 3 2 0 n/a +
30 Pre 2 0 0 0 1 0 0 557 72%
18 Post 0 1 0 0 1 0 0 128 +
31 Pre 2 3 0 0 1 0 0 76 32%
20 Post 1 1 1 0 1 0 0 116 -
32 Pre 1 0 1 0 1 0 0 285 Static
26 Post 2 0 0 0 1 0 0 56 +
33 Pre 2 0 0 0 3 0 0 1000 85%
14 Post 0 0 0 0 2 0 0 83 +
34 Pre 1 0 0 2 2 0 0 177 82%
14 Post 1 0 1 1 0 0 n/a 42 +
35 Pre 1 0 3 0 1 0 0 65 Static
28 Post 0 1 3 1 0 0 0 40 +
36 Pre 1 1 0 2 1 0 0 166 59%
17 Post 0 2 2 2 1 0 0 81 -
37 Pre 1 0 0 0 1 0 1 292 38%
15 Post 0 3 0 0 1 1 0 n/a +
38 Pre 0 1 0 0 3 0 0 14% 65%
18 Post 0 3 0 0 0 0 * n/a +
39 Pre 1 2 3 3 2 0 0 73 Static
12 Post 2 1 0 2 1 0 0 12 -
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Table 14.1 Continued
Patient Rx Sample Ki-Sl pS2 c-erbB-2 P-Glyc. Bcl-2 EGFR p53 ER (EIA) L.N. Response
40 Pre 2 0 1 2 1 0 0 279 25%
18 Post 1 0 2 2 1 0 0 16 -
41 Pre 0 0 0 1 3 0 0 1388 76%
18 Post 0 1 0 0 3 0 0 n/a -
42 Pre 2 0 3 2 3 1 0 306 61%
18 Post 0 0 0 0 0 0 0 60 -
43 Pre 2 0 0 0 1 0 0 40 Progression
19 Post 1 1 0 1 1 0 0 64 +
44 Pre 2 1 0 1 1 0 * 201 Static
17 Post 2 1 0 3 3 0 * 35 -
45 Pre 1 1 0 0 1 1 0 134 Static
18 Post 0 0 0 3 2 2 2 99 +
46 Pre 1 0 1 0 2 0 0 120 81%
25 Post 0 0 0 1 1 0 0 58 -
47 Pre 0 2 0 0 2 1 * 16 Static
30 Post 0 2 0 0 * 0 * 100 +
48 Pre 1 0 0 1 3 0 0 620 40%
12 Post 0 2 0 1 2 0 0 22 +
49 Pre 1 2 0 0 0 0 0 552 77%
12 Post 0 1 0 0 3 0 0 109 -
50 Pre 0 0 1 1 1 0 0 25 66%
12 Post 1 0 1 1 0 1 2 45 -
51 Pre 0 1 0 1 3 0 0 623 73%
12 Post 0 2 2 2 2 0 0 77 +
52 Pre 1 0 0 0 3 0 0 386 99%
12 Post 0 0 0 0 3 3 0 n/a -
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Table 14.1 shows all the immunohistochemical data from tumour samples obtained
pre and post tamoxifen treatment. Sections stained with each individual antibody were
scored by an independent single pathologist. The scoring system used denotes the
number of tumour cells stained; 0 = <5%, 1 = 5-25%, 2 = 25-75% and 3 = >75% of
cells stained.
Rx is the treatment period in weeks between commencement of therapy and definitive
surgery.
ER (EIA) is the Oestrogen receptor content measured in fmol/mg cytosol protein.
There were several tumours with insufficient material in the post treatment specimen to
obtain ER level.
L.N. is the axillary lymph node status determined from the axillary procedure
performed at the time of definitive surgery and has been simply divided into nodal
metastases present (+) or absent (-).
Response is measured by percentage decrease in tumour volume as assessed by
ultrasound.
* denotes samples in which particular stains were unassessable despite repeated
attempts.
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14.2 The Expression of Ki-Sl and Response
Ki-S 1 is a proliferation associated nuclear antigen which can be detected by a
monoclonal-antibody both in fresh and formalin-fixed material. A typical example of a
tumour strongly positive on staining with antibody to Ki-Sl is shown in Figure 14.1
In the group of 52 patients studied and reported in this section 37 (71%) demonstrated
a response and 15 (29%) no response to treatment after three months. Prior to
tamoxifen therapy, 39 (75%) patients had tumours with expression of Ki-Sl in greater
than 5% of cells (Table 15.2a). On comparison of the degree of Ki-Sl staining (ie. the
% of tumour cells stained) and subsequent overall response, there was no significant
trend demonstrated. In the tissue obtained after treatment only 44% of tumours
expressed detectable Ki-Sl but there was again no statistically significant trend in
comparison to overall response (Table 14.2b). However when tabulating the change in
expression and overall response a significant trend emerged with responding tumours
demonstrating a decrease in the level of Ki-Sl expression and non-responders an
increase in expression (Table 14.2c). The degree of the change in expression is
tabulated with overall response in Table 14.2d, where the change in expression is
represented by the change in staining index. A significant trend was once more
demonstrated.
The relationship between Ki-Sl staining indices in the pre-treatment biopsy specimens
and the degree of subsequent response as measured by ultrasound is shown in Figure
14.2. No significant correlation was apparent. The change in Ki-Sl staining index
between tumour samples taken before and after treatment is related to reduction in
tumour volume in Figures 14.3. There was a trend, which just reached statistical
significance, for those tumours with the greatest decrease in volume to show the
greatest decrease in Ki-Sl staining index.
Ki-Sl expression, therefore, in those patients studied, does not appear to predict for
the overall or actual degree of response to tamoxifen. However the change in
expression does reflect the degree of clinical response.
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Figure 14.1 Immunohistochemical Staining for Ki-Sl
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Figure 14.1 shows immunohistochemical staining with Ki-Sl monoclonal antibody
in a section from a primary breast cancer prior to tamoxifen therapy (x40). Note the
nuclear staining.
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<5% 5-25% 25-75% >75%
Responders(37) 8 15 13 1
Non-Responders(15) 5 6 4 0




<5% 5-25% 25-75% >75%
Responders(37) 24 8 4 1




c) Overall Change in Expression
Change in No. of Cells Staining
Increase No Change Decrease
Responders (37) 3 11 23
Non-Responders (15) 7 3 5
X2 Trend =8.73
p =0.003
d) Degree of Change in Expression
Change in Staining Index
-3 -2 -1 0 + 1
Responders(37) 1 6 15 12 3
Non-Responders(15) 0 1 4 3 7
X2 Trend = 6.42
p = 0.01
Table 14.2 shows immunohistochemical data from tumour tissue obtained before
and after treatment with tamoxifen. Tumours are divided into responders and non-
responders depending on the response obtained over three months of treatment as
assessed by ultrasound scanning. Table a) demonstrates positive Ki-Sl staining (>5%
of cells staining) in 39 of the 52 tumours (75%) prior to treatment. There is no
significant relationship between the percentage of tumour cells staining and subsequent
overall response. Post-treatment (Table b)) 23 tumours (44%) remined Ki-Sl positive
but again there was no significant relationship between degree of staining and prior
overall response. The inferred change in staining with treatment is demonstrated in
Table c). There is a significant trend towards a decrease in staining in tumours which
have demonstrated a response to tamoxifen. The degree of change is tabulated against
overall clinical response in table d). The degree of change represents the difference
between the pre- and post-treatment staining indices (where a staining index of <5% =
0, 5-25% = 1, 25-75% = 2 and >75% = 3), negative values representing a decrease.
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Spearman r = 0.09
p = NS
Ki-Sl Staining Index
Figure 14.2 shows the relationship between Ki-Sl staining index prior to tamoxifen
therapy and subsequent % reduction in tumour volume (as assessed by ultrasound).
There is no significant difference between the median response of tumours with each
of the staining indices.
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Spearman r = - 0.28
p = 0.04
-0009000-
-3 -2 -1 0
Change in Ki-Sl Staining Index
Figure 14.3 shows the relationship between the change in Ki-Sl staining indices
with tamoxifen treatment and the % tumour volume reduction. There is a correlation,
which just achieves statistical significance, such that greater tumour responses are
associated with greater reductions in Ki-Sl staining indices.
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14.3 The Expression of BcI-2 and Response
The Bcl-2 protein is associated with the cellular mechanisms responsible for the
resistance to death by apoptosis. Immunohistochemical staining for the protein was
possible in 51 patients only. Despite repeated attempts tumour sections from one of the
patients failed to survive the staining process. Of these 51 tumours, 44 (86%) were
classed as staining positive for Bcl-2 prior to tamoxifen therapy and an example of
positive staining is shown in Figure 14.4.
The relationships between Bcl-2 staining both before and after tamoxifen treatment and
the overall clinical response are shown in Tables 14.3 a,b,c, and d.There was no
significant trend in the degree of staining in tumour samples taken prior to treatment
and the subsequent overall response (Table 14.3a). However, there was a significant
relationship with the degree of response as measured by decrease in tumour volume
(Figure 14.5), higher staining indices being associated with tumours displaying the
greater reduction in volume. After treatment 37 (73%) tumours were positive for Bcl-
2 staining and again no significant association was apparent between the degree of
staining and overall response (Table 14.3b). There were, however, significant
associations between the change in staining index and both the overall response (Table
14.3c and d) and the degree of response in terms of reduction in tumour volume
(Figure 14.6). Decreased Bcl-2 staining was related to both qualitative and quantitative
response.
The expression of Bcl-2 has previously been shown to be related to ER status and in
this present series of tumours the quantitative relationship between these two
parameters was examined. This relationship is illustrated graphically in Figure 14.7
and shows a positive correlation between Bcl-2 staining index and cellular levels of
ER. In particular, those tumours with the highest staining index (grade 3) tended to
have very high levels of ER.
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Figure 14.4 Immunohistocheniical Staining for Bcl-2
Figure 14.4 shows immunohistochemical staining with monoclonal antibody 124 to
Bcl-2 protein in a section from a primary breast cancer prior to tamoxifen therapy
(x40). Note the granular cytoplasmic staining.
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<5% 5-25% 25-75% >75%
Responders(37) 4 11 9 13





<5% 5-25% 25-75% >75%
Responders(37) 12 12 7 6
Non-Responders(14) 2 5 4 3
X2 Trend = 1.34
p = NS
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c) Overall Change in Expression
Change in No. of Cells Staining
Increase No Change Decrease
Responders (37) 4 12 21
Non-Responders (14) 5 4 5
X2 Trend =3.73
p = 0.05
d) Degree of Change in Expression
Change in Staining Index
-3 -2 -1 0 + 1 + 2 + 3
Responders(37) 3 4 14 12 2 1 1
Non-Responders(14) 0 1 4 4 1 2 2
X2 Trend = 5.24
p = 0.02
Table 14.3 shows the relationship of immunohistichemical staining of 51 breast
tumours with Bcl-2 monoclonal antibody and overall response to 3 months of
tamoxifen therapy. Tables 14.3a and b demonstrate that there is no significant trend in
Bcl-2 expression before or after treatment when responding and non-responding
patients are compared. Although the trend in overall change in staining with response
does not quite reach significance, there is a significant trend when the degree of change
in staining is compared with overall response (Tables 14.3c and d). Those tumours
which show the greatest decrease in staining tend to be those which demonstrate
reduction in volume with tamoxifen.
176
























Spearman r = 0.37
p = 0.008
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Bcl-2 Staining Index
Figure 14.5 shows the relationship between Bcl-2 staining index in tumour tissue
taken prior to treatment and tumour volume reduction with subsequent tamoxifen
therapy. There is a significant correlation although there is a wide variation of
responses for individual staining indices.
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Change in Bcl-2 Staining Index
Figure 14.6 shows the relationship between the change in the Bcl-2 staining index
and the reduction in tumour volume with tamoxifen therapy. There is a significant
correlation in that those tumours showing the greater decreases in staining are those
responding with greater reductions in tumour volume and those which show an
increase in staining have a much smaller mean reduction in volume.
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Figure 14.7 Bcl-2 Staining Index and Oestrogen Receptor Expression



































Spearman r = 0.30
p = 0.03
Bcl-2 Staining Index
Figure 14.7 shows the relationship, prior to treatment, between Bcl-2 staining
indices and ER expression as measured by ELA.. There is a significant overall
correlation but a wide range of values for ER at individual Bcl-2 staining indices. The
median ER level associated with a Bcl-2 staining index of 3 is significantly higher than
the levels associated with lower indices (e.g index 3 vs 2 Mann-Whitney U-statistic =
42.5, p = 0.04). There is no significant difference between median ER levels at Bcl-2
staining indices of 0 to 2.
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14.4 The Interaction Between Ki-Sl and BcI-2
Since tumour growth has been simplistically described in terms of the respective rates
of cell proliferation and cell death, reduction in tumour volume could also be linked to
these two processes. Associations between tumour response, the expression of a
proliferation marker, such as Ki-Sl and the indirect marker for cell survival, Bcl-2
might, therefore, be expected. The expression of Bcl-2 is not known to be cell cycle
dependent and therefore changes in expression would not be expected simply to reflect
change in proliferation.
Although there were similar trends in the expression of both markers towards a
decrease in responding tumours, the changes of each marker in individual tumours
were largely independent, with only 11 of the 51 tumours showing concordant
changes of expression (10 decreased, 1 increased), as summarised in Table 14.4a.
Because of this independence, it was of interest to combine the changes in expression
of the two markers. Thus Table 14.4b shows tumours categorised as displaying a net
increase (an increase in both markers or an increase in one and no change in the other),
a net decrease (the reverse changes) or a net no change (an increase in one marker and
a decrease in the other or no change in either) in marker staining indices. These results
show that the pattern of change in responding tumours is highly significantly different
from that of non-responding tumours (and greater than when the markers had been
considered separately). Furthermore, when the quantitative changes in Ki-S 1 and Bcl-
2 expression in individual tumours were added together, highly significant
associations were obtained with both the overall response (Table 14.5) and the degree
of response (Figure 14.8). Thus the use of a combination of changes in both markers
results in a better correlation with response than that produced by either marker alone.
In other words response can be associated with a decrease in either Ki-S 1 (a decrease
in proliferation) or Bcl-2 ( an increase in cell death) or both and the best responses are
seen in those tumours in which both markers decrease significantly.
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Table 14.4 Combined Changes in Ki-Sl and Bcl-2 and Overall
Response to Tamoxifen
a)
Change in Staining Index
Both Increase Both Decrease Others
Responders (37) 0 9 28
Non-Responders (14) 1 1 12
b)
Chanj*e in Staining Indices
Net Increase Net No Change Net Decrease
Responders (37) 1 7 29
Non-Responders (14) 6 5 3
X2 Trend = 18.26
p = <0.0001
Table 14.4 shows the relationships between overall response and the combined
changes in Ki-Sl and Bcl-2 staining indices. Table a) demonstrates the concordance of
the changes in expression of each marker and table b) the overall change after
summation of the changes in individual markers.
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Table 14.5 The Sum of Changes in Ki-Sl and Bcl-2 Staining Indices
and Response
Sum of Changes in Staining Indices
-5 -3 -2 -1 0 + 1 + 2 + 3
Responders(37) 1 8 7 13 4 3 1 0
Non-Responders(14) 0 0 1 3 3 4 2 2
X2 Trend = 12.69
p = 0.0004
Table 14.5 shows the relationship between the sum of the changes in KI-S1 and
Bcl-2 staining indices in individual tumours and overall response to tamoxifen. There
is a highly significant trend, the greater decreases in the combined sum tending to be
in responding tumours. The trend is more significant than with either marker alone.
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Figure 14.8 The Sum of the Change in both Ki-Sl and Bcl-2 Staining
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Change in Ki-Sl + Change in Bcl-2
Spearman r = - 0.48
p = 0.0003
Figure 14.8 shows the relationship between tumour response, as measured by
reduction in volume, and the sum of the changes in Ki-Sl and Bcl-2 staining indices in
individual tumours. There is a highly significant correlation with the greater total
decreases in staining indices reflecting the greater reductions in tumour volume.
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14.5 The Expression of pS2
The protein product of the oestrogen-inducible gene, pS2, was examined by means of
immunohistochemistry in the study population of 52 patients receiving primary therapy
with tamoxifen. Staining for pS2 was detectable in >5% of tumour cells in 26 (50%)
patients prior to therapy and a typical example of positive staining is shown in Figure
14.9. There was no significant association between initial staining index and tumours
subsequently responding or not responding to treatment (Table 14.6a). Expression of
pS2, therefore, did not predict for overall response in this series and in addition did
not correlate with the degree of response in terms of reduction in tumour volume
(Figure 14.13).
The pS2 gene appears to be inducible by oestrogens in certain systems and it might,
therefore, be that a relationship exists with the ER content of individual tumours. No
such association was apparent in staining of the pre-treatment samples (Figure 14.10).
However there was a statistically significant relationship between ER prior to therapy
and the pS2 staining index after treatment (Figure 14.11). This may reflect the ability
of tamoxifen to act as a partial agonist at the oestrogen receptor and induce pS2.
Despite this association, the correlation between pre-treatment ER and the change in
pS2 staining index with treatment was not significant (Figure 14.12). Additionally,
there were significantly higher levels of pS2 staining in the post-treatment samples
from responding tumours when compared to those which had not responded to
tamoxifen (Table 14.6b) . However, when considering the association of overall
change in pS2 staining with response, although there was a trend towards a greater
number of the responding tumours showing increase in pS2 expression this did not
reach statistical significance (Table 14.6c) The degree of change in staining index also
did not significantly relate to either the overall (Table 14.6d) or the degree of response
(Spearman r = 0.1867, p = NS, data not shown). These relationships held true when
the subset of tumours which did not express pS2 either before or after therapy were
removed from the analyses.
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Figure 14.9 Immunohistochemical Staining for pS2
Figure 14.9 shows immunohistochemical staining with monoclonal antibody to pS2
protein in a section from a primary breast cancer prior to tamoxifen therapy (x40).
Note the strong cytoplasmic staining.
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Table 14.6 The Expression of pS2 Protein and Response to Tamoxifen
a) Before
Cells Staining
<5% 5-25% 25-75% >75%
Responders(37) 19 4 8 6





<5% 5-25% 25-75% >75%
Responders(37) 13 6 12 6




c) Overall Change in Expression
Change in No. of Cells Staining
Increase No Change Decrease
Responders(37) 12 18 7
Non-Responders(15) 3 8 4
X2 Trend =0.88
p = NS
c) Degree of Change in Expression
Change in Staining Index
-3 -2 -1 0 + 1 + 2 + 3
Responders(37) 0 2 5 18 6 5 1
Non-Responders(15) 1 0 3 8 3 0 0
X2 Trend = 1.98
p = NS
Table 14.6 displays the immunohistochemical results for pS2 antibody staining of
tumour sections from the fifty-two patients in the study population. Tables a) and b)
show the degree of pS2 staining in the respondin and non responding tumours before
and after treatment. There is a significant trend towards a greater proportion of cells
staining in responding patients in the samples taken after therapy. Although a tendency
for an increase in pS2 staining in responding patients is seen in tables c) and d) this
does not reach statistical significance.
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Figure 14.10 The Relationship Between the Expression of pS2 Protein
























Figure 14.10 shows the relationship between pS2 staining index and ER content, as
measured by EIA, in tissue taken from 51 tumours prior to tamoxifen treatment. One
tumour from the study population of 52 could not be assessed for ER content. In this
series there is no significant correlation between pS2 staining index and ER content.
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Figure 14.11 The Relationship Between the Expression of pS2 Protein




















Spearman r - 0.31
p = 0.03
Figure 14.11 shows the relationship between pS2 staining index in tissue taken after
treatment and the ER content of the same tumour prior to therapy. There is a
statistically significant correlation between the two parameters with higher post-
treatment staining levels associated with higher pre-treatment ER content.
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Change in pS2 Staining Index
Figure 14.12 shows the relationship between the tumour ER content prior to
treatment and the change in pS2 expresion with subsequent tamoxifen therapy. There
is no significant correlation between these two parameters although there appears to be
a trend towards a positive change in staining in tumours with higher levels of ER.
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Figure 14.13 The Expression of pS2 and the Subsequent Response to
Tamoxifen





Figure 14.13 shows the relationship between pS2 expression prior to treatment and
the subsequent response to tamoxifen as represented by reduction in tumour volume.
There is no significant correlation between these parameters in this series of 52
patients. Prior to therapy 26 tumours displayed pS2 staining and in this subpopulation
there was no significant correlation beween the degree of staining and response
(Spearman r = 0.16, p = NS)
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14.6 The Expression of c-erbB-2
Similar studies were performed in the series of tumours described to determine the
relationship between the expression of c-erbB-2 and the clinical response to
tamoxifen. An example of positive staining obtained with monoclonal antibody to the
c-erbB-2 antigen is shown in Figure 14.14. As shown in Table 14.7a 14 (27%) of the
51 tumours demonstrated positive staining for c-erbB-2 prior to therapy. Futhermore,
there was no significant difference in the degree of staining between tumours
subsequently responding or non-responding to tamoxifen. Additionally there was no
significant relationship between the staining index and the degree of response to
treatment (Figure 14.15). After treatment 17 (33%) stained positive and again there
was no significant difference in the degree of staining between responders and non-
responders (Table 14.7b). A tendancy was apparent for an increase in staining in
responding tumours with treatment (Tables 14.7c and d) but given the relatively small
numbers of positively staining tumours this did not reach statistical significance. No
significant relationship was detected between the change in c-erbB-2 staining index
and the degree of the clinical response (Figure 14.16).
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Figure 14.14 Immunohistochemical Staining for
Figure 14.14 shows immunohistochemical staining with monoclonal antibody to c-
erbB-2 protein in a section from a primary breast cancer prior to tamoxifen therapy
(x40). Note the strong membrane staining.
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<5% 5-25% 25-75% >75%
Responders (36) 27 4 2 3





<5% 5-25% 25-75% >75%
Responders (36) 23 7 3 3




c) Change in Expression
Change in No. of Cells Staining
Increase No Change Decrease
Responders(36) 9 22 5
Non-Responders(15) 3 8 4
X2 Trend =0.82
p = NS
d) Degree of Change in Expression
Change in Staining Index
-3 -2 -1 0 + 1 + 2 + 3
Responders(36) 1 1 3 22 6 2 1
Non-Responders(15) 2 0 2 8 1 1 1
X2 Trend = 0.55
p = NS
Table 14.7 shows immunohistochemical data representing staining for c-erbB-2 in
51 tumours a) before and b) after treatment. There are no significant differences
between the degrees of staining prior to and after treatment and the observed overall
response. In addition there are no significant changes in c) the overall, and d) the
degree of change in staining and clinical response.
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Figure 14.15 shows the relationship between the c-erb B-2 staining index, in 51
tumours prior to treatment, and the subsequent response to tamoxifen therapy. The
majority of tumours do not express the c-erb B-2 protein and in those which do so
their is no significant relationship with the response to tamoxifen.
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Spearman r = 0.07
p = NS
Change in c-erbB-2 Staining Index
Figure 14.16 shows the relationship between the change in c-erb B-2 staining index
and the degree of response seen with tamioxifen treatment in 51 patients. There is no
significant correlation between these parameters.
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14.7 The Expression of P -Glycoprotein
The expression of P -Glycoprotein has been linked to the MDR phenotype and is one
mechanism by which tumour cells may exhibit resistance to several commonly used
cytotoxic agents. To examine the possible contribution of this mechanism to tamoxifen
resistance, tissue samples of the 52 patients in the study population were stained using
immunohistochemical techniques and a polyclonal antibody to P -Glycoprotein. A
typical positively staining tumour section is shown in Figure 14.17.
Prior to treatment 22 (42%) of the 52 tumours stained positively. There were no
significant trends in the degree of staining and subsequent overall response or non-
response (Table 14.8a). Interestingly neither of the only two tumours with >75% of
cells staining (a staining index of 3) demonstrated a response to tamoxifen. Similarly
the degree of staining failed to predict for the degree of response as measured by
ultrasound volumes (Figure 14.18). There was, however, a significant trend in the
samples taken after treatment in that tumours that had failed to respond displayed
higher levels of staining than those which had responded (Table 14.8b). The degree of
staining in the post treatment sample was also significantly negatively correlated to the
degree of response (Figure 14.19). The increase in staining in non-responding
tumours compared to those demonstrating a response was statistically significant both
as an overall change and more highly so when the degree of change was calculated
(Tables 14.8c and d). There was not, however, a significant correlation between the
degree of change in the staining index and the actual measured tumour volume
responses (Figure 14.20).
It must be remembered that changes in the staining index can be interpreted in at least
two ways. An increase in staining, such as that noted for P-Glycoprotein in non-
responding patients may be a result of induction of the protein in individual cells or
selection of those cells which express the protein and may therefore be resistant to
tamoxifen. In either scenario P-Glycoprotein appears to be linked to tamoxifen
resistance but of course this data cannot prove that it is ultimately responsible.
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Figure 14.17 Immunohistochemical Staining for P-Glycoprotein
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Figure 14.17 shows immunohistochemical staining with polyclonal antibody to P-
glycoprotein in a section from a primary breast cancer prior to tamoxifen therapy
(x40). Note the cytoplasmic staining.
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<5% 5-25% 25-75% >75%
Responders (37) 21 9 7 0





<5% 5-25% 25-75% >75%
Responders (37) 24 8 5 0




c) Change in Expression
Change in No. of Cells Staining
Increase No Change Decrease
Responders(37) 4 26 7
Non-Responders(15) 8 4 3
X2 Trend =4.35
p = 0.04
d) Degree of Change in Expression
Change in Staining Index
-3 -2 -1 0 + 1 + 2 + 3
Responders(37) 0 3 4 25 5 0 0
Non-Responders(15) 0 0 3 4 4 3 1
X2 Trend = 7.35
p = 0.007
Table 14.8 shows data generated from the immunohistochemical staining, with a
polyclonal antibody to P -Glycoprotein, of 52 tumours before and after treatment with
tamoxifen. Table a) shows no significant trend in the relationship between the degree
of staining prior to treatment and the subsequent overall response. The two tumours
with the highest degree of staining, however, failed to demonstrate a response. There
was a significant trend in the samples taken after treatment (Table b) with higher
staining indices in non-responding tumours. The overall and actual changes in staining
indices on comparison of the pre- and post-treatment samples were also significantly
different in responders and non-responders (Tables c and d). There was a trend
towards an increase in staining index in non-responding compared to responding
tumours.
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Figure 14.18 The Expression of P-Glycoprotein Prior to Tamoxifen




























Figure 14.18 shows the relationship, in 52 tumours, between the P -Glycoprotein
staining index prior to tamoxifen therapy and subsequent response. There is no
significant correlation between the two parameters. Note that two tumours had a
staining index of 3 and neither responded to tamoxifen.
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Figure 14.19 The Expression of P-Glycoprotein after Tamoxifen













































Figure 14.19 shows the relationship between P -Glycoprotein staining index of
tumour specimens taken after treatment with tamoxifen and the observed response to
therapy. There is a significant negative correlation between these parameters with those
tumours with higher staining indices displaying smaller clinical responses. Three
tumours are represented by the single point with a staining index of 3 and no prior
response to tamoxifen.
203
Figure 14.20 The Change in Expression of P-Glycoprotein and the






Spearman r = - 0.18
p = NS
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Change in P-Glycoprotein Staining Index
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Figure 14.20 shows the relationship between the change in P -Glycoprotein staining
index with treatment and the clinical response measured. There is no statistically
significant correlation between these two parameters in the population studied. None
of the four tumours showing a change in staining index of either +2 or +3
demonstrated a response to tamoxifen.
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14.8 The Expression of Epidermal Growth Factor Receptor
The tumours in the study population of 52 patients were stained by
immunohistochemical techniques to determine the relationship between EGFR
expression and the response to tamoxifen. A typical example of tumour tissue staining
positively is shown in Figure 14.21. In the tumour samples taken prior to tamoxifen
therapy only 12 (23%) stained positive with monoclonal antibody (Table 14.9a).
Previously, several authors have reported a negative relationship between the
expression of EGFR and the possession of oestrogen recepors (See Capter 5.3). This
may explain, therefore, the relatively small number of tumours staining positive in the
exclusively ER-positive study group. Indeed, in the pre-treatment samples there was a
negative correlation between EGFR staining index and the level of ER expression but
this was not statistically significant (Figure 14.22).
EGFR expression has also been suggested as a predictive factor for lack of response to
hormone therapy. In this study there appeared to be no association between the degree
of staining prior to treament and the overall response to therapy (Table 14.9a).
Similarly there was no correlation between staining index and the degree of response
as measured by the percentage reduction in tumour volume (Figure 14.23). However,
given the limitations of small numbers, there was a highly significant positive
correlation between EGFR staining index and the degree of response in those 12
tumours staining positive prior to therapy (Spearman r = 0.75, p= 0.005).
After treatment with tamoxifen 16 (31%) tumours stained positive for EGFR but with
no significant association with the individual responses achieved (Table 14.8b).
Similarly there were no significant trends in the change in staining index of tumour
samples taken before and after treatment and the observed response (Tables 14.8c and
d).
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Figure 14.21 Immunohistochemical Staining for EGFR
Figure 14.21 shows immunohistochemical staining with monoclonal antibody to
EGFR protein in a section from a primary breast cancer prior to tamoxifen therapy
(x40). Note the strong membrane staining.
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Table 14.9 The Expression of EGFR and Response to Tamoxifen
a) Before
Cells Sitaining
<5% 5-25% 25-75% >75%
Responders (37) 29 2 3 3





<5% 5-25% 25-75% >75%
Responders (37) 25 5 4 3




c) Overall Change in Expression
Change in No. of Cells Staining
Increase No Change Decrease
Responders(37) 8 23 6
Non-Responders(15) 4 9 2
X2 Trend =0.18
p = NS
d) Degree of Change in Expression
Change in Staining Index
-3 -2 -1 0 + 1 + 2 + 3
Responders(37) 1 1 4 23 4 2 2
Non-Responders(15) 0 0 2 9 2 2 0
X2 Trend = 0.17
p = NS
Table 14.9 shows data derived from immunohistochemical staining, with EGFR
antibody, of tissue sections taken from 52 tumours before and after treatment with
tamoxifen. There are no significant trends in sections taken, a) before and b) after
treatment on comparison of the degree of staining and observed overall response.
There are also no significant trends in either the c) overall or d) the degree of change in
staining index with treatment and the observed response.
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Spearman r = - 0.18
p = NS
EGFR Staining Index
Figure 14.22 shows the relationship between EGFR expression and ER content
prior to tamoxifen therapy. The data displayed is for only 51 tumours as ER
information was unobtainable for one tumour which in fact expressed EGFR. There is
a tendancy to a negative correlation between the two parameters but this fails to reach
significance. This is, however, a selected study population of tumours, all of which
have an ER > 20 fmol/mg and the vast majority do not express EGFR. There is not a
significant correlation between EGFR staining index and ER in those 11 tumours
which do stain positive (Spearman r = 0.5377, p = NS) although surprisingly there is
a positive correlation coefficient.
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Spearman r = - 0.07
p = NS
EGFR Staining Index
Figure 14.23 shows the relationship between EGFR staining index prior to
treatment with tamoxifen and the subsequent observed response. There is no
significant correlation between these two parameters in this study population.
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14.9 The Expression of p53
In order to study the relationship between the expression of mutant p53 and response
to tamoxifen, tumours from the series of 53 patients treated with primary therapy were
immunohistochemically assessed. The antibody used in the study detects both mutant
and wild type p53 but since the half-life of the wild type antigen is very short it was
presumed that the vast majority of the staining observed corresponded to mutant p53.
The staining methods involved a microwaving step to aid antigen retrieval and despite
repeated attempts interpretable staining (negative or positive) was achieved in samples
obtained both before and after treatment in only 44 tumours. An example of positive
staining is shown in Figure 14.24. Of the 44 tumours assessed only 5 (11%) showed
staining in >5% of tumour cells prior to tamoxifen therapy (Table 14.10a). The same
number of tumours were positively staining after treatment although the distribution of
the degree of staining was different (Table 14.10b). The small numbers of positively
staining tumours makes further assessment of the relationship to response
uninformative.
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Figure 14.24 Immunohistochemical Staining for p53
Figure 14.24 shows immunohistochemical staining with monoclonal antibody to
p53 protein in a section from a primary breast cancer prior to tamoxifen therapy (x40).
Note the strong membrane staining.
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Table 14.10 The Expression of p53 and Response to Tamoxifen
a) Before
Cells Sttaining
<5% 5-25% 25-75% >75%
Responders (33) 29 4 0 0
Non-Responders (11) 10 0 0 1
b) After
Cells Staining
<5% 5-25% 25-75% >75%
Responders (33) 30 1 1 1
Non-Responders (11) 9 0 1 1
X2 Trend = 1.11
p = NS
Table 14.10 shows the distribution of staining for p53 antigen in responding and
non-responding tumours a) prior to and b) after treatment with tamoxifen. There are
only very few tumours staining positively for the antigen and there are no significant
associations between staining and tumour response.
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14.10 Multivariate Analyses of Data Generated by
Immunohistochemistry
Multivariate analyses were performed to establish which markers were independently
related to the overall and actual degree of response to tamoxifen. The markers included
in the analyses were the initial calliper-measured tumour diameter and ultrasound-
assessed volume, initial ER content (logarithmically transformed) and the pre- and
post- treatment expression of Ki-Sl, Bcl-2, pS2, c-erbB-2, EGF-R and P -
Glycoprotein (For working data see Table 14.1). The overall differences in the pre-
and post-treatment antigen expression were also modelled (coded as -1 = decrease, 0 =
no change, 1 = increase) There were too many missing values to include the p53 and
post-treatment ER data. For response multiple logistic regression and for the degree of
response multiple normal regression models were fitted. In both cases a stepwise
forward variable selection procedure was employed to identify independent predictors
of response. Only variables significant at the 5% level were entered and retained in the
models. A forward variable selection procedure was performed on patients with all
measurements available (48 patients). A final model was then refitted on the maximum
possible number of patients.
Two markers were found to be associated with the overall response to tamoxifen, ER
measured before treatment and P -Glycoprotein expressed after treatment. High values
of ER increasing the probability if response and high values of P -Glycoprotein having
the opposite effect (Table 14.11a).
The degree of response was found to be related to the ER level prior to treatment and
the changes in both Ki-Sl and Bcl-2 with tamoxifen therapy. Higher values of ER
being associated with greater degrees of response and an increase in either Ki-Sl or
Bcl-2 indicating a lower degree of response (Table 14.1 lb).
Axillary lymph node status, an important prognostic indicator in primary breast cancer,
was available for 52 of the patients. In order to examine the relationship between nodal
involvement (positive = 1, negative = 0) and the markers listed above along with
tumour diameter and volume, a further forward stepwise variable selection procedure
was used. None of the markers, their changes on treatment or tumour characteristics
were found to be associated with nodal involvement.
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Table 14.11 Final Logistic Regression Models for a) Overall and b)
Degree of Response and ER, Ki-Sl, BcI-2, pS2, c-erbB-2, EGFR and
P - Glycoprotein.
a)
Variable Coefficient O.R. 95% C.I.
for O.R.
z p-value
log ER (pre) 1.44 4.23 1.51 - 11.85 2.74 0.006
P - Gly (post) -0.91 0.40 0.19-0.86 -2.34 0.019
constant -5.72 -2.21 0.027
b)
Variable Coefficient 95% C.I.
for Coefficient
t p-value
log ER (pre) 18.19 11.70 - 24.68 5.64 <0.001
Ki-Sl (change) -12.37 -20.48 - -4.26 -3.07 0.004
Bcl-2 (change) -14.59 -23.16 - -6.01 -3.42 0.001
constant -66.63 -101.97 - -31.29 -3.79 <0.001
Table 14.11 shows the results of multivariate analyses to determine those factors
which are independently associated with a) overall and b) degree of response. Only
those factors which were statistically significant are shown.
O.R. = Odds Ratio, C. I. = Confidence Interval.
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14.11 Oestrogen Receptor
The relationship of Oestrogen receptor content prior to treatment and the subsequent
response to tamoxifen has been demonstrated in Chapter 14 in a group of 95 patients.
The strong correlation remains in the selected group of 52 patients described in this
chapter and indeed ER has the most significant correlation with the overall and the
degree of observed response when subject to multivariate analyses.
ER content post-treatment was only available for 40 tumours and was therefore not
included in the analyses. Of these 40 tumours 37 demonstrated decreased levels of ER
in the post- compared to the pre-treatment specimens. Univariate analysis by Wilcoxon
signed rank sum test found the difference in post- and pre-treatment ER values to be
highly significant (z statistic = -5.21, p <0.001).
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14.12 Tumours from Patients Treated in the Edinburgh Trial of Primary
Systemic Therapy
Material from pre-treatment wedge biopsies and post-treatment definitive loco-regional
surgical procedures was available from 25 patients treated according to the protocol of
the Edinburgh study. These included 14 patients treated with chemotherapy, six treated
with tamoxifen and one treated with both tamoxifen and chemotherapy, all of whom
are described above (chapter 13). Four patients have been included, for comparison,
from whom archival tumour material was available and who were treated, according to
protocol, with the LHRH agonist Goserelin.
It has been previously commented that it is difficult to derive useful information on the
biological characteristics of response from the patients included in the study of primaiy
systemic therapy. This is primarily due to the small numbers of patients studied but
also due to the very good responses obtained in all but one patient given chemotherapy
and two patients given tamoxifen (one of whom did not proceed to definitive surgery).
Indeed several patients treated with chemotherapy had insufficient tumour cells in the
post-treatment specimens for immunohistochemical investigations. The results
obtained are recorded in Table 14.12. With the exception of pS2 and EGFR which
should, theoretically, only relate to response to hormonal manipulation, the antibodies
used for immunohistochemical analysis of chemotherapy treated tumours were the
same as those described above and used in the assessment of tumours treated with
tamoxifen.
Only general observations can be made from the data obtained from the fourteen
tumours treated with chemotherapy alone:
a) Staining for the proliferation marker Ki-Sl decreased in five out of the nine
tumours that responded to treatement from which adequate tumour tissue was available
and increased in the one tumour which did not respond.
b) The two patients with strong staining for c-erbB-2 have both died during the
relatively short period of follow-up
c) Staining for P- Glycoprotein was present in only three of thirteen assessable
tumours. One of the tumours failed to respond, one tumour, although responding,
showed the smallest reduction in tumour volume and the third tumour although
responding very well showed a large increase in P- Glycoprotein staining and the
patient had veiy early recurrence of metastatic disease.
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The six tumours of patients treated with tamoxifen demonstrated staining patterns that
appeared to reflect the findings of the large group of tumours reported earlier in the
chapter.
The four pre-menopausal patients with ER-positive tumours treated with an LHRH
agonist showed interesting staining with pS2 and P- Glycoprotein antibodies. All four
tumours stained positively for pS2 prior to treatment and negatively after treatement.
Two out of the four tumours showed an increase in P- Glycoprotein staining with a
third tumour showing a high degree of staining before and after treatment.
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Table 14.12 Results from Immunohistochemical Analysis of Tumours
from Patients Treated in the Edinburgh Trial of Primary Systemic
Therapy
Patient No. Treatment Sample Ki-Sl et<£ c-erbB2 pGLY Bcl-2 EGFR £a ER(EIA) Response
2 C.A.P. WBx 0 0 0 0 0 10 88%
Mx 0 0 0 nt *
5 C.A.P. WBx 1 0 0 0 0 0 100%
WLE nt nt nt nt nt
7 C.A.P. WBx 0 1 I 3 * 14 58%
Mx 0 0 0 * *
9 C.A.P. WBx 0 0 1 1 0 19 static
Mx 2 0 1 0 0
12 C.A.P. WBx 0 1 0 0 0 10 96%
Mx 0 0 0 nt nt
15 C.A.P. WBx 1 0 0 * 0 2 69%
WLE 0 0 0 * 0
16 C.A.P. WBx 2 0 0 3 3 10 96%
Mx 0 0 1 3 0
18 C.A.P. WBx 1 0 0 2 0 12 69%
Mx 0 0 0 1 0
20 C.A.P. WBx 1 0 0 0 3 10 96%
WLE 0 0 0 1 3
21 CJV.P. WBx 0 0 0 * 0 3 90%
WLE nt nt nt nt nt
b C.A.P. WBx 0 3 0 0 0 95%
Mx 0 0 0 0 0
c C.A.P. WBx 1 3 1 1 0 21 95%
Mx 0 3 3 0 0
d C.A.P. WBx 1 0 0 1 0 79 73%
WLE nt nt nt nt nt
e C.A.P. WBx 0 0 nt nt 0 100%
Mx nt nt nt nt nt
4 TAM+CA.P. WBx 0 0 1 1 2 0 108 static
Mx 0 0 0 0 1 *
1 TAM WBx 1 2 0 0 0 0 0 552 87%
Mx 0 1 0 0 3 0 0
6 TAM WBx 0 1 0 1 3 0 0 623 73%
Mx 0 2 2 2 2 0 0
13 TAM WBx 0 0 1 1 1 0 0 45 66%
Mx 1 0 1 1 1 1 2
14 TAM WBx 1 0 0 1 3 0 0 620 40%
Mx 0 2 0 1 2 0 0
19 TAM WBx 1 0 0 0 3 0 0 386 99%
WLE 0 0 0 0 3 3 0
a TAM WBx nt nt 1 2 3 * * 351 93%
WLE 0 0 0 0 1 nt nt
f L.H.R.H WBx 1 2 0 0 0 0 0 394 73%
Mx 1 0 1 1 1 0 0
g L.H.R.H WBx 3 3 0 3 0 0 42 59%
Mx 0 0 0 0 1 0 0
h L.H.R.H WBx 1 1 0 1 2 0 ♦ 23 88%
Mx 0 0 0 3 2 1 0
i L.H.R.H WBx 0 1 2 3 2 0 * 112 *♦
Mx 0 0 0 3 1 0 0
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Table 14.12 shows the results obtained from immunohistochemical staining of
tumour sections taken before and after primary systemic therapy in a series of 25
patients treated according to the protocol of the Edinburgh Trial.
C. A. P .= Cyclophosphamide, Adriamycin and Prednisolone.
TAM = Tamoxifen.
L.H.R.H. = L.H.R.H. agonist, Goserelin.
WBx = Specimen taken at time of wedge biopsy.
W.L.E. = " " " wide local excision
Mx = " " " mastectomy
Figures in the columns corresponding to each marker visualised represent the staining
indeces assigned by the pathologist after examination of tissue sections.
ER(EIA) = Oestrogen receptor content (fmol/mg cytosol protein).
Response = Percentage reduction in tumour volume as assessed by ultrasound.
nt = no tumour cells in tissue section.
* Slides uninterpretable despite repeat staining x2.
** No figures available for the exact response although the tumour had been classified
as a "responder" on ultrasound assessment.
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Chapter 15: Flow Cytometry and Serial Fine Needle Aspirates
Fine needle aspiration in conjunction with flow cytometric analyses of tumour antigen
expression and cell cycle distribution is, potentially, a powerful tool in assessing
tumour response to systemic therapy. A subset of patients in both the Elderly Patient's
Study and the Trial of Primary Systemic Therapy had serial FNA's taken from their
tumours before, after and also, for the majority, during treatment. Patients included
were those who had granted permission for additional tumour FNA's to be taken and
those for whom it was technically possible for the author to be present to perform the
sampling. The results of flow cytometric analyses of antigen expression could then be
compared to those obtained from immunohistochemical staining of tissue samples
taken before and after treatment from the same tumours (reported in chapter 14). In
addition new information from DNA analysis could be considered in relation to the
observed tumour responses. The nature of the lymphocyte infiltrate into the tumours
was also assessed using antibodies to surface antigens prevalent on Natural Killer
(NK) cells (CD56) and B cells (CD 19). The presence of both these classes of
lymphocyte have been suuggested to relate to therapeutic response. The results from
tumours treated with tamoxifen will be considered firstly, followed by those from
tumours treated with chemotherapy.
15.1 Tumours Treated with Tamoxifen
The raw data obtained from those tumours treated with tamoxifen is shown in table
15.1. Parameters measured consisted of the lymphocyte markers, expressiuon of c-
erbB-2, pS2 and Ki-Sl, BrdU incorporation and DNA analysis. P -Glycoprotein
expression was only measured in six non-responding and three responding tumours.
The results for antigen expression are listed in two columns headed "%" and "mean".
These refer to the two measurements obtainable from analysis of the histograms of
fluorescence generated from the flow cytometer. The "%" fluorescence records the
percentage of cells staining with a greatrer intensity than background (the control), or
loosely, the percentage of cells in the total population expressing the antigen. The
"mean" fluorescence records the overall intensity of staining in relation to background,
or the amount of antigen expression in a population regardless of the number of cells
which express this antigen.
Significant correlations between the parameters measured and the observed response to
tamoxifen in samples taken prior to, during and after treatment are shown in Table
15.2 and graphically in Figures 15.1 to 15.9
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Table 15.1 Flow Cytometric Assessment of Tumour Samples Obtained
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Table 15.1 shows results obtained from flow cytometric analysis of tumour samples
obtained by fine needle aspiration before, after and, in some cases, during tamoxifen
treatment.
Reduction = Reduction in tumour volume as assessed by ultrasound.
WBx = FNA taken at time of pre-treatment tumour wedge biopsy.
Mx/WLE = FNA taken at time of post-treatment mastectomy/wide local excision.
Figures for each marker studied are expressed as the percentage of events (cells)
staining with fluorescence greater than background or the ratio of the means of the test
sample over the background.
Figures for cell cycle analyses were calculated by the computer software as previously
described.
ni = DNA histogram not interpretable.
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Table 15.2 Significant Correlations Between Marker Expression i) Prior
to ii) During and iii) After Treatment and Final % Tumour Volume
Reduction
i) Prior to Tamoxifen
Marker Spearman r value p value
In all tumours
c-erbB-2 (%) 0.654 0.001
c-erbB-2 (mean) 0.674 0.0006
pS2 (%) 0.554 0.008
Responding tumours only
Ki-Sl (mean) 0.639 0.014
CD 56 (%) 0.660 0.01
CD 19 (%) 0.744 0.002
ii) During Treatment
c-erbB-2 (mean) 0.468 0.043
iii) After Tamoxifen
All tumours
pS2 (mean) 0.480 0.028
CD56 (%) - 0.504 0.017
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Figure 15.1 The Relationship Between i) Percentage and ii) Mean





Figure 15.1 shows the relationship between the observed reduction in tumour
volume and i) the percentage of tumour cells expressing c-erb B-2 and ii) the mean
fluorescence (as compared to background and expressed as a ratio), in FNA's of 22
tumours prior to treatment. Both correlations are statistically significant although that
between volume reduction and mean level of c-erbB-2 expression is better.
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Figure 15.2 The Relationship Between Percentage Cellular pS2
Expression Pre-Treatment and Reduction in Tumour Volume
1001
20 -
Spearman r = 0.55
p = 0.008
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pS2 Expression (%)
Figure 15.2 shows the statistically significant correlation between pS2 expression
prior to treatment and the subsequent ultrasound-assessed reduction in tumour volume
after three months tamoxifen therapy. Prior to treatment only the percentage of cells
showing fluorescence greater than background showed a significant correlation not the
mean level of flourescence (= mean cellular expression)
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Figure 15.3 The Relationship Between Mean Cellular Ki-Sl Expression












Spearman r = 0.64
p « 0.01
Ki-Sl Expression (Mean)
Figure 15.3 shows the relationship between tumour response and mean fluorescence
levels (as compared to background and expressed as a ratio) in cells stained with Ki-
S1 antibody taken by FNA prior to treatment. There was not a significant relationship
when the whole population was included and the above data represents responding
patients only.
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i) Samples Taken Prior to Treatment
The above table and figures illustrate only the significant correlations obtained when all
the parameters measured by flow cytometry were tested as predictive factors for
tumour response. Interestingly c-erbB-2 expression as determined both by the
percentage and mean cellular expression was a strong predictive factor for the degree
of response to tamoxifen (Figure 15.1). Both parameters of the measurement of c-
erbB-2 expression were also significantly related to overall response with responders
having higher levels than non-responders (percentage cellular expression: MWU
statistic = 22.5, p = 0.024 and mean cellular expression: MWU statistic = 22.0, p =
0.022). This had not been demonstrated in the immunohistochemical studies reported
in Chapter 14. Indeed when the relationship between immunohistochemical and flow
cytometric staining for c-erbB-2 in the same tumours was tested statistically it was not
significant. The percentage of cells staining with pS2 antibody but not the mean levels
of staining was predictive of the degree of response (Figure 15.2). The relationship
with overall response just failed to reach statistical significance (MWU statistic = 30, p
= 0.08). A relationship with response had not been demonstrated in the
immunohistochemical studies and, in a similar fashion to c-erbB-2, there was not a
statistically significant correlation between the two methods of pS2 analyses when
these were formally tested.
Cellular proliferation prior to treament as determined by S-phase fraction, BrdU uptake
and percentage cellular expression of Ki-Sl was not significantly related to the
reduction in tumour volume. However, the mean cellular expression of Ki-Sl did
correlate with the degree of response but only in responding tumours (Figure 15.3)
Other information obtained from DNA analysis also failed to reveal any significant
associations with overall or actual degree of tumour response. In terms of ploidy only
one of nine aneuploid tumours did not respond wheras five of ten diploid tumours
failed to show a response. Three tumours could be classified as tetrapoid prior to
treatment, one of which had a subsequent response.
The percentage of cells, in pre-treatment FNA samples, expressing the leucocyte
antigens CD19 (B lymphocytes) and CD56 (Natural Killer cells) both correlated
positively with the degree of response when assessed in the sub-population of
responding tumours only (Figure 15.4).
ii) Samples Taken During Treatment
Midpoint samples ( six to eight weeks into treatment) were available from 19 of the 22
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patients studied. When these samples were analysed in terms of correlation with final
degree of response only the mean cellular fluorescence of c-erbB-l remained
significant. All other parameters had lost statistical significance.
iii) Samples Taken After Treatment
In samples taken after treatment there were significant correlations between the degree
of the observed prior response and mean pS2 expression (and not percentage as seen
in the pre-treatment samples) and percentage of cells expressing CD56 (negative
Spearman r value). These results imply greater levels of pS2, although not larger
numbers of cells actually expressing pS2, in tumours that have responded best to
treatment and also a greater reduction in the number of NK cells in these sensitive
tumours after tamoxifen therapy. The levels of NK cells were positively correlated
with the degree of response in pre-treatment samples.
Changes in Marker Expression with Treatment
When the levels of expression, of the various markers examined, were compared
before, during and after treatment for individual tumours few significant trends were
found (Table 15.2). There was a significant decrease in cellular expression of c-erbB-2
(both percentage and mean fluorescence) on comparison of the before and after
samples taken from responding tumours (but not non-responders). Likewise there
were significant decreases in CD56 expressing cells in responding as opposed to non-
responding tumours. However there was a significant decrease in CD19 cells in only
non-responding tumours. There was no significant change in these three markers in
the midpoint samples and such changes, therefore, could not have been picked up
earlier in treatment. There was, however, a significant decrease in mean Ki-Sl
expression between the pre-treatment and the midpoint sample in responding tumours.
DNA analysis of serial samples from individual tumours failed to show any significant
trends, in particular no changes in S-phase or Go/Gi phase. Three tumours showed
the development of aneuploid peaks during treatment and one aneuploid tumour
became diploid.
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Figure 15.4 The Relationship Between Response and Lymphocyte
Markers i) CD56 and ii) CD 19 in Responding Tumours Only
i)
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Figure 15.4 shows the correlations in pre-treatment FNA's between subsequent
tumour response and levels of Natural Killer cell and B lymphocyte infiltrate as
estimated by the percentage of cells expressing i) CD56 and ii) CD 19 surface markers.
There are statistically significant correlations for both markers.
234

















CD19 (%) WBx and Mx/WLE 0.042
Table 15.2 shows only the statistically significant changes in expression of the
markers tested when samples taken before, during and after treatment of individual
tumours were compared. All parameters displayed above decreased with treatment.
WSR =Wilcoxon Signed Rank Test
WBx = FNA taken at time ofWedge Biopsy
Mx/WLE = FNA taken at time of Mastectomy /Wide Local Excision
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Relationships Between Different Markers
There were several significant correlations between the different markers studied on
samples obtained from individual tumours prior to treatment. These are listed below;
a) c-erbB-2 (%) and Ki-Sl (mean), Spearman r = 0.540, p = 0.01
b) c-erbB-2 (%) and CD56 (%), Spearman r = 0.458, p = 0.032
c) c-erbB-2 (%) and CD19 (%), Spearman r = 0.374, P = 0.002
d) CD56 (%) and CD 19 (%), Spearman r = 0.619, p < 0.0001
e) pS2 (%) and CD19 (%), Spearman r = 0.520, p = 0.013
f) Ki-Sl (mean) and CD19 (%), Spearman r = 0.557, p = 0.007
Of interest, given the results of the work reported on the relationships between
proliferative markers in preceeding chapters, the correlation between BrdU
incorporation and S-phase just failed to reach statistical significance (Spearman r =
0.494, p = 0.061 in FNA's taken prior to treatment). There were no significant
relationships between Ki-Sl, BrdU incorporation and S-phase.
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15.2 Tumours Treated with Chemotherapy
Data obtained from flow cytometric assessment of FNA samples taken from tumours
treated as per the protocol of the Edinburgh Trial of Systemic Therapy is shown in
Table 15.3. The data is limited by the very few numbers of tumours from which
samples were available and by the narrow range of responses measured by ultrasound.
Only one tumour failed to respond to treatment and the vast majority of the responders
displayed a reduction in tumour volume of greater than 90%. Four tumours could be
sampled four times; at wedge biopsy, at the first and third administrations of
chemotherapy and at the time of definitive surgery. The other tumours listed were
sampled at the time of the first treatment with chemotherapy but with rapid responses
became impalpable or yielded unanalysable material on FNA. It was possible,
however, to sample some of these tumours after treatment under direct vision at the
time of definitive surgery.
There were no significant correlations between the degree of response and any of the
parameters measured at any time. Neither did there appear to be any distinguishing
features of the sample obtained prior to treatment of the one tumour that failed to
respond to treatment.
Adriamycin uptake was measured in FNA samples taken one hour after the completion
of intra-venous infusion of the drug. The appearance of one such sample, viewed
under a fluorescence microscope, is shown in Figure 15.5. The intrinsic fluorescence
of adriamycin could also be measured by the flow cytometer and expressed as the ratio
of the mean fluorescence of the post infusion sample and the pre-infusion sample as
shown in Figure 15.6. There was no correlation between adriamycin uptake and the
degree of response or any other parameter, including P-glycoprotein expression,
although numbers were limited.
Of the four tumours that were sampled at four time points, two produced interesting
series of DNA histograms (Figures 15.7 and 15.8). The tumour from patient 20 was
diploid and the changes in the cell cycle distribution with treatment are entirely in
keeping with previous work suggesting that adriamycin induces a G2 block. The
tumour from patient 18 was initially diploid, prior to treatment, but an aneuploid
subpopulation is seen to develop during treatment. This tumour was shown to express
P -glycoprotein but on dual staining it was the diploid and not this new aneuploid
population that was predominantly responsible for the staining.
There were no significant differences between parameters measured prior to, and after
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Table 15.3 shows results obtained from flow cytometric analysis of tumour samples
obtained by fine needle aspiration before, after and, in some cases, during
chemotherapy.
Adr Mean = Ratio of mean red fluorescence of a sample taken one hour post
adriamycin infusion to a sample taken just prior to treatment.
* = Histograms not interpretable.
Legend otherwise as for Table 15.1.
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Figure 15.4 Fine Needle Aspirate Examined by Flourescence
Microscopy
Figure 15.4 shows cellular material derived by fine needle aspiration of tumour 15
(see table 15.3) one hour after intra-venous infusion of adriamycin, and examined
under a fluorescence microscope. Adriamycin within cells shows as a red colouration.
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Figure 15.5 Measurement of Adriamycin Uptake by Flow Cytometry
CD
\OH
Figure 15.5 shows superimposed histograms created by the flow cytometer
demonstrating red fluorescence in FNA samples taken from a breast cancer prior to
and one hour after intravenous infusion of adriamycin. The mean increase in cellular
fluoresence after treatment represents cellular uptake of adriamycin.
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Figure 15.6 Series of DNA Histograms from Patient 20
Figure 15.6 shows a series of histograms taken at a) time of wedge biopsy, b) prior
to the third cycle of chemotherapy and c) at the time of definitive surgery. Note the
accumulation of cells in the G2/M phase of the cell cycle.
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Figure 15.7 Series of DNA Histograms from Patient 18
Figure 15.7 shows a series of histograms taken at a) time of wedge biopsy, b) prior
to the first cycle of chemotherapy, c) prior to the third cycle of chemotherapy and d) at






This thesis aims to characterize the response of primary breast tumours to systemic
therapy involving the use of both cytotoxic chemotherapy and anti-hormone agents.
The following discussion will focus principally on tumours in elderly patients treated
with tamoxifen simply because of the greater numbers of this particular population
presenting to the Edinburgh Breast Unit during the study period. Firstly the clinical
responses achieved in both the elderly patient and the primary systemic therapy trials
will be discussed and thereafter the approach to, and the results of, the assessment of
tumour biological responses to therapy will be reviewed. Finally, as this thesis covers
a wide variety of aspects of response assessment, the significant findings will be
discussed in terms of the prospects for further research.
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Chapter 16 : The Clinical Response to Primary Systemic Therapy
16.1 : Tumour Measurement
Primary systemic therapy allows a direct assessment of the sensitivity of a particular
tumour to a particular therapy by monitoring the tumour response in situ. Several
different methods of monitoring response have been proposed ranging from serial
tumour diameter measurements with engineers' callipers to Magnetic Resonance
Imaging (Gilles, 1994). The Edinburgh Breast Unit has assessed the use of ultrasound
imaging in measuring breast tumours and as a means of monitoring the response to
treatment in an early series of patients treated in the primary systemic therapy trial
(Forouhi, 1994). Ultrasound scanning is, to a certain extent, operator dependent and
therefore it was necessary for the benefit of this thesis to confirm its accuracy in
tumour measurement when operated by the author. A good correlation between
ultrasound measured tumour diameter and that measured pathologically was obtained.
A similarly good correlation was obtained between clinical diameter, measured with
the use of engineers callipers, and pathological diameter . However, the correlation at
smaller tumour volumes was poorer and indeed some tumours in the series that had
been measured by ultrasound could not be clearly identified on clinical palpation and
calliper measurements could not therefore be performed.
Forouhi et al. demonstrated that sequential calliper measurements were an accurate
method of monitoring response to treatment. However the majority of patients in their
study underwent primaiy chemotherapy with often very large reductions in tumour
volume. The response to tamoxifen over the first three months of treatment is not
usually of the same order. Calliper measurements are indirect in that the skin and
subcutaneous tissues are included in the measurement. The thickness of these tissues
can vary with time as can the degree of compression exerted through the callipers by
the operator. The former problem has been addressed by the use of estimates of the
thickness of the subcutaneous adipose tissue (Dixon, 1984b), but this is time-
consuming and not always accurate. The latter problem is aided by employing a single
operator to make all measurements. These potential inaccuracies may make
comparisons of serial measurements on individual tumours difficult. Therefore, in
order to measure what were likely to be small changes in tumour volume with
tamoxifen therapy, the greater reproducible accuracy of ultrasound was thought to be
preferable. An accurate assessment of response was particularly important as
relationships with corresponding biological responses were to be examined.
Ultrasound measurements were made on all tumours reported in this thesis but as a
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comparison calliper measurements were taken where possible.
16.2 : The Response to Tamoxifen
There have been very few reports in the literature concerning the early response of
breast tumours to tamoxifen therapy and none to our knowledge using ultrasound as a
means of assessment. A previous study from Edinburgh examining predictive factors
for long term "worthwhile" response to tamoxifen detailed response at three months in
a group of unselected patients with both ER negative and positive tumours (Gaskell,
1992). Response was measured by engineers' callipers and graded according to
U.I.C.C. criteria. Of 59 tumours assessed 12 (20%) demonstrated either a partial (11)
or a complete (1) response, 35 were graded as static and 12 demonstrated progression.
In the group of 95 patients reported in Chapter 14, 80 were assessed for U.I.C.C.
response. In this population all tumours were ER positive and 27 (34%) demonstrated
either a partial (19) or a complete (8) response, 51 were graded as static and only one
tumour was classified as showing progression. The relatively high number of
complete responses and low number of progressive tumours probably reflects the ER
positivity of the group studied here. The U.I.C.C. criteria of response are based on
clinical measurements with the attendant potential drawbacks outlined above and give
little indication of the degree of response as a continuum for an individual tumour. By
sequential ultrasound scans it has been possible to characterise the early macroscopic
response to tamoxifen for the first time. Somewhat surprising was the rate at which
tumours can respond. After only one month of therapy 44% of tumours had
demonstrated a reduction in tumour volume of greater than 10%. By two months 64%
had responded and after three months a total of 74% of tumours had responded.
Alternatively of those which were going to respond by three months 61% and 87%
had demonstrated a decrease in ultrasound assessed volume by one and two months
respectively. A figure of 74% of tumours responding to tamoxifen is similar to that
reported in the literature. It is a little higher than some reports but the 25 patients
followed to six months of treatment may give a clue as to the reasoning behind this and
the suitability of three months as a determinant for likelihood of response. Although
only relatively few patients were studied beyond three months no patient classified as
static demonstrated a response by six months and five patients who had demonstrated
a response showed signs of tumour regrowth. It seems, therefore, that by ultrasound
the vast majority of the tumours that are going to respond have been detected by three
months of treatment. In addition some early responses may have been demonstrated in
a group of tumours that develop resistance to tamoxifen by three to six months of
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treatment and would have been classified in other studies, based on a later assessment,
as non responders.
The degree of response observed at three months asks questions of the underlying
histopathological processes. The responding tumours decreased by a mean of 58.5%
in ultrasound measured volume. Of the 70 responding tumours 19 decreased by more
than 75% in volume and of these two patients who underwent local excision after three
months of treatment had achieved a complete pathological response. These
observations prompted a detailed study of both cellular proliferation and, indirectly,
cell death occurring in the cells of the tumours for which response had been assessed.
The results of these studies are described in Chapter 15 and discussed below. The
clinical implications of such responses with short term treatment are also important,
particularly perhaps in the elderly population. It remains to be seen whether the degree
of short term response predicts for overall recurrence-free survival in this population
as the follow-up time is still relatively short. In attempting to determine predictive
factors for overall worthwhile response to tamoxifen Gaskell et al. (Gaskell, 1992)
failed to show a predictive value for response at three months as assessed by U.I.C.C.
criteria or by sequential calliper measurements demonstrating a consistent trend of
reduction in size over the three months. Horobin et al. (Horobin, 1991) showed that
only 30% of those patients with ER positive tumours demonstrating a response to
tamoxifen had persisting control of disease at five years. Thus it seems thst the
majority of patients will require surgery at some point. If, however, surgery is delayed
for three to six months the form of surgeiy required can be downstaged (i.e. from
mastectomy to wide local excision) which is important in this population in that it is a
shorter operation and can if necesaiy be performed under local anaesthetic and has
lower attendant morbidity. Indeed in this study population of 26 patients who
proceeded to local surgery and who were assessed prior to tamoxifen as requiring a
mastectomy 10 patients were treated effectively by wide local excision.
The data generated from the study of the response of individual tumours to short-term
tamoxifen therapy provided a powerful base on which to examine clinical and
biological factors which may predict and/or reflect the observed responses. These are
dicussed further below.
249
16.3 The Trial of Primary Systemic Therapy
The Edinburgh trial of primary systemic therapy for breast cancer commenced
recruitment in January 1990 and had randomised 67 patients prior to the author's
involvement. Over the time period of this present study a further 48 patients were
entered into the trial, of whom 22 were randomised to receive primary systemic
therapy and of these, two patients changed their minds after randomisation and opted
for conventional management. This relatively small group of patients were further
subdivided into treatment groups according to the oestrogen receptor status of their
tumours (11 being ER negative and nine ER positive). The numbers were boosted
slightly by the inclusion of five patients who expressed a wish to receive primary
systemic therapy outwith the trial. These still, however, represent small numbers from
which to draw any significant conclusions.
The move towards primary systemic or "neoadjuvant therapy" as a treatment option for
primary breast cancer originated from the results of systemic therapy for locally
advanced inoperable tumours. Overall response rates of 70 - 91% were reported for
anthracycline containing regimens (Swain, 1987; Hortobagyi, 1988; Jacquillat, 1988;
Mauriac, 1991). In these trials responses were determined clinically by calliper
measurement and responders defined by U.I.C.C. criteria. These studies also
demonstrated an increased survival in those patients responding well to primary
therapy with, for example, one study demonstrating a clear survival advantage for
those whose tumours had reduced in clinically estimated volume by greater than 75%
in comparison with those with only a 50-75% reduction (Jacquillat, 1988). The trials
of neoadjuvant therapy for early, operable, breast cancer are still reporting with
relatively short median follow-up periods but the response rates to the initial
chemotherapy are in keeping with the figures quoted in the earlier studies. The initial
pilot study of primary systemic therapy in Edinburgh achieved a response rate of 85%
with primary CHOP (cyclophosphamide, adriamycin vincristine and prednisolone)
chemotherapy, if patients having failed initial endocrine therapy were excluded
(Anderson, 1991). Bonadonna, one of the pioneers of primary systemic therapy,
treated five groups of 33 women, all presenting with primary breast tumours greater
than 3cm in clinical diameter, with five different chemotherapy regimens. There were
no significant differences in response rates with different drug regimens with response
rates of 70-87% reported (Bonadonna, 1990). In the study reported in this thesis,
fifteen patients received primary therapy with cyclophosphamide, adriamycin and
prednisolone and of these 14 (93%) demonstrated a response, all acheiving a greater
than 50% reduction in tumour volume, as assessed by ultrasonography, with a mean
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reduction in volume of 87%. The response rate obtained is high but given the small
numbers is probably within the range that would be expected from the results of the
reported studies. Furthermore ten patients (67%) responded with a greater than 75%
reduction in volume and three (20%) achieved a complete histopathological response
with no evidence of invasive carcinoma in the specimens obtained after treatment by
mastectomy or wide local excision. Bonadonna's study suggested that at three years,
relapse free survival was greater in those that had demonstrated the greater initial
response to primary therapy (confirming Jacquillat's earlier findings in locally
advanced disease). In his study seven of eight patients with a pathological response to
primary therapy were disease free at three years. The 15 patients reported here have a
median follow-up of 24 months (range 16 to 30 months) and of these five have
developed metastatic disease and four have died of their disease. Included in the deaths
was the one patient in the series who had not responded to chemotherapy but of the
four other recurrences all had responded with a reduction in tumour volume of 88% or
greater and, indeed, one had achieved a complete pathological response. It seems
unlikely therefore in this series that the degree of response will be significantly related
to survival. This group of tumours which have recurred early after an apparent good
response to primaiy therapy are particularly important for further study. If indicators
of poor prognosis and likely early recurrence could be identified either before treatment
or derived from biological changes induced by treatment then these patients may be
candidates for more intensive, high dose, chemotherapy. The two other recurrences in
this present series (including one patient ultimately dying of her disease) ocurred in the
only patients whose tumours were unresponsive to tamoxifen and which also,
subsequently, proved unresponsive to chemotherapy. The observation that ER positive
tumours which fail endocrine therapy tend to respond poorly to chemotherapy
thereafter was also made by Anderson et al. in the earlier Edinburgh study. A possible
explanation lies in the observation that P -glycoprotein expression (and therefore multi¬
drug resistance) appears to be induced, or selected for, during tamoxifen therapy in
these tumours. This proposition has been raised by the investigation of tissue fom
these and other tamoxifen resistant tumours during this study and will be discussed
further below.
Nine patients with ER positive tumours were treated with tamoxifen with seven (78%)
demonstrating a response. The responses were generally slower and of a smaller
overall degree than those achieved by chemotherapy. The mean reduction in tumour
volume over the three months of therapy was 70% with five tumours demonstrating
reductions over 50% and a mean time to reach 50% of the initial volume of 38 days (in
comparison with 27 days for those treated with chemotherapy).
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The trials of primary systemic therapy reported to date have principally determined
tumour response rates and thereafter whether a significant number of patients can
avoid mastectomy and be safely treated by breast conservation. Results have been
encouraging with figures for the number of patients avoiding mastectomy after
treatment ranging from 20-88% (Bonadonna, 1990; Mauriac, 1991; Rodier, 1993;
Smith, 1993). In addition all studies report low rates of local tumour recurrence after
conservational surgeiy, in keeping with the experience when this procedure is
employed as primary treatment (Fisher, 1989). The option to downgrade the surgical
procedure required in individual cases has not, as yet, been included in the Edinburgh
protocol, and all patients deemed to require mastectomy prior to primary systemic
therapy have undergone this procedure after treatment regardless of response. It may
well be that the downstaging of the local surgeiy required is the main benefit of
primary as opposed to adjuvant therapy and this option should be included in any
future trials.
Some of the theoretical arguments proposed to support the concept of primary
systemic therapy would be expected, if bome out clinically, to lead to improved
survival. Improved survival is also needed to justify treating smaller primary breast
cancers with primary systemic therapy as, in this group, conservational surgery would
be possible at presentation. The relatively few randomised trials testing primary
therapy against conventional post-surgical adjuvant therapy. These trials are still
ongoing and are yet to report. One small, non-randomised, French study has found no
difference in relapse-free survival between the two treatment groups at a median
follow-up period of 33 months (Rodier, 1993). A larger study, also non-randomised,
with a similar median folow-up found more frequent isolated local recurrences but an
improved overall survival in patients receiving primary systemic therapy (Mauriac,
1991). The group of 26 patients randomised to conventional therapy and reported here
have now been followed-up for a median of 25 months. There have been four
recurrences (all distant metastatic disease) and two deaths. At this early stage in
follow-up and with these small numbers there appears to be little difference between
the two trial groups in terms of survival. It is likely that national randomised trials will
be required to determine survival benefits with any degree of significance. The
NSABP (National Surgical Adjuvant Breast and Bowel Project) B-18 trial, instituted
in the U.S.A. and Canada in 1988, with a projected accrual of 1275 patients, has as
one of its main aims the determination of relapse-free and overall survival in patients
treated with the same chemotherapy either pre- or post-operatively (Fisher, 1991b).
The results of this trial are awaited with interest.
The clinical data generated by the present study comprising records of the rate and
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degree of response of individual tumours to either chemotherapy or tamoxifen
provided a base upon which to build the study of the underlying tumour biology. The
main aims of such a study were to i) detect markers that would predict for response,
preferably in material obtained by fine needle aspiration and ii) find markers which by
their change of expression during treatment might reflect the sensitivity of the tumour
to that particular treatment. This might also help in predicting those patients likely to
relapse early and who may, therefore, need additional or more intensive therapy. Such
a study should also generate data that provide insights into mechanisms of action of,
and resistance to, individual therapies. The results of these investigations are discussed
in the following chapter.
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Chapter 17 : The Biological Response to Primary Systemic Therapy
17.1 Cell line Experiments
The broad approach to the investigation of cellular characteristics which may predict
for or reflect tumour response to systemic therapy involved the development of
methodology in model systems before the application of techniques to clinical material.
Such model systems comprised either tumour derived cell lines grown by tissue
culture techniques or as xenografts in immunocompromised animals and a primary
breast tumour grown as a xenograft.
Several studies have linked the rate of tumour proliferation to the response observed
with systemic therapy. Tumours with high proliferative rates tend to have a greater
response to chemotherapeutic agents (Remvikos, 1993b; Spyratos, 1992) and possibly
also to hormonal manipulation with agents such as tamoxifen (Paradiso, 1988)
although this is more debateable. However it would be expected that for both forms of
systemic therapy a change in tumour cell proliferation would accompany response.
Therefore, it was felt to be important to make an assessment of proliferation as both a
predictor and reflector of tumour response. Three methods of measuring tumour
proliferation were tested.i) The classical flow cytometric "S -phase" measurement
derived from cell cycle analysis of cells stained for their DNA content, ii) the
incorporation of the thymidine analogue, bromodeoxyuridine and iii) the expression of
cell cycle-related nuclear antigens, Ki-67 and Ki-Sl. All methods involved the use of
the flow cytometer as the aim was to develop methodology applicable to material
obtained by fine needle aspiration of breast tumours. In cell lines the three methods
correlated well with each other, the closest relationship being that between S-phase and
BrdU uptake. After these initial experiments no further work was carried out with Ki-
67 because of the poor stability of the antigen on freezing which would have made it
unsuitable for the examination of stored clinical samples.
To assess the suitability of these techniques to material derived from fine needle
aspirates from primary breast tumours the three markers were assessed in a group of
unselected patients. As in the cell line experiments, significant correlations were
observed between the markers although the degrees of association were lower in the
clinical samples. This may be because the material derived from a fine needle aspirate
of a breast tumour is heterogenous comprising several cell types whereas that from a
cell culture should be homogenous. This factor may be expected to have implications
for the measurement of each of the parameters because there is no certain way of
distinguishing benign, stromal cells from the malignant cells by flow cytometry. The
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identification of malignant cells is possible indirectly if by their DNA content they are
defined as being other than diploid. This is illustrated by the good correlation obtained
between S-phase fraction and BrdU uptake in aneuploid tumour cells and the lack of
correlation between these two parameters in diploid tumours. Other possible reasons
underlying the poor correlation between S-phase and BrdU uptake relate to the in vitro
method of measuring the latter parameter. The cell line experiments involved a simple
tiypsinisation step to remove cells from the plastic culture bottles and thereafter
incubation in BrdU containing media. The tumours from which the fine needle
aspirates were taken had all been surgically resected and had therefore suffered a
degree of ischaemia despite the samples being taken as soon after surgical removal as
possible. The mechanical process of needle aspiration involves removing cells from
their environment and also must induce a degree of damage both of which may limit
the capability of the cells to synthesise DNA. This is compatible with other reports in
which the in vitro technique of BrdU incorporation has been used (Remvikos, 1991;
Buley, 1992).
These techniques were then applied to xenograft models in an attempt to monitor
tumour proliferation during systemic therapy in material derived from serial fine needle
aspirates. This is the first report of such investigations. The use of the model system
had the advantage that tumour growth and proliferation could also be studied in control
tumours not undergoing systemic therapy (which is not usually ethically feasible in
human primary tumours). Additionally, frequent sequential samples could be taken
and assessed. The two xenografts studied in detail, ZR 75.1 and T1068 were of
differing origins and displayed different growth characteristics. The former, an
established ER positive breast cancer cell line which had then been successfully grown
as a xenograft, grew relatively slowly with only a moderately high flow cytometric S-
phase fraction. T1068 xenografts were derived directly from a primary mucoid breast
carcinoma and grew rapidly with a veiy high S-phase fraction.
ZR 75.1 control tumours, monitored during the experiment described in Chapter 12,
continued to grow at a steady rate with an increasing S-phase fraction as measured by
flow cytometric analysis of specimens obtained by fine needle aspiration. The treated
tumours responded well to both 2.5 and 5mg of implanted tamoxifen with a decrease
in the two parameters measured to assess cellular proliferation by two weeks after the
commencement of therapy. Another change noted in the serial samples taken for cell
cycle analysis was an increase in the proportion of cells within the Go/Gi phase of the
cell cycle in treated, but not control tumours, in the sample taken two weeks after the
commencement of therapy. This confirmed earlier reports on the effects of tamoxifen
on the cell cycle (Sutherland, 1983; Osborne, 1983), although the majority of previous
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work has been performed in tissue culture systems. The decrease in tumour size
lagged the change in cellular proliferation and cell cycle distribution by approximately
one week. This may have implications in the clinical setting in that it is important to
find indicators of tumour response as early in treatment as possible so that alternative
therapies may be substituted in resistant tumours. If a decreases in S-phase fraction or
an increase Go/Gi phase fraction occur early in the treatment of human tumours these
may be valuable predictors of response and in addition could potentially be measured
on material obtained by fine needle aspiration. The other means of assessment of cell
proliferation, BrdU uptake, measured in a subgroup of tumours, showed slightly
different changes. All tumours showed an increase in BrdU uptake at two weeks
compared with that measured in the pre-treatment samples, although the greatest
increase was in the control samples. All tumours thereafter showed a decrease in
uptake, controls as well as treated tumours. These findings are not easily explained
and needs further investigation with larger numbers before meaningful conclusions can
be drawn.
The T1068 xenograft, however, behaved differently in that control tumours showed a
steady decline in cellular proliferation with increasing tumour size, with a good
correlation between the two parameters of proliferation measured. This might be
explained by the fast rate of growth displayed by these tumours so that they may have
outgrown their blood supply early in the experiment and hence an increasingly smaller
proportion of tumour cells within a given aspirate would show evidence of DNA
accumulation. This explanation is supported by the observation that one tumour
measured to be very small at the start of the experiment showed a consistently high S-
phase fraction throughout the experiment, despite systemic treatment (Tumour 2b table
11.3). The T1068 xenograft demonstrated significant resistance to increasing doses of
adriamycin therapy. Although there was a tendency for a progressively lower rate of
tumour growth with increasing doses these differences were not significant. All
tumours treated with 0.5mg/kg adriamycin showed a decline in S-phase fraction and
BrdU uptake similar to that seen in the control tumours. However, in this group of
tumours, unlike the controls, there was not a good correlation between the values of
these two parameters in individual tumours. There was the impression, given the
limitations of small numbers, that serial BrdU uptake measurements were a more
accurate method of assessing proliferation since serial values showed a more
consistent decline than the more scattered values for S-phase. A potential complication
in measuring S-phase in adriamycin-treated tumours is that the drug acts upon cells
synthesising DNA, classically causing an accumulation of cells within late S / G2M
phase. No such increase in cells within the G2M phase could be demonstrated in the
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experiment reported above in which the tumours appeared particularly resistant to
adriamycin. An alternative explanation may be related to the fact that adriamycin
displays intrinsic fluorescence within the same part of the spectrum as propidium
iodide, used to stain DNA for cell cycle analysis. Adriamycin bound to the DNA, in
the treated group, may therefore interfere with the analyses.
In summary, the series of experiments with xenografts provided insight into tumour
growth kinetics by employing the techniques of serial fine needle aspiration and flow
cytometry. They illustrated the potential value of cell cycle analysis with measurement
of S-phase and Go/Gi phase in the assessment of early response to tamoxifen but also
the potential problems of such measurements in adriamycin therapy. It was felt that in
the assessment of human primary tumours undergoing systemic therapy the technique
of serial fine needle aspiration should be tested and that at least two methods of
assessment of celullar proliferation should be used.
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17.2 Clinical Material - Tamoxifen Therapy
Tumour samples were obtained from 53 patients before and after a median of 18
weeks treatment with tamoxifen. To date there are very few studies that have reported
results using such material and none that have accurate clinical response data for the
tumours studied. Each of the markers detected by immunohistochemical staining in
this group of tumours will be discussed in turn but firstly reference will be made to the
measurement of oestrogen receptors and the response to tamoxifen.
a) Oestrogen Receptors
50 tumours had pre-treatment ER measured both by EIA, on material obtained by
wedge biopsy, and ER-ICA, on cells obtained by fine needle aspiration. Such samples
were valuable in assessing the predictive value for response of these respective
methods of measurement. All tumours studied were deemed ER+ve by the fact that
they contained receptors at >20 fmol/mg cytosol protein by EIA, although three
tumours did have a value of <10% cells staining by ER-ICA. Thus, unlike previous
studies, where ER positivity as assessed qualitatively by either method has shown to
be a good predictor of overall response to endocrine therapy (****)(Skoog, 1991) this
study was concerned with the relationship between quantitative values of both ER
expression and tumour response. Values obtained by both methods of analysis
significantly correlated with the actual tumour volume reduction as assessed by
ultrasound over the relatively short treatment period. EIA produced values for ER that
correlated with response to a higher degree of significance than ER-ICA and gave a
cut-off value of 222fmol/mg, levels above which always related to a response during
the treatment period. No such "cut-off' value existed for ER-ICA estimations. In a
slightly different population of 53 patients, studied for changes in expression of other
markers before an after treatment, the ER value as assessed by EIA was the only
marker which predicted for both overall and actual response in tissue obtained prior to
treatment on multivariate analysis.
If primary systemic therapy for a short period is to be used primarily to achieve such a
degree of tumour shrinkage as to avoid mastectomy then these results become highly
significant. This is particularly pertinent in the elderly population in whom delay of
surgery should be avoided unless there is a high likelihood of response to tamoxifen
therapy. It appears from these results that EIA estimations of pre-treatment ER content
are particularly useful in the prediction of the quantitative response to tamoxifen.
Unfortunately such analyses are dependant upon a requirement for biopsy material
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and, where this is not available or appropriate, ER-ICA estimations are still predictive
of response although not with such accuracy as ELA.
b) pS2
Expression of the oestrogen-inducible pS2 gene has, not surprisingly, been shown to
occur predominantly in ER+ve breast tumours (Rio, 1987) and has been suggested to
be an indicator of an intact ER mechanism, in similar fashion to progesterone receptor
expression. In the group of exclusively ER+ve tumours in this study there was,
however, no correlation between the degree of ER expression and the pS2 staining
index in material taken prior to tamoxifen. This confirms previous studies in breast
tumours of both pS2 protein expression and mRNA content which found a similar
poor quantitative correlation with ER (Manning, 1993; Luqmani, 1993). Interestingly
there was a positive quantative correlation between the expression of pS2 after
tamoxifen therapy and ER content prior to treatment. This could be interpreted as
displaying evidence for oestrogenic effects of tamoxifen with greater induction of pS2
in tumours expressing higher levels of ER. This relationship appeared independent of
tumour response as statistical significance was lost if only responding tumours were
analysed.
The expression of pS2 has been suggested to be a marker of responsiveness to
endocrine therapy, and has even been suggested, in some studies, to be a better
predictor of response than ER status (Schwartz, 1991). Most studies however have
found no advantage for pS2 over ER status as a predictor of response (Skilton, 1989;
Luqmani, 1993). This study found no predictive value for pS2 protein expression, as
assessed by immunohistochemistry, for either the overall or the degree of tumour
response in this selected group of ER+ve tumours. There was a significant trend
towards higher levels of pS2 expression after treatment in tumours that had
demonstrated a response than those which had not. This finding has been suggested
by one previous study (Henry, 1989). Although this inferred increase in pS2
expression in responding tumours was clear on comparison of pre- and post-treatment
samples of individual tumours the trend failed to reach statistical significance.
It had been hoped that pS2 would provide an additional tool to ER to improve the
selection of patients likely to respond to tamoxifen. To this end during the course of
this study a new technique to measure pS2 expression by flow cytometry was
developed, initially in tissue culture systems. This was then applied to cellular material
derived from FNA's of primary breast tumours. With FNA samples allowing
assessment of potential changes in antigen expression early in treatment an increase in
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pS2 may be of prognostic significance both for short and long-term response. The
small series of patients reported who underwent serial FNA's did show increased
levels of pS2 at 6-8 weeks of treatment. However this did not correlate with response
and, interestingly, several non-responding tumours displayed, in comparison to pre-
treatment levels, an initial increase in pS2 before a decrease at the time of definitive
surgery.
In summary it appears that pS2 protein expression measured either by
immunohistochemistry on tumour tissue samples or by flow cytometry of material
derived from FNA's can provide little extra value in determining short term response
to tamoxifen. The relationship to long term response and relapse-free survival will be
interesting to follow and further work on serial sampling of tumours undergoing
treatment may aid understanding of tamoxifen interactions with ER mechanisms within
the cell.
c) EGF-R
The expression of the EGF-Receptor in breast tumours has been described as an
indicator of poor responsiveness to tamoxifen therapy (Nicholson, 1993). However,
many studies have described an inverse relationship between EGF-R expression and
ER content (Sainsbuiy, 1985; Bolla, 1992; Bilous, 1992). It may be, therefore, that
the relationship merely reflects the ER status of the tumours with ER-ve/EGF-R+ve
tumours showing low rates of response to tamoxifen. The group of tumours in elderly
patients, reported in this thesis, were all ER+ve and, as expected, there was a low
level of EGF-R expression. Interestingly, however, among the EGF-R+ve tumours
there was a significant positive correlation between quantitative measures of
expression and response. This is not easy to explain, and indeed it may be dangerous
to attempt such given the small numbers but a putative explanation may lie in the
functions of the EGF-R. It is thought that one of the most important ligands of the
receptor is the growth factor, TGFa, which shares approximately 35% homology with
epidermal growth factor (Derynk, 1986). TGFa induces cell proliferation and is also
thought to be important in tumour angiogenesis (Jordan, 1993). Tamoxifen has been
shown to decrease levels of TGFa and this has been proposed as a possible
mechanism of anti-tumour action (Noguchi, 1993). Tumours with greater levels of
EGF-R and with therefore more dependance on stimulatory factors such as TGFa may
respond to a greater degree than those without. It will be interesting to follow this
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initial observation in greater numbers of tumours,
d) c-erbB-2
Positive membrane staining for the c-erbB-2 protein product was detected in 27% of
tumours prior to therapy which is in keeping with figures of 14 to 42% reported in
previous series of breast tumours assessed by immunohistochemstry (Gusterson,
1988; Nicholson, 1993; Lipponen, 1993a). These studies, unlike that reported here,
did not take oestrogen receptor status into account and, indeed, a negative correlation
has been suggested between the two markers (Gusterson, 1992; Todd, 1992). One
might expect, therefore, a lower proportion of positively staining tumours in an
exclusively ER+ve series, although other studies have shown gene amplification or
immunohistochemical staining in 9.7-30% of ER+ve tumours (Todd, 1992; Skoog,
1992).
In the group of 51 tumours reported here there was no apparent relationship between
c-erbB-2 expression prior to treatment and the observed response to tamoxifen after
three months. In cell lines, transfection of the c-erbB-2 gene has been shown to confer
tamoxifen resistance in vitro and in vivo (Benz, 1992) and there has been a
suggestion that expession of the protein is also related to poor clinical response to
tamoxifen (Wright, 1992; Nicholson, 1993). These studies, however, failed to also
examine for ER expression and can therefore not be compared to that reported here.
There has been little previous work on the effect of tamoxifen on the cellular
expression of c-erbB-2. One study of ER+ve and ER-ve breast cancer cell lines found
induction of c-erbB-2 in the ER+ve cell line in keeping with an anti-oestrogenic effect
(Antoniotti, 1992) (oestrogens, in previous studies, having been found to inhibit
expression (Dati, 1990)). In clinical material, however, both a reduction and an
increase in c-erbB-2 RNA levels have been shown with tamoxifen treatment in
seperate series (Le Roy, 1991)[Johnson ***(refereed paper). Interestingly, in the
former series, the effect was noted principally in ER -ve tumours. In the group of 51
tumours reported here no statistically significant trends in the change of expression
were noted although the numbers of "positive" tumours were small. There was,
however, a tendancy for an increase in staining in responding tumours and a decrease
in staining in non-responding tumours. This will be intersting to review in larger
numbers of tumours as induction/suppression of c-erbB-2 may, respectively, reflect
intact or abnormal ER apparatus , and hormone responsiveness. The implications of




In the group of elderly patients studied the majority of pre-treatment biopsies were
negative for staining with the polyclonal antibody to P -glycoprotein and although the
proportion of positive samples was greater in patients not subsequently responding to
tamoxifen the difference in relation to responding patients was not statistically
significant. However there were highly significant differences in the percentage of
tumour cells staining post-treatment with higher levels of staining in non-responding
tumours than those which had demonstrated a response. Indeed in the multivariate
analysis performed for all the markers studied P -glycoprotein staining after treatment
was the only marker to have a significant relationship with clinical response other than
ER expression prior to treatment. As implied by this finding there was indeed a
significant trend towards increased P -glycoprotein expression in "non-responders"
compared with "responders"
At this stage it is not possible to define the mechanism behind these observed changes
with tamoxifen or even to determine whether increased staining seen in non-
responders results from induction of P -glycoprotein or clonal selection of cells
expressing P -glycoprotein. Several studies have demonstrated an interaction of
tamoxifen with P -glycoprotein showing that high concentrations of tamoxifen inhibit
P -glycoprotein-mediated resistance to chemotherapeutic agents in vitro (Ramu,
1984). Although such an effect has not been convincingly demonstrated clinically
(Stuart, 1992) it seems likely that tamoxifen may be a substrate for the P -glycoprotein
mechanism. This would be consistent with the speculation of the presence of an efflux
pump mechanism invoked to explain the finding of low levels of tamoxifen and its
metabolites in resistant tumours (Johnston, 1993). It is important to note, however,
that a study of a MCF-7 breast cancer cell line transfected with the mdr-1 gene could
not demonstrate resistance to tamoxifen (Clark, 1992). Equally not all the non-
responders in this present study expressed P -glycoprotein and other mechanisms of
resistance must be operative. However, clinical studies have shown mdr-1 gene
amplification during tamoxifen therapy (Lonn, 1992) although this has subsequently
been shown to occur during other endocrine therapies more frequently (Lonn, 1993).
Nonetheless induction and/or clonal selection of P-glycoprotein expression may help
to explain the relatively poor survival following chemotherapy of patients who have
not responded to primary tamoxifen therapy (Swenerton, 1979). Additionally, early
reports from the Edinburgh trial of primary systemic therapy noted a poor response
rate to chemotherapy in ER+ve tumours which had not previously responded to
tamoxifen (Anderson, 1991). Although only two patients failed tamoxifen therapy, in
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the series from the trial reported in this thesis, both of these also appeared resistant to
chemotherapy. Importantly their tumours were found to have increased expression of
P -glycoprotein after tamoxifen, and prior to chemotherapy, as assessed by flow
cytometry.
The relationship between P -glycoprotein expression and resistance to tamoxifen was
unexpected, but nevertheless deserves further investigation since the implications both
for combined hormonal and chemotherapeutic approaches to systemic treatment and
the increasing use of adjuvant and prophylactic tamoxifen therapy are potentially veiy
important.
f) p53
The low incidence of positive staining for p53 protein (11%) in the study group of
patients treated with primary tamoxifen is not unexpected. Previous studies have
shown a negative relationship between p53 expression and the presence of oestrogen
receptors with figures ranging from 14 to 32% positivity in ER+ve breast tumours
(Bosari, 1992; Poller, 1992; Friedrichs, 1993). One of these studies also demonstrated
a significantly lower incidence of p53 expression in post-menopausal as compared to
pre-menopausal patients. The group of post-menopausal patients with ER+ve tumours
reported here confirm, therefore, the predicted low incidence of p53 expression. With
such a low incidence of positivity it has been impossible to draw any meaningful
conclusions from the data reported here. This is unfortunate, particularly in the light of
the positive findings reported above which relate proliferative and surrogate apoptotic
markers to tamoxifen response. Previously p53 mutations have been related to highly
proliferative tumours (Allred, 1993), EGFR expression (Poller, 1992) and potentially
therefore resistance to tamoxifen due to development of oestrogen independent growth
promotion. Control of tumour cell growth has also been suggested to involve links
between p53, bcl - 2 and c-myc expression and thus further work with these markers
in larger numbers of patients would be interesting.
g) Ki-Sl and Bcl-2
Most early studies of the mechanism of action of tamoxifen suggested it to be a
cytostatic agent (Sutherland, 1983). However, as demonstrated in the work reported in
this thesis, patients often achieve dramatic responses to therapy with large reductions
263
in tumour volume. This may occur as a result of the normal process of cell death
(which has been described in normal breast tissue (Ferguson, 1981)) being
superimposed upon tamoxifen induced cytostasis. However tamoxifen might also
directly increase rates of "programmed cell death"; the tamoxifen analogue toremifene
having been shown to induce apoptosis in normal breast tissue by an, as yet,
unidentified pathway (Warri, 1993). The present study included an examination of the
events following tamoxifen treatment by measuring markers which may be associated
with proliferation and apoptosis. Most importantly, it was also possible to make
correlations with changes in the size of individual tumours assessed by ultrasound
during the course of therapy thus providing a more detailed evaluation of clinical
response than has previously been reported.
The incidence and degree of immunohistochemical staining for Ki-Sl were comparable
with those reported by others for similar proliferation markers in breast cancer such as
PCNA (Aaltomaa, 1992b) and Ki-67 (Nicholson, 1993). Similarly the incidence of
positivity for Bcl-2 of 86% is compatible with the findings of Leek et al. (Leek, 1994)
and Nathan et al. (Nathan, 1994), although somewhat higher than that reported by
Johnston et al. (Johnson, 1994). However it is important to note that the present
study was performed on oestrogen receptor-positive tumours in which the incidence of
Bcl-2 has been reported to be higher (Chan, 1993; Leek, 1994).
The presence and degree of expression of Ki-Sl in pre-treatment biopsies did not
predict for subsequent response to tamoxifen. Previous reports, in which markers of
tumour cell proliferation such as S-phase and thymidine labelling index have been
studied have found varying relationships between response and proliferation
(Paradiso, 1988; Amadori, 1993). Although others have suggested that the presence
of Bcl-2 in breast carcinomas is a better predictor of response to tamoxifen therapy
than are oestrogen receptors (Gee, 1994), we were unable to show that simple
presence of Bcl-2 was predictive for overall response to tamoxifen in the series of
oestrogen receptor-positive tumours studied. However, there was a significant
correlation between levels of pre-treatment Bcl-2 and the degree of subsequent clinical
response to treatment. This result is superficially paradoxical since it might be
expected that, if Bcl-2 is a marker of cell survival then high expression would be
associated with a lesser degree of response to treatment. However, there are several
potential explanations for this finding. For example Bcl-2 may be a surrogate marker
for oestrogen responsiveness, either because of its relationship with oestrogen receptor
(a significant correlation between levels of ER and Bcl-2 expression was demonstrated
in pre-treatment biopsies) or because since oestrogen induces Bcl-2 in breast cancer
cells (demonstrated in vitro (Gee, 1994)) its presence may reflect a state of oestrogen
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stimulation. In either event cells staining positively for Bcl-2 may be more prone to
antioestrogen effects.
The important feature of the present study is the ability to monitor changes in Ki-Sl
and Bcl-2 with treatment and compare these with clinical response. Thus it was
possible to show that, in keeping with tamoxifen's anti-proliferative effects, the
majority of responding tumours showed a decrease in the expression of Ki-S 1; similar
effects using other markers have been reported by others (Clarke, 1993; Johnson,
1994). In contrast, the majority of non-responding tumours either showed an increase
or no change in proliferation as monitored by Ki-Sl. It should be noted, however,
that whilst these group differences are highly significant there were substantial
minorities in both responding and non-responding tumours which failed to show the
appropriate changes with treatment. Thus, despite showing a clear decrease in tumour
size, three tumours showed an increase in proliferation with tamoxifen treatment. It is
possible that this reflects clonal selection of tumour cells which are both highly
proliferative and resistant to tamoxifen. It will be of interest to determine whether with
further follow-up these particular patients present with early recurrent disease.
Conversely, within the group of 14 non-responding patients there were five tumours
which showed a decrease in proliferation which was not translated into a reduction in
tumour size. It could be that in these patients sequential measurements of tumour size
does not accurately reflect cellular responses but equally the possibility needs to be
addressed that proliferation is not the single or major mechanism by which tamoxifen
exerts its effect on tumour growth.
In this respect it is widely accepted that tumour growth reflects a balance between
proliferation and cell loss (in particular that occurring by apoptosis). It was because of
this that measurements of Bcl-2 were included in the present study. If Bcl-2 is a
marker of resistance to cell death then a reduction in the expression of Bcl-2 with
tamoxifen treatment might be expected to be associated with response. Some
experimental data support this in that exposure of breast cancer cells to antioestrogens
appears to be associated with a decrease in Bcl-2 expression (Gee, 1994).
Paradoxically, a recent small study (Johnson, 1994) has reported greater incidence of
Bcl-2 expression in tumour samples taken after tamoxifen treatment, but these results
were not related to response to treatment. The results of the present study are therefore
particularly informative. These show that 21 of the 37 tumours responding to
tamoxifen showed a decrease in the percentage of cell staining for Bcl-2. In contrast in
non-responding tumours only a minority showed a decrease in expression. Whilst this
is apparently at odds with the study of Johnstone et al. (Johnson, 1994), it should be
noted that even the present study did identify individual tumours in which response to
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tamoxifen was associated with an increase in expression of Bcl-2. However, the fall
in Bcl-2 expression in tumours decreasing in size is consistent with the putative role of
the Bcl-2 product as a factor influencing cell viability.
Given that decreases in Ki-Sl and Bcl-2 were both associated with response to
tamoxifen it is important to determine whether these are a manifestation of a single
process or whether they reflect independent mechanisms. It has been suggested that as
tamoxifen induces cytostasis in Gi, and Bcl-2 has been shown to be largely absent
during this phase of the cell cycle, there may well be a relationship between these two
markers in tumours undergoing treatment (Gee, 1994). However, the observations
reported here do not confirm this hypothesis. Thus, in only 11 of 51 tumours was the
pattern of change with tamoxifen treatment similar for both markers and in nine of
these cases this was to show concordant decreases in responding tumours.
Furthermore, in terms of the quantitative changes which occurred with treatment
combined assessment of both markers was significantly more strongly associated with
reduction in tumour size than either Ki-Sl or Bcl-2 alone. It would seem, therefore,
that tamoxifen treatment predominantly affected either Ki-Sl or Bcl-2 expression,
suggesting a dissociation between mechanisms of cell survival and proliferation.
Whilst these results have illustrated profound effects of tamoxifen on the expression of
markers associated with either proliferation or apoptosis and shown that these may
differ in responding and non-responding tumours, the clinical utility of the findings is
not immediate. Pre-treatment expression of the markers cannot discriminate between
responding and non-responding tumours on an individual basis. Similarly, whilst
changes in levels of expression are significantly different between responding and
non-responding tumours, there are a substantial number which behave exceptionally.
Response to tamoxifen in terms of effects on cellular proliferation and apoptosis
clearly remains a complex issue but one that needs to be resolved if this agent and
future antioestrogens are to be used optimally in breast cancer treatment.
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17.3 Clinical Material - LHRH Agonist Therapy
Only four premenopausal patients with ER+ve tumours were treated with the LHRH
agonist goserelin. The data generated from such a small population cannot be used to
draw any significant conclusions. However, it was interesting to note that all tumours
responded to treatment and all demonstrated a decrease in pS2 staining. This would be
indicative of pure antioestrogenic effects (indirectly via the inhibition of oestrogen
production) as opposed to the trend towards induction of pS2 demonstrated in
tamoxifen treated tumours. The observation that two of the four tumours showed
increased staining for P -glycoprotein after goserelin therapy whilst a third had high
levels both before and after treatment deserves further attention. It would be interesting
and important to examine a larger number of patients given primary treatment with
LHRH agonists and review the response to second line treatment with chemotherapy
in this group. Mixed changes in staining were observed for c-erbB-2, Bcl-2 and Ki-
Sl.
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17.4 Clinical Material - Chemotherapy
Only limited conclusions may be drawn from material derived from patients treated by
chemotherapy as per the protocol for the trial of primaiy systemic therapy. This is
primarily due to the low number of patients recruited during the study period and to a
lesser extent a result of the small volume and poor quality of material available from
tumours after treatment. Many tumours displayed a 90% or greater reduction in
volume and some showed a complete pathological response. In addition only one
tumour failed to respond to chemotherapy, therefore it is diflcult to make comparisons
between response and immunohistochemical staining. Perhaps most interesting are the
staining patterns with Ki-Sl, c-erbB-2 and P- glycoprotein antibodies. The only
tumour to show an increase in proliferation during treatment (as defined by an increase
in Ki-Sl staining) was that which failed to respond.
The non-responding tumour would perhaps be expected to show an increase in
proliferation and it was reassuring that no responding tumours displayed such an
increase. Indeed the one non-responding patient has since died during follow-up (after
16 months). However, the tumour material from this patient did not show positive
staining for c-erbB-2. Positive staining with this antibody does not appear to be
associated with poor response of the primary tumour to chemotherapy but yet in this
group is a marker of poor overall prognosis, in that the two patients whose tumours
stained strongly positive for c-erbB-2 have died of metastatic disease during the
relatively short follow-up period. The implication of previous studies demonstrating
the poor clinical outcome of patients receiving postoperative adjuvant chemotherapy
for tumours overexpressing c-erbB-2 has been that the gene confers a degree of
chemoresistance (Gusterson, 1992; Allred, 1992b). If this is the case such resistance
was not assessable, in this present study, by measuring the reduction in tumour
volume with primary chemotherapy. The conclusion from this limited data is that c-
erbB-2 expression does not predict for the initial tumour response, but, in fact, may a
better marker for early relapse and poor survival following primary therapy than the
degree of the observed clinical response. Of course the only patient not to respond to
primary therapy has also died and overall response is likely also to be a predictor of
survival.
P- glycoprotein expression, as has been described above, occurs in association with
resistance to adriamycin chemotherapy. In this very small study population, only four
tumours expressed P- glycoprotein prior to treatment, allbeit at low levels. This
subgroup included the one non-responding tumour. Of the three that did demonstrate a
clinical response two patients have since died and the remaining tumour showed the
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smallest reduction in volume of the population studied. One of the tumours, despite
demonstrating a 95% reduction in tumour volume, showed a marked increase in the
percentage of cells staining for P- glycoprotein when post treatment tissue was
compared to that taken prior to therapy. This would be in keeping with the clonal
selection of resistant cells and this patient has since died with no response of recurrent
disease to second line chemotherapy. An increase in staining index was seen in one
additional tumour which had no significant staining prior to treatment. Although the
staining index of the post-treatment specimen was relatively low it is possible that a
clone of resistant cells remained after surgery and on clinical follow-up this patient
should be monitored closely. The possible importance of P- glycoprotein expression in
these patients clearly supposes that micrometastatic disease responds to therapy in the
same fashion as the primary tumour. Further insight into this selection process may be
gained from the flow cytometric assessment of serial fine needle aspirate specimens
discussed below.
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17.5 Clinical Material - Flow Cytometry and Fine Needle Aspirates
The tumour expression of several potentially interesting antigens have been shown by
immunohistochemical techniques, as described above, to be related to the clinical
response (and possibly survival) of patients treated with primary endocrine and
chemotherapy. Fine needle aspiration of breast tumour xenografts and flow cytometric
analyses of the material obtained also proved a useful technique in assessing tumour
growth and response principally in terms of cell cycle analysis and other measurements
of proliferation. This technique could also provide information as to the expression of
other antigens removing the necessity for biopsies to obtain tissue fragments.
Row cytometric assessment of material derived from fine needle aspirates produced
differerent and some additional data when compared to those obtained by
imunohistochemical investigations of tissue samples from the same tumours.
There was a clear trend towards response in aneuploid, and non-response in diploid
tumours. This, however, did not reach statistical significance, in agreement with
previous inconclusive studies (Robertson, 1991; Skoog, 1991). A possible
explanation for this apparent trend would be related to the greater response seen in
tumours with higher proliferative rates as shown in at least one previous study
(Paradiso, 1988). Aneuploid tumours have been reported to have higher proliferative
rates than diploid tumours. In this present study, however, there was no difference in
the mean S-phase fraction of aneuploid as compared to diploid tumours and of
responding as compared to non-responding tumours. The assessment of proliferation
by flow cytometric measurement of Ki-Sl did, however, demonstrate a significant
correlation between mean levels of expression and the degree of observed response.
This correlation held for only the responding tumours which would suggest that
overall response does not rely upon the rate of proliferation prior to treatment.
However, in those tumours which do respond, greater degrees of response are
associated with greater rates of cell proliferation. This does not correspond to the
immunohistochemical findings from the pre-treatment biopsy material which failed to
show predictive value for staining with Ki-Sl. Indeed, there was no statistically
significant correlation between flow cytometric and immunohistochemical
measurement of Ki-S 1 expression. The reason for this is unclear particularly since the
same monoclonal antibody was used in both investigations. In fact, the results showed
no significant correlations between the two methods of analysis for any of the
individual markers studied. In the cases of measurement of c-erbB-2 and P-
glycoprotein expression different antibodies, as necessitated by the different
techniques used in the two methods, may partly explain the poor correlation. There
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were also differences in tissue fixation with material for flow cytometry fixed in
alcohol and formalin fixation used for immunohistochemistiy. Perhaps more
importantly, flow cytometric analyses are problematical in that vaiying amounts of
stromal cells are included in the analyses whereas in immunohistochemical
assessments only directly identifiable tumour cells are included. However, samples
derived from fine needle aspiration do, theoretically, provide a better representation of
the tumour as a whole, since the needle is passed through a relatively large volume of
tumour during collection. Material for immunohistochemical studies, however,
necessarily represents only a very small portion of tumour, allbeit in cross section.
On assessment by both techniques the expression of pS2 after tamoxifen treatment was
shown to positively correlate with the degree of response. Interestingly, by flow
cytometry the percentage of cells expressing pS2 prior to treatment correlated with
subsequent degree of response but after treatment it was the mean cellular expression
which was relatedto the prior response. In other words the proportion of tumour cells
expressing pS2 predicts response but the degree of individual cellular expression after
treatment reflects response. So that tumour cells are not recruited to express pS2 but
those which do so are induced to express higher levels. pS2 expression is under
oestrogenic control as, indeed, is the expression of c-erbB-2 according to some
authors. Oestrogens have been shown to induce pS2 but inhibit c-erbB-2 expression in
hormone sensitive cell lines. There was a positive correlation between response and
the initial expression of c-erbB-2 and a significant decrease in expression of the marker
in responding tumours. The results relating to the expression of pS2 and c-erbB-2
might suggest that the oestrogenic effects of tamoxifen are important in tumour
response. It is not possible to determine whether these oestrogenic effects per se are
important or whether they reflect the possession of fully functional oestrogen receptor
mechanisms through which tamoxifen may exert other actions.
The numbers of both B-lymphocytes and Natural Killer cells present in pre-treatment
FNA's, as measured by the numbers of cells expressing CD19 and CD56 antigens
respectively, did show associations with response. Numbers of both cell types were
significantly correlated with the degree of response to tamoxifen when the responding
population only were assessed. The presence of both of these cell types within primary
breast tumours have been shown in a previous study to be related to good overall
prognosis (Lawry, 1993). This study did not, however, relate these parameters to the
response to systemic treatment. Other studies have examined the effect of tamoxifen on
the activity of Natural Killer cells isolated from venous blood samples. There appears
to be an increase in activity after short-term treatment (one month) but a decrease in
activity after longer periods of tamoxifen therapy (years) (Robinson, 1993).
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Few conclusions could be drawn from the material obtained by FNA in tumours prior
to undergoing primary treatment with chemotherapy as there were relatively few
numbers and only a small variation in the degree of response recorded. Within these
limitations, S-phase fraction and DNA ploidy prior to treatment did not predict for the
clinical response seen. There were no significant associations with response noted for
the other tumour antigens measured; c-erbB-2, P -glycoprotein and Bcl-2.
Fine needle aspirates taken during treatment allowed monitoring of changes in tumour
cell cycle distribution and antigen expression. Overall S-phase fraction did not prove to
be as reliable as Ki-Sl expression in demonstrating the expected decrease in cellular
proliferation in responding tumours. The potential problems of S-phase measurements
in treated tumours had been demonstrated in animal models and described above.
BrdU uptake proved difficult to measure reliably on the relatively small amount of
material obtained by FNA given that several other analyses were also required on each
sample. Serial FNA's demonstrated a significant decrease in Ki-Sl expression in the
midpoint (6 weeks) samples compared with those taken prior to therapy in tumours
treated with tamoxifen. Similarly, a tendancy towards reduced expression was seen in
the sample taken before the third cycle of treatment in patients given chemotherapy.
However, although this may be a promising tool to monitor biological response at a
relatively early stage in treatment, more tumours will need to be assessed before
definite conclusions can be drawn. No clear trends in changes in cell cycle distribution
were evident such that Go/i and G2 blocks were not generally seen in tumours treated
with tamoxifen and adriamycin respectively. Such effects of these drugs have
previously been reported in cell culture systems and the failure to demonstrate these in
this study may reflect the heterogenous nature of a primary breast carcinoma.
There were interesting changes in DNA content during treatment with two diploid
tumours developing an aneuploid and a tetraploid histogram when treated with
tamoxifen and one tumour demonstrating the development of an aneuploid peak when
treated with chemotherapy. All three tumours demonstrated clinical response, but if
these new peaks represent resistant clones of tumour cells it may well be that these
patients develop recurrent disease during follow-up.
Clinical follow-up will be extremely important to determine the relationship with
relapse-free and overall survival of the expression of tumour cellular antigens and cell
cycle analyses. These relationships are probably as important as those relating to the
short term response to primary therapy.
Adriamycin uptake was measured in the few tumours treated with chemotherapy that
were studied. Two out of five tumours demonstrated a decrease in uptake with the
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third cycle compared with the first and the remainder showed consistently low levels
of fluorescence. This apparent reduction in adriamycin-associated intracellular
flourescence may simply reflect poor quality specimens from treated tumours but could
demonstrate the development of cellular resistance or more likely reflect poor
vascularity and hence delayed access of the drug to the tumour. In an attempt to
investigate this theory, doppler ultrasound scans performed on one of the patients
studied demonstrated a complete loss of arterial signal after two cycles of treatment
(data not shown). Future studies of adriamycin uptake may have to account for this
probable delay in drug transport. It is uncertain whether the decrease in vascularity is a
direct effect of adriamycin on the vasculature or on indirect effect of tumour cell death.
The poor vascularity may prevent exposure of a proportion of the tumour cell
population to the cytotoxic drug allowing continued proliferation and metastasis.
The rapid and often large response to chemotherapy in terms of reduction in tumour
volume, in many cases after two cycles of treatment, made tumour sampling
technically very difficult and produced poor quality specimens. This will limit future
work with serial FNA samples in chemotherapy-treated tumours particularly when the
primary tumour is relatively small prior to treatment.
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Chapter 18: Conclusions
This thesis has attempted to examine the response of breast cancer to primary systemic
therapy by a variety different methods and at several levels. It has confirmed the
usefulness of ultrasound scanning to monitor macroscopic response in terms of
reduction in tumour volume. Indeed it is the first study to report serial ultrasound
measurements in patients treated with primary tamoxifen and has produced surprising
results in that response can be detected after only a relatively short treatment period.
The relevance of the speed of response of an individual tumour to primary tamoxifen
with respect to overall patient survival will only be detemined after significant clinical
follow-up. Ultrasound also gives an accurate assessment of the degree of response in
terms of reduction in tumour volume. This may be particularly important in assessing
various predictive markers since, increasingly, it is felt that the prime benefit of
primary systemic therapy will be the avoidance of mastectomy after tumour shrinkage.
This certainly appears to be bome out in the patients from the Trial of Primary
Systemic Therapy who demonstrate little difference in survival between those treated
conventially and those given primary drug treatment (although follow-up is short). To
this end if the degree of likely response can be predicted before treatment then this
would be the major selection criteria for primary drug therapy. In this thesis serial
ultrasound scanning enabled the demonstration that whilst estimates of oestrogen
receptor content both by ERICA and EIA correlated with overall response to primary
tamoxifen only EIA estimations correlated closely with the degree of the observed
response. None of the other markers assessed by immunohistochemistry predicted for
the observed response either to hormone or chemotherapy. Flow cytometric analysis
of a small sub-population of tumours, however, did suggest that the expression of c-
erbB-2 predicts for both the overall and the degree of response to tamoxifen. The
model, however, will allow further markers to be assessed and, indeed, archival
material is available for future analysis from the majority of tumours whose clinical
response has been documented.
An accurate measurement of tumour response also allows a better understanding of the
response to systemic therapy at a cellular level. The changes in expression of a variety
of cellular markers revealed some interesting trends. However, the relatively few
patients receiving primary chemotherapy in the study population and the small
variation in their observed responses has made it difficult to draw any very useful
conclusions from this section of the work. In those tumours treated with tamoxifen,
potentially the most interesting markers have been that of proliferation, Ki-Sl, and that
of resistance to cell death, Bcl-2. The examination of changes in the expression of
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these two markers and the degree of response exhibited to tamoxifen have raised the
possibility of two different pathways through which tamoxifen exerts its effects.
Firstly through decreasing cellular proliferation, the classical cytostatic mechanism but
also secondly through a distinct effect to reduce Bcl-2 expression. This may in turn
lead to an increase in cell death by apoptosis. Further work is under way to confirm
this finding through other methods of estimating rates of apoptosis and to understand
the molecular pathways involved in translating exposure to tamoxifen into the protein
changes seen by immunohistochemistry. The relationship between the changes in
expression of P -glycoprotein and observed response, although surprising, may have
significant clinical implications. If the expression of P -glycoprotein is induced in
tumours that are resistant to tamoxifen then this drug may be contraindicated in patients
who would be candidates for future treatment with chemotherapeutic agents which are
susceptible to this resistance mechanism. This would also, therefore, highlight the
need for more definitive predictive factors for tamoxifen response/resistance. The
current trend for a combined approach to the systemic treatment of breast cancers with
simultaneous (or closely separated) courses of tamoxifen and chemotherapeutic drugs
may also be questioned. There are also large trials underway examining the use of
tamoxifen as a preventative therapy in young women with several risk factors for the
development of breast cancer (Powles, 1989). One wonders how chemosensitive such
tumours will be if they have developed during, and are hence resistant to, the effects of
tamoxifen. Because of the potential implications of this finding further work with the
expression of P -glycoprotein and exposure to tamoxifen needs to be undertaken.
Much of this proposed future work could be performed profitably in animal model
systems. The small studies reported here, the first work to our knowledge to describe
serial fine needle aspirates from animal xenografts, confirm the potential of such
systems. Ideally such work would be performed with xenografts taken from a variety
of primary human breast tumours. However breast tumours remain notoriously
difficult to xenograft and all attempts (unreported) made by the author to do so during
the work for this thesis, despite a variety of different conditions, were unfruitful.
The potential promise of the combined techniques of fine needle aspiration and flow
cytometry although giving useful results in the xenograft material only partly realised
such potential in the human tumours studied. The limiting factors appeared to be of
tissue quality and quantity, particularly at later time points in responding tumours.
Surprisingly, there was not a single positive correlation between antigen expression as
measured by immunohistochemistiy and by flow cytometiy, and although various
theories have been discussed above this warants further investigation. Nevertheless,
the significant positive correlations between the degree of response and pre-treatment
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expression of both pS2 and c-erbB-2 are potentially important in the understanding of
the mode of action of tamoxifen and should be examined further. Flow cytometric
analyses allowed additional information relating to DNA content and cell cycle
distribution to be obtained. One of the advantages of such techniques is the minimally
invasive nature of fine needle aspiration. If the immunohistochemical changes noted in
Ki-Sl, Bcl-2, and P -glycoprotein expression are confirmed in other studies then
further work on the expression of these antigens in fine needle aspirates early in
treatment would be appropriate. Results reported here suggest that changes in Ki-S 1
and P -glycoprotein could be noted by six weeks of treament with tamoxifen. Bcl-2
has not been examined by flow cytometry in fine needle aspirates in this study but the
methodology does exist. It would be a significant advance if after six weeks of
treatment (or perhaps earlier) one could predict, by changes in cellular antigen
expression, that the desired volume reduction will not be achieved or that in apparently
resistant tumours there was a risk of developing an element of chemoresistance.
This thesis, by the nature of the proposed content, has included a broad overview of
methods of assessment of the response to primaiy therapy of breast tumours. It has,
however, made significant observations of the macroscopic response to treatment,
confirmed the power of standard predictors of response such as the oestrogen receptor
and indicated new potential markers of response and resistance to primary therapy. It
forms the basis for future, more detailed, work on individual parameters designed to
optimise the use of the currently available, but unfortunately far from perfect,
therapeutic options for the treatment of breast cancer.
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